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Abstract of a thesis submitted in partial fulfilment of the 
requirements for the Degree of Doctor of Philosophy. 
Abstract 
Computational Framework for Early Detection of Breast Cancer  
 
by 
Ali Al-yousef 
Breast Cancer is the second leading cause of death after lung cancer in women all over the 
world whose lives could be saved by an early detection. This could be achieved by improving 
the diagnostic accuracy of the present Computer Aided Diagnosis systems (CAD) for breast 
cancer, which use both clinical and biological data. As a means of achieving this goal, the 
thesis focussed on examining and evaluating both clinical and biological data used in the 
present Breast Cancer CAD systems. Results were then applied for early detection of breast 
cancer in women from a low income country, Jordan, where breast cancer incidence (32%), 
ranks among the highest in the world.  
In the first part of the study, the clinical part, we identified a new mass feature related to 
mass shape, called Central Regularity Degree (CRD) from Ultrasound images, which was then 
used along with five other powerful mass features: one geometric feature: Depth-Width 
ratio (DW); two morphological features: shape and margin; blood flow and age, in the 
classification with four different classifiers: Artificial Neural Networks (ANN), K Nearest 
Neighbour (KNN), Nearest Centroid (NC) and  Linear Discriminant Analysis (LDA).  ANN gave 
the best performance with an improved accuracy of classification, from 81.8% to 95.5% after 
adding CRD. The overall improvement of the diagnostic accuracy of the CAD, after adding 
CRD was 14%, which was a significant improvement.   
The second focus of the study was centred on biological data. The aim was to enhance the 
diagnostic accuracy of CADs that use gene expression profiling of peripheral blood cells, by 
introducing a novel feature selection method called Bi-biological filter and Best First Search 
with SVM (BFS-SVM). The bi-biological filter contained two biological filters; the first one to 
find the shared biomarkers between two cancer subsets and the second one to eliminate the 
healthy biomarkers from the shared ones. The study evaluated the diagnostic accuracy of 
three classifiers; Artificial Neural Network (ANN), SVM and Linear Discriminant Analysis (LDA) 
 iii 
with 5-fold out cross validation. The study used 121 samples – 67 malignant and 54 benign 
cases as input for the system. The Bi-biological filter selected 415 genes as mRNA biomarkers 
and BFS-SVM was able to select 13 out of 415 genes for classification of breast cancer. ANN 
was found to be the superior classifier with 93.2% classification accuracy which was a 14% 
improvement over the original study (Aaroe et al. 2010). 
The third focus of the study was on female patients in Jordan, a low income country with a 
high rank in breast cancer incidence. We used Bi-Biological filter and BFS-SVM wrapper to 
analyse 56 blood serum samples to detect circulating breast cancer miRNA biomarkers in 
Jordanian women and use them to improve the diagnostic accuracy of circulating miRNA 
based breast cancer CADs. The Bi-biological filter selected 74 miRNAs as breast cancer 
biomarkers. And 7 out of 74 were selected by BFS-SVM for breast cancer classification. SVM 
was found to be the superior classifier with 98.2% classification accuracy which was a 12% 
improvement compared with Schrauder et al. (2012) and %7 compared with Hu et al. (2012). 
 
Keywords: Breast cancer, CAD systems, Breast ultrasound, Breast anatomy, Gene expression 
of prepheral blood, circulating miRNA, microarray technology, artificial neural networks, 
support vector machines, Spectral Clustering, Co-expression,  K nearest neighbour, nearest  
Centroid, linear discriminant analysis, self-organizing maps, hierarchal clustering, Jordan. 
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 1 
Chapter 1 
Introduction 
Breast Cancer is the second leading cause of death after lung cancer in women all over the 
world. One of the key points that plays a significant role in the patient’s survival is early 
detection of the cancer, as a patient diagnosed in stage 0, the early stage, is more likely to 
reach a cancer free state. The knowledge of this fact plays a vital role in breast cancer 
diagnosis. Currently, there are several different methods of breast cancer diagnosis. The 
most popular methods for early detection of breast cancer are, clinical tests, such as, 
Mammography and Ultrasound and biological tests, such as, fine needle, biopsy and 
recently, gene expression analysis.  
Early detection of breast cancer can benefit from both clinical and biological data, research 
needs to explore a computational framework for early detection of breast cancer, using both 
clinical and biological tests in a Computer Aided Diagnosis (CAD) system. This chapter 
provides an overview of breast cancer and current CAD systems for diagnosis of breast 
cancer. The chapter concludes with the research objectives and an overview of thesis 
chapters. 
1.1 Breast Cancer 
The Breast is composed of milk glands, connective tissues and fat. The Milk glands consist of 
lobules, where milk is produced and ducts which carry milk to the nipple. Breast cancer 
typically originates either in ductal tissues (the tissues that compose the tubes that carry 
milk to the nipple) or lobular tissues (the tissues that create the glands that produce milk). 
Breast cancer can be in both men and women but it is more common in women than in men. 
Breast cancer is of different types based on its starting location. According to the National 
Breast Cancer Foundation (2012), the most common type is Invasive Ductal Carcinoma (IDC), 
making about 80% of diagnosed breast cancer cases. The second type is Invasive Lobular 
Carcinoma (ILC), making about 10% of diagnosed breast cancer cases. The remaining 10% of 
the cases are distributed among other types of breast cancer, such as, Mucinous carcinoma, 
mixed tumours, Medullary carcinoma, Inflammatory breast cancer, Triple-negative breast 
cancers, Paget's disease of the nipple and Adenoid cystic carcinoma. The actual causes of 
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breast cancer are still not fully understood. Among the number of risk factors identified as 
related to breast cancer are age, family history, personal history, first menstrual cycle, 
density of breast tissue, pregnancy history, exposure to previous chest radiation, being 
overweight, using combined hormone therapy after menopause, use of oral contraceptives 
in the last 10 years and alcohol use. However, the mechanisms of the effect of these factors 
are still unclear. The main symptom or sign of breast cancer is the presence of a lump at 
some point in breast. In addition to this, there may be swelling of part of the breast, nipple 
discharge, nipple redness and pain in the breast or nipple.  
There are several stages of diagnosis of breast cancer ranging from stage 0 to stage IV, which 
are determined by Tumour-Node-Metastasis (TNM) system, developed in 1942 by Pierre 
Denoix. The TNM system describes breast cancer using three features. The first is the 
tumour size (T), which ranges from T0 to T4, based on the size of the primary tumour. The 
second feature reflects the regional lymph nodes involvement (N), where the values of this 
feature range from N0 to N3. Finally, the M character represents the metastasis of the 
cancer, where the values of this feature are M0 or M1 (Singletary & Connolly, 2006). A study 
of five survival rate of breast cancer patients and the cancer stage at the time of diagnosis 
found the survival rate of patients in stage I to be 92%, stage II A and B to be 82% and 65% 
respectively, stage III A and B to be 47% and 42%, respectively, and for stage IV to be 14% 
(Marc, 2005). According to this, the survival rate is found to be strongly related to the stage 
at which the cancer is diagnosed.  
1.2 Breast Cancer Diagnosis Methods 
There are different tests designed for the diagnosis of breast cancer at its early stages. These 
tests are classified into two main types, the clinical and biological. In the clinical test, the 
doctor looks for external changes, such as, redness of the breast, changes in the texture of 
the skin, or an internal change such as, the presence of a mass within the breast tissue, 
which usually is detected by a mammography or ultrasound. On the other hand, the 
biological test looks for biological changes of the body, such as, the changes in the white 
blood cells, molecular biology of breast fluids or the presence of genetic mutations that lead 
to the development of breast cancer. The most common clinical tests are Mammography, 
Ultrasound and self-examination of the breast. The most common tests designed for 
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detecting biological changes are Nipple Aspirate Fluid (NAF) Analysis, Breast biopsy, and 
Genetic test.  
In this study, we will focus on Ultrasound and Genetic tests (mRNA and miRNA). 
Digital Mammography is a low dose x-ray test designed to find normal changes in the breasts 
(Arfelli, 1998), where it plays an important role in the early detection of breast cancer, 
especially, in women who have a family history with the disease  and those who are over 40 
years old (Saslow et al., 2004). A mammography test is of two types; screening and 
diagnostic. The screening is applied to women or men who have no breast cancer signs, 
while the diagnostic is customized to diagnose specific symptoms of a patient, previously 
observed by the radiologist (Dee & Sickles, 2001), to make as correct a decision as possible.  
Ultrasound is a common diagnostic medical procedure that uses inaudible sound pressure 
with a high frequency. The sound waves break through a medium and the echo signals are 
recorded and transformed into a video or photographic image (Novelline, 1997a). There are 
four types of ultrasound. The first one gives a simple view with a plotted series of peaks and 
is called A-mode. The second one is Brightness-modulated display Ultrasonography (B-mode) 
which provides a real-time 2-D evaluation that has a wide range of applications such as 
imaging of liver, kidney, breast, etc. Ultrasonography that merges real-time B-mode with 
pulsed Doppler signals to reflect the motion within a tissue is called the Duplex. The last one 
is M-mode (motion display modality) where the echo is recorded on a moving paper strip 
(McGrow Hill 2002). The most common type used for breast cancer screening is B-mode 
ultrasound.  
Mammography is limited by the density of the breast, which makes it difficult to detect the 
abnormality in women with dense breasts. On the other hand, ultrasound works well with 
dense breasts and also is considered to be the perfect examination for differentiating liquid 
from solid mass. 
In recent years, as a result of the emergence of microarray technology, which provides 
massive information about genes, the field of genetic research has become prosperous and 
sophisticated. Accordingly, studies began striving to link disease and genes by finding 
biomarker(s) associated with the presence of a particular disease, in order to facilitate the 
process of early diagnosis, which in turn increases the chance of cure and reduces the cost of 
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treatment. This is done by using two types of cell samples, blood or tissue to design the 
microarray. The availability and the simplicity of collecting blood samples make it a perfect 
resource for genetic data. 
In this work, we will focus on three types of breast cancer examinations, Ultrasound as the 
clinical examination and mRNA and miRNA of blood as the biological examinations.  
1.3 Breast Cancer Computer Aided Diagnosis (BC-CAD) Systems 
Diagnosis is a process of finding a symptom(s) from given symptoms that could differentiate 
a specific disease from other diseases. As a result of evolution of the medical tests whether 
laboratory, observation of external changes or medical images, recent decades have seen a 
remarkable development in the sensitivity and accuracy of the diagnosis of various 
diseases. These tests place a large amount of patient’s data in the hands of a doctor 
or specialist. However, to determine the distinctive disease symptom(s) from a large number 
of patient’s data becomes a difficult task for a doctor as it needs a lot of effort to make the 
correct decision.  
The rapid growth of Information technology, especially data mining, has evolved the quality 
of Decision Support Systems (DSS) which in turn has contributed to improvement of the 
quality of the decisions taken. A DSS gathers raw data from different sources and converts 
these to knowledge that helps make good decisions. The complexity of the patient’s data, 
the intersection between the symptoms of different diseases and the improvement of 
computer based DSS have led to the development of a new DSS in the medical field, called 
Computer Aided Diagnosis Systems (CAD).  
Although breast cancer has become one of the deadliest diseases in the world, patients who 
have been diagnosed in the early stage could reach cancer free state. Several breast cancer 
CAD systems have been developed to detect breast cancer in the early stage, using different 
sources of patient data and different data mining techniques, classifiers and clustering 
methods. The most important sources of patient data are clinical, ultrasound and biological 
gene expression. The most frequently used data mining methods are Artificial Neural 
Network (ANN), Support Vector Machine (SVM), K-Nearest Neighbour (KNN), Liner 
Discriminant Analysis (LDA), Nearest Centroid (NC), hierarchical clustering and Self-
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Organization Maps (SOM). Also, there are several statistical methods used in this field and 
they including, ANOVA test, Student’s t test and Principal Component Analysis.   
Most CAD systems take four steps in their development; Dataset pre-processing, Feature 
selection- features are a set of variables, attributes or descriptors of the instance, such as, 
genes, mass shape and patient age - Classification, Evaluation. The dataset pre-processing 
step removes incorrect data and normalizes the dataset.  The process of removing noisy data 
(irrelevant and redundant) or choosing a sub set of features (relevant) from the given set is 
called feature selection (Blum & Langley, 1997; Gilad-Bachrach, Navot, & Tishby, 2004). 
There are two types of feature selection methods filters and wrappers (Chapter 2). The 
selected features are used as inputs to the classification step. The aim of any classification 
technique is to classify objects into two or more groups based on the object attributes 
(Chapter 2) .This work will use supervised classifiers, especially those  that classify instances 
into two groups, which are called binary supervised classifiers (Japkowicz, 2001).  The last 
step is Evaluation; this step is to evaluate the diagnostic accuracy of the CAD system 
(Chapter 2). 
Several previous studies used the clinical test, ultrasound, to build CAD systems using 
different features, such as, image and patient features, and different classification 
algorithms (Chang, Wu, Moon, & Chen, 2005; Drukker, Giger, Vyborny, & Mendelson, 2004; 
Huang, Wang, & Chen, 2006; Kuo, Chang, Chen, & Lee, 2001;  Shen, Chang, Moon, Chou, & 
Huang, 2007; Sivaramakrishna, Powell, Lieber, Chilcote, & Shekhar, 2002; Zakeri, Behnam, & 
Ahmadinejad, 2012). There are two types of ultrasound features, the texture and 
morphological, that have been used for building CAD systems. The texture features depend 
on the settings of the ultrasound machine.  On the other hand, the morphological features, 
such as, mass shape and margin, are independent of the settings of the ultrasound machine 
(Chen & Hsiao, 2008). Most of the previous studies have used texture features or a 
combination of texture and morphological features as inputs to CADs (Drukker et al., 2004; 
Huang et al., 2006; Kuo et al., 2001; Sivaramakrishna et al., 2002; Zakeri et al., 2012). 
However, only few studies have used morphological features (Chang et al., 2005; Shen et al., 
2007). Currently, the best diagnostic accuracy of ultrasound based Computer Aided 
Diagnosis (CAD) systems using morphological features is about 90% and needs further 
enhancement. Therefore, in the current study, we use morphological features of ultrasound 
image to build the CAD system. This study conducts a thorough investigation of the 
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ultrasound imaging in order to extract new meaningful mass features and incorporate these 
features in CAD systems.  
As mentioned above, cell samples are required to design a microarray. There are two main 
sources for cell samples: tissues or blood cells. Collecting tissue samples for microarray 
technology may not be safe and also, such samples are not readily available, especially from 
healthy people (Marteau, Mohr, Pfister, & Visvikis-Siest, 2005). On the other hand, 
peripheral blood is readily available, easy to access and is a rich source of genetic 
information for studying human diseases that makes it a perfect source of gene expression 
(Fang et al., 2006). Also, there are only few studies that have used gene expression profile 
extracted from peripheral blood cells for early detection of breast cancer (Aaroe et al, 2010; 
Cuk et al., 2012; Schrauder et al., 2012; Sharma et al., 2005). These studies used either 
mRNA or miRNA microarrays for extracting the breast cancer biomarkers and found blood a 
good source for early detection of breast cancer. Currently, the diagnostic accuracy of blood 
based mRNA gene expression profiling is about 79% and for miRNA about 90%. However, the 
analysis of microarray data is challenged by the high-dimensionality of the data compared 
with the number of samples. In order to enhance the results obtained from the previous 
studies, this study introduces a novel gene selection method to extract group(s) of genes 
that are strongly related to breast cancer.  
1.4 Objectives. 
Most of the previous medical studies have focused on one of the diagnostic methods to 
differentiate benign from malignant lesions. Similarly, in the computational field, specific 
machine learning studies have also used data from only one of the diagnostic methods for 
newly developed breast cancer CAD systems. There is still a need for fundamental 
knowledge from both medical and computational studies to improve CADs for breast cancer. 
We aim to address these and outline the essential available information by asking the 
following questions: 
1) What is the current situation of breast cancer? 
2) What are current diagnostic methods that have been used for building CAD systems? 
3) What are the current computational approaches that have been used to build breast 
cancer CAD systems?  
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We address these questions in Chapter 2 by reviewing the existing literature using keywords, 
”breast cancer, machine learning, breast ultrasound, gene expression and CAD systems” 
which are relevant to this study. 
Our review led us to the selection of this topic, which focuses on computer aided diagnosis 
for early detection of breast cancer using radiological, clinical, and biological data. The 
primary purpose of this thesis is to understand better and acquire more insight into Breast 
Cancer Computer Aided Diagnosis Systems (BC-CADs) in order to develop a computational 
framework (Fig. 1.1) for early detection of breast cancer that enhances the current 
accuracy of breast cancer CAD systems. We will focus on both types of breast cancer 
examinations, Clinical (Ultrasound) and Biological (mRNA and miRNA), in this framework.  
The first specific objective focuses on the clinical part of the framework, while the second 
and third specific objectives focus on the biological parts of the framework.  
 
Figure ‎1.1. The Breast Cancer Computer Aided Diagnosis (BC-CAD) Framework showing the 
three CAD systems; one for clinical data (ultrasound) and two for biological data (mRNA 
and miRNA). 
Currently, the diagnostic accuracy of breast cancer based on ultrasound imaging that uses 
morphological features is about 90%. Further enhancement of the method is needed to save 
the lives of the undetected. This led to the first specific objective of this study:  the first 
specific objective is to enhance the diagnostic accuracy of ultrasound based BC-CADs.  This 
objective is accomplished by using breast ultrasound samples obtained from the Digital 
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Database for Ultrasound Images (Tian et al., 2008). The samples were collected by the 
Second Affiliated Hospital of Harbin Medical University between 2002 and 2007. To enhance 
the diagnostic accuracy of ultrasound based BC-CAD, we answered the following questions:  
1) What features are extracted from a breast ultrasound image? Out of these, what are 
the features that are strongly related to breast cancer?   
2) Do all benign masses have a regular shape in an ultrasound image? When is the mass 
said to be irregular?  
To answer the two questions above, we extracted all mass features listed in the 
database and converted the linguistic values of the features, the value of the feature 
is word or sentence, to numeric values. Then, we analysed the frequency of the 
features to find the goodness of the individual features in differentiating benign from 
malignant cases. We investigated the shape of the mass in the ultrasound images in 
search of any potentially new geometric features that would differentiate benign 
from malignant cases. We discovered a new mass feature in this investigation. 
3) What is the set of features to be selected for breast cancer classification?  
We tested the ability of different subsets of features in differentiating benign from 
malignant masses by using hierarchical clustering and Self Organization Maps (SOM). 
The subset of features with the highest discriminating value was selected for 
classification. 
4) How can we validate the discriminating ability of the new mass feature?  
We built two CAD systems; the first, using all the selected features as inputs, 
including the new feature; the second, without the new feature as an input. The 
results of the two CAD systems were then compared. 
From the first specific objective, we expect the outcome to be a significant enhancement in 
the CAD system due to the incorporation of the new geometric mass as an input. 
As we mentioned in section 1.3, analysis of microarray data is challenged by the high-
dimensionality of the data compared with the number of samples. Aaroe, et al., (2010) used 
a ranking filter to identify 738 differentially expressed genes as breast cancer biomarkers in 
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peripheral blood cells and obtained a diagnostic accuracy of 79.5%. The number of selected 
genes for classification is large compared to the number of samples used. Also, the CAD 
system still has 21% misclassified samples and needs further development. This led to the 
second specific objective of this study. The second specific objective is to introduce a novel 
gene selection method based on biological relations between genes to identify breast 
cancer biomarkers in blood samples, and enhance the diagnostic accuracy of BC-CAD 
systems that use gene expression profiling of peripheral blood cells.  
This objective was achieved by using 121 samples (Aaroe, et al., 2010), Topological Overlap 
Matrix (TOM), the ratio of the number of the pairwise connections between genes i and j to 
the smaller of the number of connections to all genes of one of them, so is a “local link to 
global link” comparison, and Spectral Clustering (SC) for developing the gene selection 
method. Selected genes were tested on ANN, SVM and KNN to assess their classification 
performance. The study was carried out by answering the following questions: 
1) How can we represent the biological relationship between genes?  
TOM is a mathematical method that has been used to find the relationship between a pair of 
genes by calculating the similarity between them. The similarity matrix resulting from TOM 
can be expressed as Gene Co-expression Network (GCN), which represents the biological 
relation of genes.    
2) How can we divide the (GCN) into functional groups? 
Spectral Clustering, as a graph clustering method can be used for dividing the GCN into 
groups of genes in order to predict their function(s). The genes in the same group are similar 
to each other and may be involved in the same pathway.  
3) How can we determine the number of functional groups (clusters) in the GCN?  
Density and Cut-Off fitness criteria have been used for evaluating the quality of clustering. 
Density focuses on the density of the sub-graph (cluster). On the other hand, centre of 
attention of Cut-Off is the number (or the summation of the weight) of removed edges from 
the original graph. We combine the two criteria and the Standard Deviation (STD) for 
evaluating the graph clustering and selecting the best clustering from the alternatives. 
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4) How can we select the functional groups (biomarkers) of breast cancer? 
The breast cancer biomarkers are the groups of genes (clusters) that are present in any 
breast cancer dataset but are absent in healthy datasets. To select such groups we designed 
a two-step filter called Bi-Biological filter. In the first step, the filter divides the cancer 
samples randomly into two subsets in order to find the shared groups between them. This is 
to filter out neither cancer nor healthy groups and to keep only the breast cancer and 
healthy groups. In the second step, we compared the shared groups with groups in the 
healthy dataset to filter out the healthy groups from the shared groups.  
5) How can we validate the biological relations between the genes in the same group? 
The Database for Annotation, Visualization and Integrated Discovery (DAVID) (Dennis et al., 
2003) is used to check whether there are any Biological Processes (BP) related to the genes 
in each cluster. 
6) Is the number of remaining genes suitable for classification? 
If the number of genes was still large compared with the number of samples we then 
selected a subset of genes from the breast cancer biomarkers (clusters) for classification. To 
do that we used Best First Search (BFS) and SVM with k-fold out cross validation.  
7) How we can validate the diagnostic accuracy of the selected genes? 
ANN with 5-fold out cross validation, SVM and KNN with Leave One Out Cross Validation 
(LOOCV) were used to classify the samples into healthy and cancer cases and the accuracy, 
sensitivity and specificity measures were used to evaluate the results of different classifiers. 
From the second specific objective, we expect the outcome to be a significant enhancement 
in the accuracy of CAD system based on blood based gene expression profiling and a group 
of genes that can be considered as mRNA biomarkers in the blood of breast cancer patients.  
In low income countries, such as Jordan, the frequency of death by cancer is much higher 
than in developed countries.  About 70% of the total cancer deaths occur in the low to 
middle income countries (Al-Tarawneh, Khatib, & Arqub, 2010). Breast cancer, which is 
considered to be the most common cancer in Jordanian women, amounts to about 32% of 
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the total cancer incidence among women (Al-Tarawneh, Khatib, & Arqub, 2010). Recently, an 
aberrant expression of miRNAs was found to contribute to carcinogenesis by promoting the 
expression of proto-oncogenes or by inhibiting the expression of tumour suppressor genes 
(Iorio et al., 2005). As mRNA, miRNA genes also work together to do biological functions 
(Guo, Sun, Jia, & Zhao, 2010; Volinia et al., 2010). There are few miRNA studies that analysed 
the miRNA GCN. Currently, the diagnostic accuracy of the circulating miRNA based BC-CAD is 
about 90% and needs further enhancement. This led us to the third specific objective of this 
study: 
The third specific objective is to undertake a case study on Jordanian women, to identify 
the breast cancer miRNA biomarkers in the serum using the proposed Bi-Biological filter, 
which in turn will be used to enhance the diagnostic accuracy of the miRNA based CAD 
systems.  
This objective is completed by using 56 samples that were especially collected for studying 
the miRNA biomarkers in the serum of Jordanian women. Also, the Bi-Biological filter and 
BFS and SVM with k-fold out cross validation were used for biomarker detection and gene 
selection for classification, while ANN, SVM and KNN were used for classification. Current 
study started with the following questions: 
1) How can we define the miRNA biomarkers in the serum of Jordanian women with 
breast cancer? 
Bi-biological filter can be used for analysing the miRNA dataset and finding the miRNA 
biomarkers for these patients. 
2)  How can we validate the biological relations between the genes in the same group? 
Because there is no oncology database for miRNAs, we started by finding the validated 
target mRNA for each miRNA gene in the group. Next, DAVID (Dennis, et al., 2003) was used 
to check if there were any Biological Processes (BP) related to the mRNA genes of the same 
cluster. Also, we investigated each miRNA gene in the selected groups to find out if there 
had been a previously identified relation with breast cancer or any other cancer. 
3) How can we enhance the diagnostic accuracy of BC-CAD systems that use miRNA 
extracted from the serum? 
 12 
We used the genes that were selected by Bi-biological filter as potential input into the CAD 
system. Then, we used BFS and SVM with k-fold out cross validation to select a subset of 
genes for classification. Also, ANN, SVM, LDA and KNN with 5-fold out cross validation were 
used to classify the samples into healthy and cancerous cases,  while the accuracy, based on 
sensitivity and specificity measures, was used to evaluate the results of different classifiers. 
From the third specific objective, we expect the outcome to be a significant enhancement in 
the accuracy of circulating miRNA based CAD system and a group of miRNA genes as breast 
cancer biomarkers in the serum of Jordanian women.  
This thesis is expected to shed some light on the understanding of breast cancer CAD 
systems in terms of identifying the structure of BC-CADs, their input data and the 
relationship between the input data and the accuracy of BC-CADs. The work is based on the 
analysis of ultrasound, mRNA gene expression and miRNA gene expression data. The 
theoretical framework and results of the analysis are presented, and future directions for 
research are highlighted in this thesis. 
1.5 Overview of thesis Chapters.   
This thesis comprises six chapters. 
 
Chapter 1: introduction 
This provides an introduction to breast cancer, breast cancer diagnostic methods, breast 
cancer CADs and the objectives of the study. 
Chapter 2: background and literature review  
In this chapter we address three relevant questions: (1) what is the current situation of 
breast cancer? (2) What are the current diagnostic methods that are used for building CAD 
system for breast cancer diagnosis? (3)What are the current approaches that have been 
used to build breast cancer CAD systems? 
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Chapter 3: Ultrasound Based Computer Aided Diagnosis system: Evaluation of a new 
feature of mass central regularity degree. 
The third chapter is to address the first specific objective of the thesis, the identification of a 
new mass feature, related to the mass shape in ultrasound image. This feature reflects the 
degree of regularity of the middle part of the mass (core) and is called Central Regularity 
Degree (CRD). To demonstrate the effect of CRD on differentiating malignant from benign 
masses and the potential improvement in the diagnostic accuracy of breast cancer using  
ultrasound, the chapter evaluates the diagnostic accuracy of different classifiers when, CRD 
was added to five powerful mass features. 
Chapter 4: Gene expression based Computer Aided diagnosis system for Breast Cancer: A 
novel biological filter for biomarker detection. 
This chapter serves the second specific objective. We define a novel method to detect the 
mRNA gene biomarkers in the blood of breast cancer patients. The focus of this method is to 
divide the genes into functional groups and select the groups of genes that are present in 
cancer samples but are absent in healthy ones. A subset of genes was selected from the 
selected biomarkers for classification. Then the blood based mRNA CAD was built using only 
the selected subset of genes. Three different classifiers evaluated the diagnostic accuracies 
of the set of selected genes and the accuracies of the classifiers are compared with a 
previous study (Aaroe, et al., 2010).  
Chapter 5: Circulating miRNA gene expression in the serum for breast cancer biomarker 
detection and classification for Jordanian women. 
The fifth chapter serves the third specific objective. We investigate miRNA biomarkers in the 
serum of Jordanian women using the same methodology as in chapter four. A subset of 
genes is then selected from the selected biomarkers for classification. These miRNA 
biomarkers are used for building a BC-CAD system. Three different classifiers evaluate the 
diagnostic accuracies of the set of selected genes while the accuracies of the classifiers are 
compared with previous studies (Hu et al., 2012; Schrauder et al., 2012). 
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Chapter 6: Conclusion and Future Works. 
The sixth chapter presents a retrospective look at the findings of this work, the contributions 
and the potential lines of future investigations.   
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Chapter 2 
Background and Literature Review 
This research falls within of the field of biological informatics, and integrates several other 
disciplines including clinical, genomics and informatics. Therefore, the purpose of this 
chapter is to provide an overview of the relevant background information of the related 
fields. Sections, 2.1 and 2.2 start with an extensive review of the breast anatomy and breast 
cancer. Since this research focuses on early detection of breast cancer using both clinical and 
biological testing, section 2.3 discusses, in detail, the clinical and biological tests that are 
designed for detecting breast cancer. A deep understanding of the breast ultrasound is 
offered from the findings of a breast ultrasound image in section 2.4. The biology of breast 
cancer has been reviewed extensively, under microarray technology, in order to identify the 
relevant genes and gain an insight into the underlying biological processes. Therefore, 
section 2.5 provides a detailed review of the analysis and processing of microarray data. For 
early detection of breast cancer, the extracted features from clinical datasets and extracted 
gene sets from microarrays are increasingly being used with data mining and graph theory 
methods for building Computer Aided Diagnostic (CAD) systems. Therefore, previous breast 
cancer CADs and the general structure of BC-CADs as well as clustering and classification 
techniques and graph theory are reviewed in section 2.6. 
2.1 Breast Anatomy 
In order to understand the basics of breast cancer, knowledge of the anatomy of breast and 
the cell cycle is helpful. Although the breast is present in both males and the females, in this 
section, we will focus only on the female breast. The female breasts are the part of the body 
that produces milk for the infant. The development of the breast begins between the ages of 
8-13 years, when the hormone, oestrogen, activates the deposition of fat, giving it the shape 
and stimulates the growth of ducts in the next 3-5 years. This phase which is considered as a 
sign of puberty may even take more than 8 years in some cases.  The second stage of breast 
development starts when the progesterone hormone is produced by ovaries. The 
progesterone stimulates the growth of the milk glands found at the ends of the ducts, but it 
does not have much effect on the breast size. The full development of the breast is achieved 
during pregnancy, when the internal parts of the breast start producing milk. 
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The anatomy of the female breast is complex; it is composed of two main components, the 
external and the internal (Cooper, 2005c) (Figure 2.1). The external component of the breast 
contains the following parts:   
1. Nipple: it is an important part of the breast that carries the milk from breast to the 
infant’s mouth and contains 15-20 milk ports connected directly with milk channels 
(Harold, 2006). The shape and size of the nipple varies from one female to another and 
may take different shapes during the female’s life. Recently, the nipple has been used to 
access the internal components of the breast in order to diagnose several breast 
diseases (Harold, 2006).     
2. Areola: is a breast part that surrounds the nipple and appears in a darker colour and 
varies in darkness from one female to another.  Also it appears in an oval or round shape 
and has different sizes. The areola contains Montgomery’s glands that appear as pumps 
under the areola skin and are responsible for lubricating the nipple (Cooper, 2005a). 
 
Figure ‎2.1. Internal and external part of the breast 
Retrieved from: http://www.healthlibrary.com/reading_room.php?action=view&id=86&cid=1025 
The internal parts of the breast are responsible for producing and transferring milk. Gray, 
Williams, & Bannister (1995) described the female breast as a group of fibres that make up 
glandular and adipose tissues. 
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 The main internal parts of the breast starting from the nipple down to the chest wall are: 
1. Lactiferous ducts: these are thin channels that carry milk to the nipple.  Also known as 
mammary ducts, their number varies between 15 and 20 from one female to another 
(Cooper, 2005b; Harold, 2006).  
2. Lactiferous sinus: under the Areola the lactiferous ducts balloon and become greater in 
size to form the lactiferous sinus. It is a milk store that stores the produced milk until 
being used and is relatively large compared to lactiferous ducts. In some animals, for 
example cows, the sinuses store large amounts of milk, several litres. Although not as 
large as in cows, human breast too can store a considerable amount of milk (Cooper, 
2005b). 
3. Gland lobules: this part of the breast is responsible for producing milk during the 
lactation period (Marieb. & Hoehn, 2006). 
4. Fat: This is the part that softens the breast and makes it more comfortable. The fatty 
tissues are spread between most parts in a breast. The amount of fat varies between one 
female to another, which accounts for the difference between the size of the breasts 
(Nickell & Skelton, 2005). This means that there is no relation between the size of the 
breast and the amount of milk that is produced by the breast. The amount of milk 
produced is determined by the amount of glandular tissues, rather than the size or the 
fat content of the breast. Therefore a small breast with a large amount of glandular 
tissues produces more milk than a large breast with a small amount of glandular tissues 
(Ramsay, Kent, Hartmann, & Hartmann, 2005). 
5. Cooper’s ligaments: this is a breast framework that supports the internal parts of a 
breast and helps maintain the structural integrity of the breasts. The amount of the 
Cooper’s ligaments determines the firmness of the breast; the breast with a large 
amount of copper’s ligaments is firmer than the one with small amounts. The strength of 
Cooper’s ligaments is affected by the age where the ligaments become more relaxed 
which leads to sagging of the breast (Lauwers & Swisher, 2010).  
6. Auxiliary lymph nodes: the lymph nodes make a complex network that is spread through 
the breast. The lymph network carries the lymph, which is a mix of water, blood and 
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white blood cells, that is responsible for fighting the bacteria and stopping the spread of 
infections (Lauwers & Swisher, 2010). 
The above description of the breast indicates that all of the breast components, internal and 
external, work together to produce milk which is the most important nutrient source for the 
infant. Surprisingly, the breasts can also become a life threat to the mother, due to the 
development of cancer. 
2.2 Breast Cancer 
Cancer, heart attacks and strokes are the most deadly diseases in the world. Both strokes 
and heart attacks are aging diseases, with low probability of occurrence in children. On the 
other hand, cancer seeks no age or gender bound, when it attacks. Thus, it has been 
considered a curse which could take lives of affected people at the most unexpected 
moments.  
The etiology of cancer is still an area extensively subjected to medical research. Incidence of 
cancer is characterised by an uncontrolled cell division and cell mortality rates, which occur 
due to a genetic problem in the DNA of the body cells (American Cancer Society, 2012; Lam, 
2003). Therefore, cancer is different from the diseases caused by viral and bacterial 
infections. In general, cancer is named after the tissue or the organ of the body which is 
affected by it, such as blood, colon, prostrate, skin, lung, lymphoma and breast cancer. 
The normal or healthy cells divide and die in an orderly manner to keep the regular functions 
of the body working, in contrast to the characteristic, uncontrolled cell division 
(proliferation) and cell death (apoptosis) of the cancer cells. Under  normal circumstances, 
cell division is the process by which the cell is duplicated and marks its  final phase in the life 
cycle, which is divided into four phases, G1, S, G2 and M, (Figure 2.2) (Alberts et al., 2008). 
There are several genes, enzymes and proteins involved in this process and each one of 
these is responsible for a specific biological role that is essential for producing identical 
copies of the parent cell. On the other hand, a cancer cell is a result of a series of mutations 
caused by damage or a change to the genetic material (DNA) of the cell over time, which 
leads to the uncontrolled cell division and the accumulation of mutated cells to form a mass.   
Several studies had been made on breast cancer cell proliferation in order to reveal the 
mutated pathway that leads to develop a cancer cell which might help diagnose the cancer 
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in its early stages of growth or to develop an effective treatment (Amin, Kumar, Nilchi, 
Wright, & Kozlowski, 2011; Beresford, Wilson, & Makris, 2006; Chen, Hardy, & Mendelson, 
2011; Pattarozzi et al., 2008; Pike, Spicer, Dahmoush, & Press, 1993; Urruticoechea, Smith, & 
Dowsett, 2005). Apoptosis or programmed cell death is a normal biological process that is 
responsible for removing most unwanted cells (Elmore, 2007), however, insufficient 
apoptosis results in cancer. A healthy body maintains a balance between cell proliferation 
and apoptosis so that cells are produced only when the body needs new cells and cell death 
occurs when it is no longer needed by the body. A disruption in the balance between these 
two processes causes defective apoptosis leading to cancer (Dowsett et al., 1999). 
Therefore, the mutations responsible for causing insufficient apoptosis in cancer patients, 
has been of great interest in medical research, (Gasco, Shami, & Crook, 2002; Ghavami et al., 
2009; Lacroix, Toillon, & Leclercq, 2006; Lipponen, 1999; Lowe & Lin, 2000; Parton, Dowsett, 
& Smith, 2001; Suzuki & Matsubara, 2011; Yang, Steinberg, Nguyen, & Swain, 2011).   
To complete the proliferation process cells needs energy, where the main source of cell 
energy is through mitochondrial oxidative phosphorylation, which is a process that produces 
ATP which is considered as energy currency of the cell (Mazurek, Grimm, Boschek, Vaupel, & 
Eigenbrodt. 2002). The cancer cells, which are highly proliferative, need more energy to 
survive. Early studies have shown that there is a difference in the mechanism of producing 
energy in cancer cells from that of healthy cells. Healthy cells produce energy by an oxidative 
phosphorylation process in the presence of Oxygen and by anaerobic glycolysis in the 
absence of oxygen. On the other hand, cancer cells, with their high demand of energy for 
accelerated cell proliferation, depend on aerobic glycolysis in the presence and absence of 
Oxygen, a fundamental cause of cancer due to the change in cell metabolism which is known 
as ‘Warburg Effect’ (Mazurek, et al., 2002; Vander Heiden, Cantley, & Thompson, 2009). 
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Figure ‎2.2. The four phases of cell Life cycle 
Retrieved from: http://www.newearthbiomed.org/145/chemo-article 
2.2.1 Breast Cancer Symptoms 
During the early stages of cancer, noticeable changes of a patient’s breast or health are 
absent when the number of cancer cells is still small. In most patients, the first sign is the 
presence of a lump inside the breast tissues, which could be either tangible, can be felt by 
hand, or intangible, seen by breast imaging methods. In both instances the number of cancer 
cells present may exceed millions (Lam, 2003). 
 Following changes in the breast have been identified as possible signs of breast cancer 
(Osteen, 2001): 
1. Thickening or swelling of part of the breast. 
2. Irritation of breast skin. 
3. Redness or flaky skin in the nipple area or the breast. 
4. Pulling in of the nipple or pain in the nipple area. 
5. Nipple discharge. 
6. Any change in the breast size or shape. 
7. Pain in any area of the breast. 
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All these signs are shared with different other breast diseases too, but it is highly 
recommended for women with one of the above signs to consult her doctor.  
2.2.2 Breast Cancer Risk Factors. 
It is important to know the cause of the disease in order to prevent the spread, understand 
the disease mechanism and find effective treatments. Although there had been no evidence 
for a specific cause(s) for breast cancer, many risk factors related to breast cancer have been 
identified (American Cancer Society, 2009;  Singletary, 2002) and include:   
1- Age: this is the most important factor related to breast cancer. The chance of developing 
breast cancer is found directly proportional to the age of women, which implies that the 
risk of developing breast cancer increases with age. Figure 2.3 shows that the incidence 
of breast cancer is quite low in women less than 30 years old (440 per 100,000 cases). On 
the other hand, the chance of developing breast cancer increases linearly until the age of 
70 years. (at 70 years, the incidence is 3730 per 100,000 cases) (American Cancer 
Society, 2009; Singletary, 2002).  
 
Figure ‎2.3. Breast cancer incidents per 100,000 as a function of age. Adapted from The 
American Cancer Society: Breast Cancer Facts and Figures, 2009 p.9  
2- Family history:  the risk of developing breast cancer increases in women with a breast 
cancer family history; especially, if the relative is from the first degree such as, the 
mother and sisters. Family history is a genetic issue where the mutated genes that 
increase the risk of breast cancer, such as BRCA1 and BRCA2, might be inherited from 
the parents (Singletary, 2002).  
3- Body Mass Index (BMI): the risk of developing breast cancer in fat women (BMI > 27 
kg/m2) is higher than in normal and slim women (Chow et al., 2005).  
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4- Previous diagnosis of breast cancer: women who were previously diagnosed with 
breast cancer have a higher chance of redeveloping breast cancer than those with no 
breast cancer history. 
5- Smoking and alcohol consumption:  prolonged cigarette smoking habit in women is 
more likely to aid the develop breast cancer than in non-smoking women (Terry & 
Rohan, 2002). Also, it has been found that the risk of developing breast cancer 
increases with the increased number of drinks consumed per day (Sinletary, 2002). 
6- Reproductive factors: the risk of breast cancer is low in women who began 
menstruating after 15 years old or reached menopause before 45 years old 
compared to those who began menstruating before 12 years old and reached 
menopause after 55 years old.  Furthermore, the women who had their first full-
pregnancy after the age of 30, as well as those who did not complete full 
breastfeeding are more likely to develop breast cancer (Singletary, 2002). 
2.2.3 Breast Cancer Types 
There are several types of breast cancer which are classified based on the location of cancer 
cells in the breast tissues. The most common types of breast cancer are summarised below 
(National Breast Cancer Foundation, 2012): 
1. Ductal Carcinoma In-Situ (DCIS): this is a non-invasive breast cancer that starts in the 
epithelial cells inside the duct and the word ‘in situ’ means that the cancer cells do not 
affect the surrounding tissues. In the last century, especially, until the 80’s, the diagnosis 
of DCIS was not easy and a less than 10% of cancer cases was diagnosed as a DCIS. 
Recently, as a result of the evolution of breast cancer diagnostic methods, about 25% of 
cancer cases have been diagnosed as DCIS. The survival time of a patient with this type is 
up to 30 years (Virnig, Shamliyan, Tuttle, Kane, & Wil, 2009). 
2. Invasive Ductal Carcinoma (IDC): this is also known as Infiltrating Ductal Carcinoma. 
Invasive means that the cancer can spread outside of the duct and affect the surrounding 
breast tissue. It is the most common type of breast cancer, and amounts to about 65%-
80% of the cases diagnosed with cancer (IDC). The survival time of a patient with IDC 
depends on the time of diagnosis (Hardman., 2010). 
3. Lobular Carcinoma In Situ (LCIS): this is a non-invasive carcinoma that starts in the lobular 
cell. It is the second most common, non-invasive type, after DCIS. Similar to DCIS, the 
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survival rate of patients with LCIS is high while most women can be cured completely. 
However, there is an increasing risk for a patient diagnosed with this kind of carcinoma 
to develop IDC or Invasive Lobular Carcinoma (ILC) (Hardman, 2010). 
4. Invasive Lobular Carcinoma (ILC): this is an invasive carcinoma which starts in the lobular 
cell and spreads into the surrounding tissue. It is the second most common types of 
invasive carcinoma after IDC, where about 8% of the cases are diagnosed as invasive.  
There are other less common types of breast cancer that form in total, less than 10% of 
breast cancer cases, and there include Mucinous carcinoma, mixed tumours, Medullary 
carcinoma, Inflammatory breast cancer, Triple-negative breast cancer, Paget's disease of the 
nipple and Adenoid cystic carcinoma (National Breast Cancer Foundation, 2012).  
2.2.4 Breast Cancer Stages. 
The stage of the breast cancer is determined based on the Tumour-Node-Metastasis (TNM) 
system, which was developed in 1942 by Pierre Denoix (Singletary & Connolly, 2006). The 
TNM system describes the breast cancer using three features: the first one is tumour size (T) 
of which, the values range from T0 to T4, based on the size of the primary tumour (Table 
2.1a). The second feature reflects the regional lymph nodes involvement (N); the values of 
this feature range from N0 to N3 (Table 2.1b). Finally, the metastasis of the cancer (M) which 
shows the values of M0 or M1 (Table 2.1c) (Rice, Blackstone & Rusch, 2010; Singletary & 
Connolly, 2006).  
According to the TNM system breast cancer is classified into five stages, starting from stage 
0, the early stage with no evidence of cancer, to stage 4, metastases carcinoma (Rice et al., 
2010). To clarify the stages and to make the selection process easy, we introduce a decision 
tree as shown in Figure 2.4. This figure shows the stages of the breast cancer as leaf nodes. 
The triangles in the figure represent conditions that take only two possible states which are 
represented on the edges of the tree. Following the edges that carry the case descriptions 
leads to the case stage. Results from a five year study on the relationship between survival 
rate of breast cancer patients and the stage of diagnosis shows the patients survival rates in 
stage I as 92%, stage II A and B as 82% and 65% respectively, stage III A and B as 47% and 
42% respectively, and stage IV as 14% (Marc , 2005). According to this, the survival rate of 
breast cancer patients is strongly related to the stage in which the cancer is diagnosed. 
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Table ‎2.1.  Description of Tumour-Node-Metastasis (TNM) values A) Tumour size (T) B) 
Regional lymph node (N)  and C) Distant metastasis (M). ( Adapted from Rice, et al., 2010) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C 
Mx Cannot be assessed 
M0 No metastasis 
M1 Distant metastasis 
 
 
 
Figure ‎2.4. Decision tree for stages of breast cancer based on Tumour-Node-Metastasis 
(TNM). T, tumor size; M, distant metastasis; N, Regional lymph node  
2.2.5 Breast Cancer Treatments 
There are several techniques used in breast cancer treatment such as, surgery, 
chemotherapy, radiation and target therapy (Table 2.2). Selecting the appropriate method(s) 
depends on many conditions as each method has different uses and side effects. In most 
B 
NX cannot be assessed 
N0 No metastases 
N1 Metastases to movable ipsilateral level I, II 
axillary lymph node(s). 
 N1mi: Micrometastases≤ 2mm 
N2 N2a: Metastases in ipsilateral level I, II axillary 
lymph nodes (fixed or matted).  
N2b: in clinically detected ipsilateral internal 
mammary nodes in the absence of clinically 
evident axillary lymph node metastases 
N3 N3a: Metastases in ipsilateral infraclavicular 
lymph node(s); N3b: Metastases in ipsilateral 
internal mammary lymph node(s) and axillary 
lymph node(s)  
N3c: Metastases in ipsilateral supraclavicular 
lymph node(s)  
 
C 
Mx Cannot be assessed 
M0 No metastasis 
M1 Distant metastasis 
 
A 
Tx Cannot assess the tumour 
 T0 No tumour 
Tis Non-invasive carcinoma 
T1 T1≤ 20 mm (T1mi ≤1mm, 1mm<T1a 
≤5mm, 5mm<T1b ≤10mm,10mm<T1c 
≤20mm) 
 
 
 
  
 
 
 Tumor ≤ 20 mm  
 
 
 Tumor ≤ 20 mm  
 
T2  Size >20mm and <50mm 
T3 Tumour > 50 mm  
 T4  Any size with direct extension to the 
chest wall or skin or inflammatory 
carcinoma 
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cases, breast cancer is treated using more than one method depending on the case 
(American Cancer Society, 2012). 
Table ‎2.2. The most common treatments used for breast cancer, their uses and side 
effects. (Adapted from: American Cancer Society, 2012) 
  Method  Uses  Possible Risks and Side effects 
Surgery  Preventive surgery: prevents 
breast cancer by removing 
whole breast.  
 Staging surgery: to determine 
the stage of breast cancer. 
 Curative surgery: removes 
only the cancer cells directly 
after the cancer is located. 
 Debulking surgery: remove 
part, but not the entire 
tumour. 
 Supportive surgery: done with 
other cancer treatments. 
During surgery : 
 Bleeding. 
 Damage to internal organs. 
 Reactions to drugs used.  
 Problems with other organs. 
After surgery: 
 Pain  
 Infection 
Chemotherapy  
 Completely treats the cancer. 
 Controls or stops the growth 
and spread of cancer cell 
 Relieves symptoms of cancer 
in advanced stage. 
 Damage to blood cells. 
 Damage to hair cells. 
 Damage to cells that line the 
digestive tract. 
 Damage to cells that line the 
reproductive system. 
Long-term side effects: 
 Organ damage  
 Development delay in child  
Radiation 
Therapy 
 Cures cancer in early stage. 
 Stops spreading of cancer 
cells 
 Supports other treatments 
 Fatigue 
 Skin changes: redness, 
ticking, dryness and peeling. 
 Losing hair over the treated 
area. 
 Inflammation inside the 
mouth and sometimes loss of 
taste. 
 Teeth problems  
Targeted 
Therapy 
 
 Targets certain parts of the 
cellular changes in cancer 
cells that are needed for 
cancer cells to keep growing 
and spreading. 
 Enzyme inhibitors: target 
specific enzymes that are 
related to cell growing and 
spreading. 
The side effects of target therapy 
depend on the person and the 
type of target therapy: 
 Skin problems: itchy, redness, 
hand-foot syndrome, dry skin 
and rash. 
 High blood pressure. 
 Bleeding. 
 Clotting 
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 Apoptosis-inducing drugs: 
target the proteins that are 
strongly related to cell death.  
 Angiogenesis inhibitors: 
target the process of creating 
new blood vessels that are 
needed to supply the tumour 
with blood. 
 Problems with wound 
healing.    
Other methods  Immunotherapy: targets the body’s immune system to kill cancer 
cells. 
 Laser: uses a light beam to heat and kill cancer cells.   
 Hormonal Treatment: stops producing the hormones needed for 
cancer cell division.  
2.3 Breast Cancer  Diagnostic Methods. 
Early detection, followed by treatments reduces the risk of death from breast cancer. 
Therefore, it is recommended that all women do regular breast examinations. There are 
several methods for early detection of breast cancer such as, digital mammography, 
ultrasound, Nipple Aspirate Fluid, biopsy, self-examination, and Genetic Testing. This section 
briefly describes each type.    
2.3.1 Digital Mammography. 
Digital Mammography is a low dose x-ray test, designed to find normal changes in the 
breasts (Arfelli, 1998). It plays an important role in the early detection of breast cancer, 
especially, in women with a history of breast cancer and women over 40 years old (Saslow, 
et al., 2004). There are two main reasons for doing mammography; screening and diagnostic. 
The screening is applied to women or men who have no breast cancer signs, while the 
diagnostic is customised to diagnose previously observed signs by the radiologist from 
specific symptoms of the patient (Dee & Sickles, 2001).  
Mammograms are checked carefully by radiologists to make an accurate decision. The 
process is started by searching for a region(s) or mass that appears different from other 
regions of the same and the opposite breast. If the radiologist finds such a region then s/he 
determines whether the region or mass has a ‘normal’ appearance or not. If the abnormality 
cannot be differentiated with certainty from ‘normal’, it is classified as ‘Suspicious’ and will 
need further investigation. ‘Suspicious’ areas generally fall within Asymmetric density, 
Architectural distortion and Calcifications (VizcaÃ-no et al., 2001). Masses in general have 
different shapes, sizes, and margin characteristics. Similarly, calcifications can be 
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characterised by their size, number, morphology, distribution, and heterogeneity. From 
these differences, the radiologist can classify mammograms as benign or possibly malignant 
(McGill university, 2007). 
2.3.2 Ultrasound. 
Ultrasound is an imaging tool in medicine that has been used for nearly 60 years (National 
Council on Radiation Protection and Measurements, 2002). It is a common diagnostic 
medical procedure that uses inaudible sound pressure with a high frequency. The sound 
waves break through a medium and then echo signals are recorded and transformed into a 
video or photographic image. (Novelline, 1997b) 
There are four types of ultrasound: the first one gives a simple view with a plotted series of 
peaks and is called A-mode. The second one is Brightness-modulated display 
Ultrasonography, or B-mode, and this type provides real-time 2-D evaluation, which is 
applied in a wide range of applications such as imaging of liver, kidney, breast, etc. 
Ultrasonography that merges real-time B-mode with pulsed Doppler signals to reflect 
motion within a tissue is called Duplex. The last one is M-mode (motion display modality) 
and in this type, the echo is recorded on a moving paper strip (McGrow Hill 2002).  
Unlike mammography, ultrasound can deal with dense breast tissues. So it is highly 
recommended for women with dense breast tissues or women under 40 to have an 
ultrasound examination (Lee et al., 2008). Ultrasound is processed carefully to differentiate 
solid masses from fluid-filled cysts. The radiologist extracts a number of mass features from 
ultrasound images such as, Shape, Margin, Orientation, Lesion boundary, Echogenic pattern, 
Posterior acoustic features, Effect on surrounding parenchyma, Calcifications and 
Vascularity, which are used to differentiate benign masses from malignant ones. 
2.3.3 Nipple Aspirate Fluid (NAF) Analysis. 
This is a non-surgical technique where the fluid collected from the breast is checked under 
the microscope for irregularity (Krishnamurthy, Sneige, Ordóñez, Hunt, & Kuerer, 2002).  
2.3.4 Breast biopsy. 
Breast biopsy is a surgical technique where the breast is opened and a biopsy is taken from 
the tissue and checked by a pathologist. The final decision regarding the presence or 
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absence of breast cancer is usually done after this examination (Lourenco, Mainiero, Lazarus, 
Giri, & Schepps, 2007). 
2.3.5 Other Diagnostic Methods.  
 Genetic Test: This test is designed to study the mutations of BRCA1 and BRCA2 genes 
for patients with a strong history of breast or ovarian cancer (Ottini et al., 2000). 
 Breast Self-Exam: Here, the individual is asked to self-examine the breast for changes 
in texture, appearance, weight and volume.  
2.4 Ultrasound Findings.  
From the ultrasound image, the radiologist can extract the following features (Figure 2.5): 
1. Shape: Mass takes different shapes; some shapes are suggestive of benign such as 
round, oval and fewer than three lobulations. On the other hand, more than three 
lobulations and irregular shapes are suggestive of malignancy (Glazebrook, Morton, & 
Reynolds, 2005; Popli, 2002; Rahbar et al., 1999). 
2- Margin: This is the mass edge or transition between mass and neighbouring normal 
tissues.  It can be circumscribed or well-defined in most benign cases. Microlobulated 
margin is suggestive of benign if no more than 3 smooth margins are found and ill-
defined margins or speculated are suspicious of malignancy (Glazebrook, et al., 2005; 
Popli., 2002; Rahbar, et al., 1999). 
3- Orientation: A comparison between the skin line and the longest axis of the lesion or, 
the width and the depth of the lesion. This comparison comes in two different types, in 
first of which, the longest axis is parallel to the skin line, and this type suggests that the 
lesion is wider than its depth. The horizontal growth of lesions, such as fibroadenomas, 
partially give the lesion an oval shape and suggestive to be benign. On the other hand, in 
the second type, the lesion is deeper than its width, hence the longest axis of lesion is 
not parallel to the skin line and suggestive to be malignant (Figure 2.5D). (Madjar & 
Mendelson, 2008; Popli, 2002; Rahbar, et al., 1999). 
4- Echo pattern: The lesions are divided into four types. The first one is anechoic lesions, 
and has no internal echo (Figure 2.5C). This type of lesion is a benign cyst. The second 
one is hypoechoic lesions and has low level echoes throughout the lesion and is probably 
malignant.  The third type is hyperechoic lesions with increased echogenicity (ability to 
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return the signals of the sound) compared to their surrounding fat, are probably benign. 
The last type is isoechoic lesions with similar echogenicity compared to the fat 
echogenicity are probably benign (Popli, 2002; Rahbar, et al., 1999). 
5. Duct Extension: Malignant breast lump occasionally has projections from the surface of 
the lump that extend into a duct (Popli, 2002; Rahbar, et al., 1999) (figure 2.5B). 
6. Shadowing: Shadow behind the mass, usually caused by malignant lesion (Popli, 2002; 
Rahbar et al., 1999) (Figure 2.5E). 
7. Calcifications: Calcification is the presence of calcium inside the breast tissues. There are 
two types of calcification: the first one is macrocalcification, where the size of calcium 
mass is big and probably benign. The second one is microcalcification, where the size of 
calcium is very small, less than 0.5 mm, and this type is probably malignant and requires 
checking for microcalcification morphology and distribution (Panda, Panigrahi, & Patro., 
2009). The morphology of calcifications is the most important feature used to 
differentiate benign masses from malignant masses. Breast Imaging-Reporting and Data 
System (BI-RADS) lexicon classifies calcification morphologies into three categories. The 
first one is typically benign such as, Coarse or pop-corn like, Rod-shaped, Round and Milk 
or Calcium. The second one is of intermediate-concern such as, Indistinct. The third one 
has a higher probability of malignancy such as pleomorphic or heterogeneous and Fine 
needle (Figure 2.5A), linear or branching (Obenauer, Hermann, & Grabbe, 2005). 
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Figure ‎2.5. The ultrasound findings: A) Fine needle calcification. B) Duct extension. C) 
Anechoic lesions, round shape and clear margin. D)  Orientation of the mass. E)  Shadow 
under the mass and F) Ill-defined margin  
(Retrieved from: http://www.ultrasound-images.com/breast.htm) 
2.5 Microarray Technology. 
Deoxyribonucleic Acid (DNA) is the life code that stores all of the information needed for the 
development of an organism and control of its functions. The DNA is located inside the 
nucleus of all cells in a form of double strands. To control the body function, the cells 
produce proteins. The part of the cell that codes the needed protein is the DNA. However, 
the DNA does not get synthesised directly into protein. There are two main steps involved in 
protein synthesis: transcription and translation. 
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Transcription is a process in which the parts of the DNA that code a specific protein are 
converted to Ribonucleic Acid (RNA) (Clancy. 2008). DNA is a double stranded linear polymer 
that contains four types of nucleotides; 1) Adenine (A). 2) Guanine (G). 3) Cytosine (C) and 4) 
Thymine (T). The hydrogen bonds between the nucleotides hold the two strands together by 
base pairing A and T or G and C. On the other hand, RNA is a single strand linear polymer and 
also contains four types of nucleotides; three of these nucleotides (A, G and C) are present in 
DNA and RNA; and the fourth one is Uracil (U) instead of Thymine. Moreover, RNA 
nucleotides contain sugar ribose, not found in DNA, and that is why it is called Ribonucleic 
acid (Alberts et al., 2008).  
The process of transcription is initiated by determining the part of the DNA that codes the 
protein in need and opening the two strands in the detected part. Once the DNA strands are 
opened, one of the strands is used as the template for producing RNA, where the 
complimentary nucleotides of the DNA template strand are produced based on DNA 
sequence and connected to each other to form an RNA strand. The complementary 
nucleotide of A in DNA is U in RNA, which is the only difference between the complimentary 
pairs of DNA strands. Moreover, the nucleotides of RNA do not form hydrogen bonds with 
DNA nucleotides so that the RNA remains as a single strand. Subsequently, the RNA chain is 
released and the DNA strands are reconnected to each other (Clancy, 2008).  
Most of the DNA genes specify the sequence of amino acids of protein. Also, there are other 
types of DNA genes that code the sequence of enzymes and structural components. The 
RNA, which is copped from the genes that code the sequence of amino acids is called 
messenger RNA (mRNA). On the other hand, the RNA that is copped from the other genes in 
DNA is called non-coding RNA (ncRNA). RNA contains coding (exons) and non-coding 
(introns) parts. The percentage of mRNA to the total RNA is small, 3-5%, while most of the 
RNA is Ribosomal RNA (rRNA), which is the RNA component of the ribosome, and Transfer 
RNA (tRNA), which works as a physical link between the nucleotides sequence and amino 
acids sequence, making up 95% (Alberts et al., 2008).  
Recently, a new non-coded, short and single strand RNA has been discovered and is called 
MicroRNAs (miRNA). miRNAs are small non-coding RNAs that are cleaved from 70 to 100 
nucleotide hairpin pre-microRNA precursors in the cytoplasm by RNase III Dicer into their 
mature form of 19 to 25 nucleotides (Bartel, 2004). Single-stranded miRNAs bind mRNAs of 
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potentially hundreds of genes at the 3’ un-translated region, resulting in degradation or 
inhibition of the target mRNA. The miRNAs are involved in crucial biological processes, 
including apoptosis (Brennecke, Hipfner, Stark, Russell, & Cohen, 2003); haematopoietic 
differentiation (Chen, Li, Lodish, & Bartel, 2004), metabolism (Poy et al., 2004), skin 
morphogenesis (Yi et al., 2006) and neural development (Shankar et al., 2003) through 
imperfect pairing with target mRNAs of protein-coding genes and the transcriptional or post-
transcriptional regulation of their expressions. 
However, there is a difference between the number of words in nucleotide and amino acid 
languages, 4 and 20, respectively. Therefore, the direct (one-one) translation is impossible 
and there is a need for an mRNA-amino acid decoder. The decoder divides the mRNA 
nucleotides into sets of three nucleotides (codon), each set representing one amino acid. 
After that, tRNA matches amino acid to codon and a special machine, which is made from 
more than 50 different ribosomal proteins and several rRNAs, attach the suitable tRNA to its 
code in mRNA and bind the amino acids together to form a protein (Alberts et al., 2008). 
 A microarray is a 2D glass or silicon chip that holds a large amount of biological information. 
The evolution of microarray technology started by Southern blotting method (Southern, 
1975). Almost a decade later, different probes of DNAs were located on an array by spotting 
the DNA that synthesised from mRNA, complementary DNA (cDNA), onto filler paper 
(Kulesh, Clive, Zarlenga, & Greene, 1987). In 1995, a group of researchers  proposed the first 
miniaturised microarray for gene expression(Schenam et al., 1995).   
Cell samples required to design a microarray are obtained from two main sources, tissues 
and blood cells. Collecting tissue samples is not safe and such samples are not readily 
available, especially from healthy persons (Marteau et al., 2005). On the other hand, 
peripheral blood is readily available, easy to access and is a rich source of genetic 
information for studying human diseases. These properties make blood a perfect source of 
gene expression data (Fang et al., 2006).  
There are two types of microarrays: high density oligonucleotide microarray and cDNA 
microarray, which differ from each other in two ways (Figures 2.6 and 2.7). The first 
difference is in how a gene is represented. A gene in the oligonucleotide arrays is 
represented by a number of short, single stranded, and oligonucleotide probes. In contrast, 
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the cDNA arrays use longer chains with smaller number of representatives (Southern, 2001). 
The second difference is in the number of hybridised samples per array. While the spotted 
array is commonly used for representing two samples in cDNA (e.g. healthy and sick), the 
oligonucleotide array is used for representing only one sample (Millard & Tiwari, 2008) (e.g. 
healthy or sick). 
In this research, we used the oligonucleotide microarray and therefore, we will discuss   
oligonucleotide microarray design and analysis in the following section. 
 
Figure ‎2.6. The cDNA microarray showing two samples, experiment and control. After 
extracting the cDNA, the experiment sample is labeled with red fluorescent dye and the 
control is labeled with green fluorescent dye. Then, the samples are hybridised to the 
microarray. The output colours represent up (red) and down (green) regulated genes. 
Black represents genes with no change in expression 
Retrieved from:   
http://www.mun.ca/biology/scarr/cDNA_microarray_Assay_of_Gene_Expression.html 
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Figure ‎2.7. Illustration of U133A GeneChip, which is an oligonucleotide microarray that 
takes one sample per chip. 
Retrieved from: http://www.weizmann.ac.il/ 
2.5.1 Oligonucleotide Microarray. 
Affymetrix GeneChip (http://www.affymetrix.com/index.affx) and Applied Biosystems 
Human Genome Survey Microarray (http://www.appliedbiosystems.com.au/) are the two 
most well-known high density oligonucleotide gene expression arrays used. The main 
difference between the two platforms are the number and the length of probes where, the  
Applied Biosystems Human Genome Survey Microarray uses single long oligonucleotide to 
represent the genes, 60-mer oligonucleotide, and the Affymetrix GeneChip uses 11-20 short 
oligonucleotides, 25-mer oligonucleotides (Walker, Wang, Grant, Chan, & Hellmann, 2006). 
Each gene in Affymetrix GeneChip is represented by 11-20 different probe pairs and each 
pair contains two components: Perfect Match (PM), the sequence that matches a specific 
sequence in the gene and Mismatch (MM), identical copy of the perfect match except the 
middle nucleotide is mutated. MM is used for measuring the noise caused by non-specific 
binding (NSB). The gene expression level is calculated from the average difference between 
PM and MM. 
To design a microarray, RNA is extracted from a cell sample and converted to cDNA or cRNA 
(reverse transcription). Then, the cDNA or cRNA is amplified and labelled to obtain enough 
material for hybridization step. The hybridization step allows the base pairs of labelled cRNA 
strands to form complementary bonds with microarray probes. Forming such bond releases 
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energy and creates a spot in the heat sensitive image captured after hybridization.  The 
amount of released energy reflects the strength of bond and the number of the bonds in the 
double strand, and makes the difference between spots. After hybridization, the chip is 
washed to remove unbound material. The last step is microarray scanning and analysis using 
fluorescent microarray scanner and data analysis software (Applied Biosystems, 2006).  
The output data from the fluorescent microarray scanner is raw intensity data in the form of 
text or CEL files which need further processing. The next step is called data Normalization, 
where the systematic source of non-biological and technical variances are reduced by 
amalgamating the signals of corresponding probes in multiple arrays into a single expression 
measure (Lim, Wang, Lefebvre, & Califano, 2007). The Normalization step contains three 
main sub-steps: 
1. Background correction: this step is responsible for removing background noise from the 
intensity signal of the genes. 
2. Normalisation: this is to reduce the non-biological difference between arrays and make 
the distributions across array identical.   
3. Summarisation: this gives a single expression measure for each probe by combining the 
multiple probe intensities.  
Several methods have been developed for microarray normalization. The most 
commonly used methods are; MAS5.0 (Affymetrix, 2002), Robust Multichip Average 
(RMA) (Irizarry et al., 2005) and GeneChip Robust Multichip Average (GCRMA) (Wu & 
Irizarry, 2004). The data used in this study has been normalised by RMA by the 
developers of the original datasets.  
RMA method (Equation 2.1) starts with background correction, by subtracting the 
background intensity (BG) from the intensity of the Perfect Mach probes (PM). Then 
Quantile normalisation is used to normalise the intensities of the probes across arrays. 
Where, the quantile value of the distribution of probe intensities of each chip is 
computed and then transformed to a reference distribution quantile‘s value (Equation 
2.2). Finally, in the summarisation step RMA uses Median polish method to combine 
multiple probe intensity values to a single expression value. To do that, for each probe 
set, median polish method continues subtracting the median of the probe set for a gene 
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in an array from the normalised values of probes and then subtracting from these the 
median of the probes for the same gene across arrays. The method keeps running until 
the medians of all rows and columns become zeros. The final RMA gene expression 
measure is obtained by summing the median of the rows across all iterations.   
......1....1,)(log 2 JjandIileBGPM ijjiij    (2.1) 
where I,J, ile , j , ij   represent , the number of arrays, the number of probes in an 
array, the scale expression of array i, the affinity probe effect and independent 
identically distributed error with mean zero, respectively. 
))((1 xffX irefnorm
  (2.2) 
if  and reff  represent the distribution function of array i and the distribution function of 
the reference array, respectively. 
2.5.2 Microarray Applications 
In recent years and as a result of the emergence of microarray technology, which provides 
huge information about genes, the area of genetic research has become prosperous and 
sophisticated. Microarray technology has been used in different areas such as, studying 
genetic abnormalities in chromosomes, in which a part of chromosome(s) is added or 
deleted; this area is called Cytogenetic (Shaffer & Bejjani, 2004, 2009). Also microarrays have 
been used to study the sequence of specific genes and abnormalities related to single 
changes in DNA nucleotides, Single Nucleotide Polymorphism (SNPs), and in some cases  this 
change can cause diseases or health problems (LaFramboise, 2009). For example, 
Tyybäkinoja, Elonen, Vauhkonen, Saarela, & Knuutila ( 2008) used SNP microarray to study 
various molecular alterations of Acute Myeloid Leukemias (AMLs). The study revealed the 
relation between mutation in the Loss of Heterozygozity (LOH) location (8q24.13-q24.22) 
and genetic or epigenetic alterations of AML. Microarrays have also been used for 
elucidating gene regulatory circuitry, in which a cluster of genes impact the expression of 
each other through transcriptional factors or cis-regulatory elements in order to  perform a 
biological function (Chang, Wang, & Chen, 2007; Kim, Shay, O’Shea, & Regev, 2009). 
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In fact, it is not easy to follow and document all the applications of microarray technology 
because it is being used in various scientific areas (Figure 2.8) such as, Medical and clinical 
diagnosis (Eyster & Lindahl, 2001), Pharmacological industry (Debouck & Metcalf, 2000; 
Kumble, Kumble, & Gad, 2010) and toxicogenomics (Mei, Fuscoe, Lobenhofer, Guo, & 
Anegon, 2010). In this study the focus in on applications of microarrays in breast cancer 
research.   
 
Figure ‎2.8. The scientific areas that use microarray 
(Retrieved from: http://www.cbm.fvg.it/node/114) 
2.5.3 Microarrays and Cancer Research. 
Microarray technology is one of the most important scientific achievements in the last 
decades, where, it has introduced a refined way to study cellular processes. Cancer is a 
complex disease in nature because it makes complex cellular changes. Microarrays provide a 
comprehensive way to analyse cancer and identify what changes are produced within a cell. 
Through DNA microarrays, looking at the expressions of thousands of genes in one sample 
has become possible and this is called gene expression profiling. Gene expression profiling is 
important to capture a set of expressed genes that determine the cell phenotype. 
Recently, studies began in earnest to link diseases and genes by finding a biomarkers 
associated with a particular disease in order to facilitate the process of early diagnosis, that 
contributes to increased chances of cure and reduction in the cost of treatment. Several 
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studies have shown the efficacy of DNA microarrays in the field of disease prediction, 
diagnosis and prognosis, especially for cancers, such as breast cancer, prostate cancer and 
leukaemia (Bermudo et al., 2011; Dagliyan, Uney-Yuksektepe, Kavakli, & Turkay, 2011; Fan et 
al., 2010; Mills et al., 2009; Quackenbush, 2006; Simons et al., 2011) (Table 2.3). 
Table ‎2.3. A sample of applications of microarrays on different types of cancer and their 
findings 
Domain Cancer type  Finding  Author 
Identification of 
SNPs 
Breast 
cancer  
SNP has been identified in 5’ 
untranslated region of RAD51 
that increases the risk of breast 
cancer in the BRCA1 and BRCA2 
carriers.   
( Wang et al., 
2001) 
Ovarian 
cancer  
The study compared the 
accuracy of oligonucleotide 
microarray and DNA sequencing 
for detecting mutations in p53. 
The study found oligonucleotide 
microarray better than DNA 
sequencing method. 
(Wen et al., 2000) 
Diagnosis 
cancer  The study integrated 84 
microarray data related to 13 
cancer types and identified a list 
of 400 genes strongly related to 
cancer.     
(Dawany, 
Dampier, & 
Tozeren, 2011) 
Glioblastoma 
multiforme 
The study found YKL-40 level a 
good indicator for early 
detection of glioma. 
 
Ovarian 
cancer  
The study obtained 477 
differential expressed genes in 
high grade stage 1 ovarian 
cancer.  
(Chien et al., 
2009) 
Prostate 
cancer 
Six genes have been found to 
be significant genes for 
differentiating benign from 
malignant prostate lesions. 
These genes were used to 
classify the lesions and obtained 
92% overall accuracy.        
(Bermudo et al., 
2011) 
 Breast 
cancer 
By comparing the expression 
level of miRNA in healthy and 
breast cancer patients, the 
study identified 59 differentially 
expressed genes as biomarkers 
for early detection of breast 
cancer. The overall classification 
(Schrauder et al., 
2012) 
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accuracy was 85.2%.  
Prognosis 
Breast 
cancer 
The studies investigated the 
ability of DNA microarray in 
predicting breast cancer 
prognosis and concluded that 
DNA microarrays can be 
successfully used in breast 
cancer prognosis.  
(Fan et al., 2010) 
Breast 
cancer  
Seven pathways have been 
found to be strongly related to 
survival rates of breast cancer 
patients.   
(Miecznikowski, 
Wang, Liu, 
Sucheston, & 
Gold, 2010) 
Prostate 
cancer 
Studying the components of 
ncRNA, miRNA microarray has 
been considered a good source 
for predicting the outcomes of 
prostate cancer.  
(Martens-Uzunova 
et al., 2011) 
Treatment  Breast 
cancer  
The study compared the gene 
expression of different breast 
cancer subtypes and breast 
cancer with healthy samples in 
order to study the effect of 
Valproic acid (VPA) therapy on 
different types of breast cancer 
patients and selected the 
appropriate treatment regime. 
The study found the VPA had 
enriched sensitivity in the more 
aggressive breast cancer 
subtypes.    
(Cohen et al., 
2011) 
In summary, Microarray technology has become one of the most important tools that 
provides medical science with needed information to understand the molecular biology of 
cells. There are two types of microarray; cDNA and oligonucleotide. To design the 
microarray, cell samples are required. Also several steps are followed to produce a 
successful microarray; cDNA amplifying and labelling, hybridization, washing, scanning and 
analysing. Microarrays have been used in several domains; medical and clinical diagnosis, 
Cytogenetics, gene regulatory circuitry analysis and toxicogenomic. It has also been found 
that microarrays enrich cancer research and introduce a novel method for cancer diagnosis, 
prognosis and treatment.     
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2.6 Breast Cancer Computer Aided Diagnosis (BC-CAD) systems  
Accurate diagnosis is the first step in the march towards successful treatment for any pain or 
any abnormal body signs. Diagnosis is a deductive process so that a doctor links symptom (s) 
to a particular disease. But in many diseases, the symptoms may overlap, which increases 
the complexity of the search for key symptom(s) that differentiates a specific disease from 
other diseases and sometimes leading to wrong diagnosis. As a result of technological 
developments in the field of clinical and biological examinations, the data available from a 
patient too has become very large, which also increases the complexity of the diagnosis. For 
example, suppose that a doctor has 10 patients and each patient has a record of 10 tests and 
each test contains 5 results. In this case, it is difficult for the doctor to follow up analysis and 
make a correct decision. Hence, there is a need for diagnostic tools that aid doctors to make 
more accurate decisions and to reduce human errors as much as possible. To build such 
tools computer technology has been widely used in several medical fields. Using computer 
technology as diagnostic tools has becomes one of the active areas in Artificial Intelligence 
Systems under the title of Computer Aided Diagnosis (CAD) systems. 
 Due to the ability of data mining methods to predict and extract information from a 
relatively large amount of data, data mining has been vastly used for CAD system design. 
Machine Learning (ML) techniques, as a part of data mining, are one of the most frequently 
used techniques in building CAD systems, especially for classification and clustering 
(Gorunescu, 2007; Song et al., 2005).  
The complexity of breast cancer and the large amount of available data from examinations 
of breast cancer led to develop BC-CAD. There are two main types of input data that are 
used for building breast cancer CAD systems; clinical and biological data. The clinical data is 
divided into two main types; ultrasound data and mammography data. In this study we focus 
on Ultrasound data.  
Several breast cancer Computer Aided Diagnostic (CAD) systems have been built upon 
ultrasound to differentiate benign from malignant lesions. A computerised detection and 
classification algorithm (Drukker et al., 2004) has been reported for differentiating malignant 
from benign masses based on ultrasound images. The study used the sharpness of mass 
margin, Normalised Radial Gradient (NRG) along the margin, standard deviation of gray level 
value and gradient of lesion, posterior acoustic shadow and auto correlation depth (R) as 
 41 
inputs for a classifier. Artificial Neural Networks (ANN) and Receiver Operating Characteristic 
(ROC) curves have been used for classification and evaluation, respectively, based on 400 
cases for training and 458 cases for testing. The resulting areas under the ROC curve (Az 
values) were 0.87 and 0.81 with the training and testing respectively. A further study 
(Drukker, Giger, & Metz, 2005) used the same algorithm and features for evaluating 609 
cases obtained from two different datasets that were acquired from two different 
ultrasound platforms. The Az values achieved by the study were between 0.8 and 0.86.  
Another study (Song et al., 2005) evaluated an Artificial Neural Network (ANN) several times 
using age and three ultrasound features (margin sharpness, intensity of absorbed sound 
waves by the mass margin and angular continuity of the margin). The study obtained an 
accuracy of 0.856 ± 0.058 in the different tests of ANN. Decision trees had been used to 
diagnose breast tumours using texture features with 95.5% (86/90) accuracy (Kuo et al., 
2001). Furthermore, Linear Discriminant Analysis (LDA) has been used (Lee et al., 2008) using 
six features; two of these features are geometric (compactness and orientation) and the 
others are echo features (intensity ratios of the regions below the two sides of a mass (side 
shadow of mass), intensity ratios of the regions below the mass (below shadow of mass) and 
homogeneity). The study used ROC for evaluation and for the area under the curve, the Az 
value was 92%. Another study (Shen et al., 2007) used eight morphological features 
including shape, orientation, margin, lesion boundary, echo pattern, and posterior acoustic 
for building a breast cancer CAD system. In this study a binary logistic regression model was 
used as a classifier to relate those features and pathological results. The system evaluated 
265 samples (180 benign and 85 malignant cases). The overall accuracy of the CAD system 
was about 91%.  
Furthermore, four ultrasound image features (three morphological and one texture) were 
used as inputs to CAD system by Drukker, Lorenzo & Giger (2010). The bootstrap was used to 
evaluate the repeatability of the results of two classifiers, Bayesian Neural Network (BNN) 
and LDA. The study found the results of both classifiers were repeatable. BNN was the 
superior classifier and obtained 88% diagnostic accuracy.  
Also, five ultrasound image features (4 morphological and one texture) were used to 
discriminate benign from malignant lesions by Wu, Lin, & Moon (2012). Genetic algorithms 
and SVM were used for feature selection and classification, respectively. The study found GA 
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very fast in feature selection and the diagnostic accuracy of SVM was 95.24%. Another study 
used both texture and morphological features for building the CAD system by Renjie, Tao, & 
Zengchang (2011). Here, three geometric features related to the mass shape and size were 
extracted (DW ratio, LS Ratio: longest to the smallest axis of the equivalent ellipse and CO 
ratio: the ratio of convex area to the whole area of the mass). The study evaluated the 
diagnostic accuracies of ANN, KNN and SVM using these features. The SVM was the superior 
classifier producing 86.92% diagnostic accuracy. 
From the above studies we note that the main differences between the different CAD 
systems are:  
1. Input features: some of the above studies have used texture features that are related to 
the arrangement of the colours or intensities in an ultrasound image. On the other hand, 
some studies have used morphological features such as mass shape and mass margin, 
while others have used geometric features such as DW ratio. By contrast, there are some 
studies that used combined features. Also we found that the mass shape, margin and 
orientation are the most useful morphological features in the breast cancer CAD 
systems.  
2. Classifier type: the above studies used ANN, SVM, Decision Tree (DT), KNN and LDA. Each 
classifier has advantages and disadvantages (Table 2.4) (Cheng, Shana, Jua, Guoa & 
Zhang, 2010; Laura and Rouslan, 2008). The most common classifiers were ANN and 
SVM. 
Table ‎2.4. A list of commonly used classifiers and their advantages and disadvantages  
Classifier Advantages Disadvantages 
LDA -Simple and easy to implement. 
-Fast. 
-High performance with linearly 
separated data.   
-Poor performance with complex 
data. 
-Poor performance with nonlinearly 
separated data. 
KNN -Simple and fast for high dimensional 
data. 
-Work with nonlinearly separated 
data. 
-No training Phase.  
-Not an adaptive method.  
-The value of K is user dependent. 
SVM -Suitable for complex problems. 
-Work with linear and nonlinear data. 
-Fast.  
-Deliver one optimum solution. 
-The data should be labelled (a 
supervised method).  
-Lack of transparency of the results. 
ANN -Suitable for complex problems. -Different initial weight values can 
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-Work with linear and nonlinear data. 
-Work with unlabelled data. 
produce different outcomes. 
-Long training time. 
- Multiple solutions associated with 
local minima. 
DT  
(Decision 
Tree) 
-Simple method. -The classification accuracy depends 
on the design of the tree.   
Analogous to clinical datasets, biological datasets too have been used for early detection of 
breast cancer, especially, genetic datasets such as, mRNA and miRNA. Several studies have 
used mRNA and miRNA as inputs for breast cancer CAD systems. Recapping what was 
mentioned earlier, there are two main sources of mRNA and miRNA samples; the mass 
tissues or blood. Blood is a good and safe source for genetic data, although a few studies had 
been done using blood samples. For example, mRNA that is extracted from peripheral blood 
cells has been used by a Norwegian group for analysing the expression of 1,368 genes 
extracted from peripheral blood cells of 56 women: 24 with breast cancer and 32 healthy, 
for early detection of breast cancer. The study correctly predicted 82% of the samples using 
37 (29 unique) probes (Sharma et al., 2005). To confirm the results of this study, a larger 
sample of 11,217 genes, extracted from 130 women was analysed (Aaroe et al., 2010). The 
study obtained a set of 738 probes that differentiated healthy samples from cancer samples 
with 79.5% prediction accuracy, 80.6% sensitivity, and 78.3% specificity. The study compared 
the 738 genes with the 37 probes obtained from the previous study (Sharma et al., 2005) 
and found that 20 out of 29  genes were not significant in relation to disease status  (Aaroe 
et al., 2010). The hypothesis that a larger sample could increase prediction accuracy was not 
proved in this case.  
Furthermore, miRNA has been used for early detection of breast cancer in another study 
(Schrauder et al., 2012), where 1100 miRNAs had been analysed to identify miRNA 
biomarkers for breast cancer. The study analysed 48 cancer cases and 57 healthy cases to 
find the up and down regulated genes using the p value, where p<=0.05 indicates a 
significant biomarker. The study obtained 59 differentially expressed genes; 13 up-regulated 
and 46 down-regulated genes.  To confirm the results, SVM with 10 fold out cross validation 
was used to discriminate cancer from control cases using different subsets of genes. The 
values of accuracy, sensitivity and specificity were found to be over 80%, when using a 
subset of 30 miRNA, which were extracted from the 59 differentially expressed genes but 
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the optimum values for the three measures were reached using a subset of 240 miRNA 
genes including the 59 differentially expressed genes. The overall accuracy using 240 genes 
was 85.6% with 78.8% specificity and 92.5% sensitivity.  
To understand BC-CAD systems, we investigated the main components of BC-CADs and 
methods used for developing these systems. Most BC-CAD schemes contain four main parts; 
Raw Data pre-Processing, Feature Selection (FS), Data mining technique(s) (classification or 
clustering), and Evaluation (Figure 2.9).  
 
Figure ‎2.9. The main components of a Computer Aided Diagnosis system. The sequence of 
the steps starts with data pre-processing, then feature selection followed by classification 
or clustering and finally evaluation.  
2.6.1 Data pre-processing 
The first step of building a CAD system is preparing raw data (Input dataset). There are two 
types of datasets used for building BC-CAD systems; Clinical datasets such as ultrasound and 
mammography and biological datasets such as mRNA and miRNA microarray data. Both 
datasets contain noise, redundant or/and incomplete records. Data pre-processing is 
responsible for the following tasks: 
1- Data cleaning: real data is noisy and generally incomplete and needs to be cleaned 
before use. In order to clean raw data, missing values should be handled by deleting the 
records that contain missing values or imputing the missing records. To fill the missing 
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values there are three common methods; Median Imputation (MDI), K-Nearest 
Neighbour Imputation (KNNI) and Mean Imputation (MI) (Acuna & Rodriguez, 2004). 
2- Data Normalisation: this is a data scaling process in which the data is transformed from a 
large scale to a small scale, i.e. transform the data from [6.0 40.0] to the range [0.0 1.0]. 
Normalisation is an important step that is aimed to speed up the classification process of 
many classifiers. Also, for data mining methods that use a measure of distance, 
normalisation makes the effects of a large range attributes similar to small range 
attributes and prevents out weighing (Shalabi, Shaaban, & Kasasbeh, 2006). The most 
common techniques for data normalisation (Kotsiantis, Kanellopoulos, & Pintelas, 2006) 
are: 
a. Min-Max normalisation 
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where X’, A, n are; normalised value of X, old range and new range, respectively. 
b. Z-score normalisation: 
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where X’, meant, stdt are normalised value of X, mean of non-normalised data and standard 
deviation of non-normalised data, respectively.  
2.6.2 Feature selection. 
Learning tasks such as classification and clustering impose a challenge for high dimensional 
data, for example, microarray datasets. Such data may have many noisy features, which 
make learning tasks very complex. The process of removing noisy data (irrelevant and 
redundant) or choosing a sub set of features (relevant) from the given set is called feature 
selection (Blum & Langley, 1997; Gilad-Bachrach et al., 2004).  
Feature selection methods are classified into two main classes. The first one is the filter 
class. Methods in this class are independent of the classifier algorithm and done as a pre-
step of the classification algorithm, where the general attributes of the training set are used 
to select some features and exclude others. The selected features are used as classifier 
inputs (Blum & Langley, 1997). The advantages of the filters are that they are fast, easy to 
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compute, scalable and independent of the classifier. The disadvantages of filters are that 
they ignore the dependency between features and interaction between features and the 
classification algorithm (Saeys, Inza, & Larranaga, 2007) (Table 2.5). The most popular filters 
include; Relief (Kira & Rendell, 1992), Correlation-Based Feature Selection (CFS) (Hall, 1999), 
INTERACT (Zhao & Liu, 2007) etc. A comparison study between the above algorithms was 
done by Sanchez-Marono, Alonso-Betanzos and Tombilla-Sanroman (2007). The study found 
that the best results were the ones obtained by using CFS.  
On the other hand, the second class of feature selection methods, the wrapper class, 
searches through the space of all features using a learning algorithm to find the features that 
produce the highest classification accuracy. Wrappers may start with an empty set and then 
add features from unselected ones and calculate the accuracy, searching for groups of 
attributes (such as genes) that provide the highest accuracy. This method is called forward 
selection. In contrast, the backward elimination starts with all features and removes features 
incrementally to find the feature set that provides the highest accuracy (Das, 2001). The 
advantages of wrappers are that they interact with the classification algorithm and consider 
feature dependency (Table 2.6).  
Several searching algorithms have been used to find the best subset of features such as; 
Genetic algorithm (GA) (Zhuo et al., 2008), Simulated Annealing (Li & Liu, 2008), Beast First 
Search (BFS) (Kohavi & John, 1997) and Greedy search (Geng, Liu, Qin & Li, 2007). However, 
the wrapper approach requires the evaluation of a large number of alternative subsets, 2n 
subsets where n is the number of features in the space, in order to select a subset with the 
lowest classification error. Searching for a subset of this feature in a large space has a high 
computational cost and requires large memory space. Also, in some cases, the selected 
features produce poor classification accuracy for the instances that are not included in the 
selection phase. This is the risk of over fitting (Saeys et al., 2007). 
Both filter and wrapper have been used for building BC-CAD systems. However, most 
ultrasound and mammography based BC-CAD have used wrapper algorithms for feature 
selection(Table 2.5). This is because the total number of ultrasound and mammography 
features is limited. On the other hand, the high dimensionality of microarrays makes the 
wrappers not suitable for feature selection. Hence, filter methods are used most commonly 
with microarray datasets (Table 2.6). 
 46 
Table ‎2.5.  The advantages and disadvantages of the most common wrappers and examples from previous ultrasound and mammography breast 
cancer studies.  
Algorithm    Example  and advantage  Limitations  
Genetic Algorithm (GA) (Darzi, 
AsgharLiaei, Hosseini & Asghari, 
2011) 
32 breast ultrasound features have been used as inputs for GA algorithm. All 
features were extracted from previous works. The algorithm is robust and 
successfully enhanced the accuracies of different classifiers by selecting 12 out 
of 32 features. 
-High complexity. 
-Difficulty in determination of mutation rate, 
crossover point(s), and the population size. 
- GA searches for the best possible solution 
without finding the exact best solution. 
Sequential search (Fu et al., 2005)   62 mammography features were used as inputs. A subset of 11 features has 
been selected. The study evaluated the alibility of the selected features for 
detecting micro calcification using SVM and General Regression Neural Network 
(GRNN). The accuracies of both classifiers were improved using the subset of 
selected features.  
In general, the sequential search based feature selection algorithm finds the 
optimum and exact subset.    
-Very slow  
-Not applicable in high dimensional data for 
example, microarray data, where the input 
vector contains thousands of attributes.  
Ant colony and GA  The algorithm is used to reduce the dimensionality of the input data that is 
obtained by applying Jacobi moment on a 256X256 image. The algorithm 
successfully selected 10 out of a large number of moments. The selected 
features were used as inputs for SVM and obtained a high accuracy in detecting 
micro calcification in mammogram images. 
-Strong optimiser and powerful algorithm in relatively high dimensional data 
(Lakshmi & Manoharan, 2011).        
- Not easy to implement.  
-Finds the possible best subset not the real 
one. 
-Not for very high dimensional data, i.e., 
mRNA microarray that contains 32000 
attributes; applying such algorithm adds 
Complexity to the CAD system.    
 
Greedy search The study used both GA and Greedy searches (GS) for feature selection, where 
both algorithms were run individually. The algorithm then found the union 
between GA selected features and GS selected features. 8 out of 26 breast 
mammography features were selected for classification, which improved the 
classification accuracy.   (Vasantha,Bharathi & Dhamodhran, 2010). 
-Greedy search is easy to implement. 
-Works well with clean datasets. 
-A strong optimisation algorithm.  
-Slow 
-Does not find the exact solution. 
-using noisy data, the algorithm produces 
poor results.  
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Table ‎2.6. The advantages and disadvantages of the most common filters and a brief description of each method.  
Method Advantages Limitations 
Correlation-Based 
Feature Selection 
(Hall, 1999) 
As a first step of these methods the features are ranked according to 
their importance and the ability in differentiating the class labels. 
Where the highest K features or the features that have an importance 
value above that of the threshold are considered as candidate 
features. Next, the correlations between the selected features are 
computed. Then, the highly correlated features are considered as 
redundant features and removed from the set. 
-Easy to implement 
-Can work with high dimensional data. 
-Can deal with noisy data.  
- The ranking is done based on the relation between individual 
feature and class label and does not take into account the 
possibility of existence of a group of features that are not included 
in the candidate features but work together and give better 
classification results. 
-In the microarray data (Gene expression), high gene correlations 
make the correlation-based feature selection unstable, where a 
small change in the training data leads to a change in the selected 
subset. Also, these methods do not take into account the biological 
relations between genes (Toloşi & Lengauer, 2011). 
- Discards the interaction between features and the classification 
algorithm. 
Ranking (Relief) 
 (Kira & Rendell, 
1992) 
The algorithm weighs the features based on the ability of the feature 
to distinguish sample points that are close to each other, using Near-
hit and Near-miss functions. For example, Joshi, Jethava & Bhavsar 
(2012) evaluated the effect of Relief feature selection method on the 
performance of BC-CAD system. The Relief algorithm successfully 
reduced the dimensionality of the data from 24,481 to 4,547 genes 
and sped up the training of the classifier. 
 
-Simple, fast and easy to implement and deal with high dimensional 
data. 
- Discards the interaction between features and the classification 
algorithm. 
-In microarray data the biological relations between genes are 
discarded.   
ANOVA or t-tests This is a statistical method that ranks the features according to the 
significance level of the feature.  
Most of gene expression based studies have used p-value for selecting 
a subset of differentially expressed genes (Schrauder et al., 2012; 
Sharma et al., 2005).  For Example, Thakkar et al., (2010) used t-test 
to identify the gene signature in +ER breast cancer cases. The study 
obtained 108 genes as differentially expressed in ERα (+) and ERα (-). 
-Fast and easy to implement  
-Ignores the dependency between the features and the classifier.  
-using the microarray data, the method ignores the biological 
interaction between the features. 
 48 
-suitable for high dimensional data. 
Principle component 
analysis (PCA) 
features selection. 
(Dai, Lieu, & Rocke, 
2006) 
The aim of this method is to project the original dataset to another 
space with lower dimensionality. To do that, the covariance matrix of 
the features of the original data is extracted and the eigenvectors and 
eigenvalue of the covariance matrix are computed. Then, the k 
eigenvectors corresponding to the k largest eigenvalues are selected 
to represent the new space where k is much less than the number of 
features in the original data. For example Liang, Singh, Dharmaraj and 
Gam (2010) identified 34 differentially expressed protein profile 
between cancerous and normal breast tissues. Then, the PCA was 
used to reduce the dimensionality of the data. The first 6 PCs were 
used as inputs for LDA classifier. The study obtained 88.9% 
classification accuracy. 
-Easy to implement and works well with high dimensional data. 
-Subjective in Determine the value of K. 
-Ignores the relationships between the features and the classifier 
and the new space is only selected based on the relation between 
the original features. 
-The relationship between the features is computed based on 
covariance of a pair of features and discards the effect of other 
features in this relationship. 
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Recently, researchers have started developing new types of feature selection algorithms that 
take into account the biological interaction between genes. For example, Bandyopadhyay, 
Kahveci, Goodison, Sun and Ranka (2009) proposed a method for feature selection that 
started by selecting a group of genes (S) from the set of all genes (G). These genes 
biologically belong to the same pathway. This pathway is known to be related to disease. If 
the pathway was not clearly identified, the subset of genes S was selected based on a 
ranking algorithm, in which the discriminating power of individual genes was computed and 
ranked and the highest n genes were selected. Then, the algorithm computed the 
classification accuracy of the subset (S) using a Support Vector machine SVM. Next, for each 
gene in G-S, the algorithm added the gene to the S and re-computed the classification 
accuracy. A set of candidate genes (C) that enhanced the classification accuracy was 
selected. Finally, a candidate gene was removed if the relation between it and the genes in S 
is strong. However, there is a problem with selecting the first subset of genes as well as the 
candidate genes because it follows the filtering methods and have the same disadvantages 
of the filtering methods that were mentioned earlier. Also, selecting the candidate subset (C) 
was based on the added value to the classifier when the candidate gene is added to the first 
subset of genes (S). This method overlooked the case where the added feature may 
enhances the accuracy of the classifier, if one or more of the existing features are removed. 
Moreover, the study has no clear method of how to define the interaction between genes.  
Another study started by ranking the genes based on p-vales and selecting a group of 2000 
highest differentially expressed genes from the dataset (Ma, Kosorok, Huang and Dai, 2011). 
Then, gene co-expression network, (chapter 4), of the 2000 selected genes was built and 
divided into functional groups based on hierarchical clustering. The study then selected 
representative genes (Hub genes) from each group based on principle component analysis 
(PCA). Finally, the representative genes were used as inputs to predict the prognosis of 
cancer patients. However, the starting point of this method shares the disadvantages of 
filtering methods, where the highest 2000 genes have been selected based on a statistical 
method that does not taken into account the possibility of existence of a group of features,  
not included in the 2000 selected genes and work together to give better classification 
results. Also, clustering such dense networks needs a powerful evaluation criteria to avoid 
random dividing of the gene co-expression network, which was not used in the study.    
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2.6.3 Data Mining (Classification and Clustering) 
Classifiers focus on classifying objects into two or more groups based on the object 
attributes. There are two groups of classifiers: supervised (classification) and unsupervised 
(clustering). The main difference between the groups lies in the nature of training data. In 
the supervised algorithms, each instance in the training data consists of an input vector and 
the desired output. On the other hand, the instances in the unsupervised algorithms are not 
labelled with desired outputs. This study will use supervised classifiers, especially those that 
classify instances into two groups, which are called binary supervised classifiers (Japkowicz, 
2001). In this section, a brief introduction to the most common supervised and unsupervised 
classification methods is given. 
Supervised classification methods 
From the above definition, the learning step in these methods uses paired samples where, 
each sample consists of an input vector and a desired output. The learning process is an 
iterative process to adapt the machine variables (parameters) and infer a function that can 
predict the class label for any input, whether it is included or not in the training process. The 
most common supervised classification methods that have been used in medical applications 
(Kovalerchuk, Vityaev, & Ruiz, 2001) are: Artificial Neural Networks (ANN) ( Chen et al., 2003;  
Chen, Xu, Ma, & Ma, 2010; Shiraishi et al., 2003; Suzuki, Li, Sone, & Doi, 2005) , K-Nearest 
Neighbour (KNN) (Burroni et al., 2004;  Liu et al., 2011; Mariolis et al., 2010), Support Vector 
Machines (SVM) (Chaves et al., 2009; Polat, Akdemir & Güneş, 2008; Yao, Dwyer, Summers & 
Mollura, 2011) and Linear Discriminant Analysis (LDA) (Huo, Giger, Vyborny, Olopade, & 
Wolverton, 1998; Jesneck, Lo & Baker, 2007).  
Artificial Neural Networks (ANN) 
Biologically, neural network is a group or several groups of neurons that are connected to 
each other through complex networks in order to represent the organism’s knowledge. From 
computer perspectives, artificial neural network is a group of connected neurons, in which, 
each neuron contains an activation function to mimic the biological function of neurons. 
Also, the connections between the neurons carry and modify the signals between neurons, 
as connections in a biological network that carry electronic signals between neurons. 
Accordingly, ANN mimics the structure and functions of biological neural networks in order 
to solve a specific problem.    
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Supervised Neural Networks in the form of feed forward networks are used frequently in 
classification tasks. It contains a number of neurons organised in layers. Every neuron in a 
layer is linked with all the neurons in the previous layer. Each link has a weight. The weights 
of the links represent the knowledge of a network. The number of layers and neurons in 
each layer depends on the nature of the problem. The learning phase of the network is a 
process by which the weights of a neural network are modified to encode the knowledge of 
the network. The learning of a Feed Forward Neural Network (FFNN) is usually done by using 
back propagation algorithm (Rojas, 1996), which contains two phases: the first phase is 
forward where the input vector is transmitted to the network layers until the output layer. 
At the end of this phase the algorithm calculates the error by finding the difference between 
the network output and the actual target. The second phase is backward, where the error is 
back propagated from the output layer to input layer and the weights of all links are 
updated. To explain the learning phase of the neural network, assume there is a network 
with three layers; input, hidden and output (Figure 2.10). 
 
Figure ‎2.10. Feed Foreword Neural Network (FFNN). The network contains three layers; 
input, hidden, and output. After each iteration, the error is computed and returned 
through the layers as a feedback to adjust the weights in each layer in order to minimize 
the output error of the network  
The input layer contains m neurons where m represents the dimensionality of the input 
vector V={X1, X2, X3, ..., Xm}. Each neuron in the input layer has a direct link to all neurons in 
the second layer. The connections between the input and hidden layer form the input-
hidden weight matrix (Table 2.7). The connections between the hidden and output layers 
form the hidden-output weight vector Wv={b1, b2, b3,…, bn}.  
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Table ‎2.7. The weight matrix of the Input-Hidden layer.  Nn is the neuron n in the hidden 
layer, Xm is the feature m in the input vector x and the cell Wmn is the weight of the feature 
m to neuron n  
 
In
p
u
t 
 la
ye
r 
 
 
  
N1 N2 N3 Nn 
X1 W11 W12 W13 W1n 
X2 W21 W22 W23 W2n 
X3 W31 W32 W33 W3n 
Xm Wm1 Wm2 Wm3 Wmn 
 
The learning phase is done as shown in the following steps. 
1- Initialisation: this step is responsible for initializing the input-hidden weight matrix and 
hidden-output weight vector. 
2- For each neuron find the Ui value that represents the weighted sum of the input neurons 
to the hidden neuroni : 

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3- Compute the values of hidden neuron activation. For example, in this work we used 
sigmoid functions, tangent and log sigmoid, (Equations 2.6 & 2.7 respectively), as a 
nonlinear function and straight line as a linear function, Equation 2.8: 
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4- Compute the weighted sum of input to output neuron: 
 iibyV  
(2.9) 
5- Compute the value of output neuron activation function using V as a function input 
similar to step 3. This value represents the final network output  (out) where in the case 
of tangent activation function is: 
v
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(2.10) 
Hidden layer  
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6- Then the output (out) and the target (t) are used to compute the error (E) and update 
the connections weights following gradient descent method (for online learning) : 
2)(
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Update the hidden-output weights: 
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where  is the learning rate. 
Update the input-hidden weights: 
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(2.15) 
7- Compute the Mean Square Error (MSE). This is the most common criterion that is used to 
evaluate the network performance 
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8- Repeat steps 2-7 until MSE is below a threshold or the maximum number of set 
iterations is reached or no further enhancement is attained by further learning.  
There are many variants of this basic learning algorithm that includes gradient descent with 
momentum, gradient descent with adjustable learning rate and second order learning 
methods including Quickprop, Gauss Newton and Leverberg marguardt learning algorithms 
(Samarasinghe, 2007).  
Support Vector Machines (SVM) 
This is a statistical based supervised classifier that has been widely used for classification 
tasks. SVM classifies the objects by drawing a hyperplane between different classes. The 
selection of the hyperplane is a complicated process because there are several alternatives 
(Figure 2.11). SVM is trained to fit the hyper plane that separates the different classes, 
where the margin between the classes is at its maximum (Figure 2.12).  
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Figure ‎2.11. The alternatives for fitting a hyperplane between two classes. The lines 
represent the possible positions for the hyperplane; dark dots indicate the first class and 
stars indicate the other class. All the lines correctly separate the stars from the dots  
 
Figure ‎2.12. The SVM selects the hyper plane that maximizes the margin between different 
classes. The arrows represent the support vectors (the points that lie on the margin lines); 
the blue area is the margin between the two classes 
To further understand the SVM algorithm, we will follow Burges’ (1998) tutorial. Assume the 
training data is defined as {Xi, Yi} where Xi is the input attribute vector and Yi is the 
corresponding class label {1, -1}. Also assume that all the positive points satisfy w.x+b >= +1 
and all the negative points satisfy w.x+b <= -1. Now, a point x on the hyperplane that 
separates the positive class from the negative class satisfies w.x + b = 0 where w is the 
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normal to the hyperplane and b/|w| is the distance between the hyper plane and the origin 
(Figure 2.13).  From  Figure 2.13, the margin M=(D+)+(D-), where D+ is the distance between 
the red and black lines (hyperplane) and D- is the distance between the blue and the 
hyperplane. Now, we can combine the positive and negative points in one formula Yi (w.x+b) 
-1>= 0. Furthermore, the positive support vectors satisfy w.x+b=1 and the negative support 
vectors satisfy w.x+b=-1. So the D+=D-=1/|w| and M=2/|w|. Subject to the combined 
formula (positive and negative), there is a need to minimise the value of |w|2 in order to 
maximise margin (Burges, 1998). 
To minimize the value of |w|2 subject to the combined function Yi (w.x+b) -1>= 0, the 
algorithm uses Lagrangian formulation to solve the minimisation problem as follows: 
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Where Lp is the positive Lagrangian and i =1,…, n are the positive Lagrange multipliers. To 
minimize the |w|2, we must minimize the Lp with respect to b, and w. In order to do that the 
algorithm computes: 
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By substitution of the Equations 2.18 and 2.19 into Equation 2.17, final SVM formula becomes: 
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Figure ‎2.13. Linear SVM where the black line represents the hyper plane that separates 
positive from negative cases, the red line represents the border for positive cases where 
the closest positive points to the hyper plane lie on the red line and are called support 
vectors. The blue line represents the border of negative cases where the closest negative 
points to the hyper plane lie on the blue line and also called support vectors 
 
K-Nearest Neighbour (KNN) 
The process of classifying objects in this method depends on the distance between the new 
object and neighbouring objects in the training data. The training samples are represented 
as marked points in space where each mark denotes one class. The new object is 
represented in the same space and classified depending on K neighbour points as shown in 
Figure 2.14 ( Wu et al., 2007). The classification performance depends on the number of 
neighbours that are used for classifying a sample. 
 
Figure ‎2.14 The distribution of malignant and benign cases based on Age and WD ratio 
(width-depth ratio of the mass) where o represents malignant cases, + represents benign 
cases and * is the new object. If K=5 the circle represents the closest 5 samples to the new 
sample. 
KNN algorithm is fast and easy to implement because there is no training phase for the 
algorithm. To classify a new instance the algorithm follows the steps listed below: 
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1- Before classifying the new instances and as a first step, it is necessary to determine the 
value of K that controls the classification process. To do that following steps are 
followed: 
i. Divide the training dataset randomly into two sets (Training 1 and Testing 1): 
ii. For each instance Ti in the Testing 1, find the distance between Ti and all instances in 
the Training 1. 
iii. Store the results in Distance Matrix (DM). 
iv. Set V= n-1 where n is the number of instances in Training 1. 
v. For K=1 to V 
1. KNN(DM, K) 
2. Compute and save the accuracy in the in ACC vector. 
vi. Set the value of K to be the index of the cell that contains the maximum value of ACC. 
2- For the new instance, find the distance between the new instance and all instances in 
the training dataset. 
3- Sort the values in ascending order and select the class labels of the closest K instances to 
the new instance. 
4- Find the count of each class label in the selected K labels and set L to be the class label of 
the highest one. 
5- Set the class label of the new instance to L.    
  
Unsupervised classification (Clustering) 
This is a task of dividing the objects into groups (clusters), where the objects in the same 
cluster are more similar to each other than to the objects in other clusters. Clustering 
methods have been widely used in biological and medical applications; in particular, Self-
Organization Maps (SOM) and Hierarchal clustering have been widely used for visualizing the 
correlation in biological data, i.e., genes and proteins, (Datta & Datta, 2003; Levenstien, Yang 
& Ott, 2003; Wang, Delabie, Aasheim, Smeland & Myklebost, 2002; Zhang & Zhang, 2006). 
Here, we describe these two methods as they will be used in this study for clustering. 
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Self-Organizing feature Map (SOM) 
This is an unsupervised neural network that projects high-dimensional data into a low-
dimensional space. Also, it is an effective and powerful tool for classification and clustering. 
To build an SOM, we first determine the topology and the number of nodes in the map. The 
topology of an SOM layer determines the physical position of each neuron in the layer such 
as, rectangular, hexagonal or random topology.  Then we begin the process of network 
training as follows (Samarasinghe, 2007): 
1. The weight of each neuron in the map is initialized. 
2. Select a vector from the training sample randomly.  
3. Find the neuron in the map closest to the input vector by finding the distance between 
the input vector and map neuron (Equation 2.21). The closest neuron is usually called the 
Best Matching Unit (BMU):  
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where, Wj is weight vector of node j, x is the input vector and n the length of vector. 
 
4. Find the radius of the neighbourhood of the neurons using Equation 2.22 : 
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where σ0 is the initial radius of the neighbour and usually is equal to the radius of the map, t 
is the iteration number, λ is the time constant, NOI is the total number of iterations and MR 
is the map radius. 
5. Any nodes found within the radius of the BMU are adjusted to move them closer to the 
input vector (Equation 2.23). 
))()()(()()()1( twtxtLttwtw   ;

-t
e0)( LtL  ;   
)(22
2
)(
t
dfBMU
et



  
 
  (2.23) 
where L(t) is the learning rate and dfBMU is the distance of the neighbouring node from the 
BMU. 
 
6. Repeat steps 2 to 5 until the weights update become insignificant.  
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Map accuracy is cheeked by the total distance between the input vector and their final 
BMUs. Map is trained several times with different weight initialisations to select the best 
map. 
Hierarchical clustering  
This is an unsupervised method for data clustering. It is widely used for visualizing and 
clustering biological data including gene expressions and proteins, (Daxin, Chun, & Aidong, 
2004; de Souto, Costa, de Araujo, Ludermir & Schliep, 2008; Kull & Vilo, 2008). There are two 
main types of hierarchical clustering; Agglomerative and Divisive (Rajalingam & Ranjini, 
2011). The agglomerative is a bottom up method that starts with n clusters, where n is the 
number of observations. Then two clusters are merged based on similarity until the number 
of clusters becomes one or a number specified by the user. The second type of hierarchical 
clustering is Divisive clustering. This is a top down method, which starts with one cluster and 
divides the cluster into two clusters and so on until n clusters, where n is the number of 
observations, are found. In this work, we will focus on the Agglomerative clustering. There 
are several methods for measuring the similarity between two clusters (Soman, Diwakar & 
Ajay, 2006); 
1) Single Linkage: this is done by calculating the Euclidian distance between the closest 
members of the two clusters and merging the two clusters with minimum distance 
(Equation 2.24). 
),( jiijxy yxdMIND   2.24 
where, Dxy is the distance between cluster x and cluster y, xi is the i
th observation in 
cluster x and yj is the j
th observation in cluster y and d is the distance. 
2) Complete linkage: this is done based on the farthest members between two clusters. 
Two clusters with minimum farthest members are merged (Equation 2.25). 
),( jiijxy yxdMAXD   2.25 
3) Average linkage: this is done by computing the average distance between the 
members of two clusters and merging ones with smallest values (Equation 2.26).   
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where l and k are the number of observations in x and y, respectively.     
The output clusters can be graphically represented using a dendrogram. This is a tree 
representation for the clusters in which the first layer represents all observations and the 
other layers represent the merged clusters. The nodes of the dendrogram are connected by 
lines where the length of the line reflects the distance between the clusters (Figure 2.15).  
 
Figure ‎2.15. Dendrogram of five observations. The leaf nodes in the first layer are the 
observations and each one represents a cluster. In step 1, Op1 and Op2 were the closest 
clusters, distance= 2, and merged in one cluster. In step 2, Op3 and Op4 were found to be 
the closest clusters and also merged in one cluster. In step 3, the resulting clusters from 
the first and the second steps were the closest. Finally the Op5 and the resulting cluster 
from step 3 form one cluster that contains all observations. 
 
Graph theory and Spectral Clustering 
A graph is an ordered pair G= (V,E) where, V is a set of vertices and E is a set of edges. The 
order of the graph, |V| is an integer number that represents the number of vertices in the 
graph and the size of the graph |E| represents the number of edges in the graph. There are 
two main types of graphs; directed and undirected. The directed graph is a formed structure, 
where the edges between the pair of vertices x and y are represented by an arrow from x to 
y (xy) and/or from y to x (yx) and (xy) ≠ (yx) (Figure 2.16 A). On the other hand, the 
edges in an undirected graph are represented by a line and means (xy)=(yx) for any 
connected nodes in the graph (Figure 2.16 B). Each type also contains two sub-types; 
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weighted and unweighted graphs. The weighted graph is a graph where each edge carries a 
number to represent the strength of connection between the pair of nodes (Figures 2.16 C & 
D). In contrast, in the unweighted graph, the edge carries no values. In this study, we focus 
on undirected and weighted graphs to build Gene Co-expression Network (GCN), where the 
similarity between a pair of genes, x and y, is between 0 and 1 and (xy) =(yx) (Figure 
2.16 D) (Balakrishnan & Ranganathan, 1997).   
In the undirected graph, the pair of vertices x and y are adjacent if there is a direct 
connection between the two vertices and usually written as xy or yx. If all vertices in the 
graph are adjacent, the graph is called a complete graph. Accordingly, the total number of 
edges in the complete graph with n vertices (Kn) is computed using Equation 2.27. The 
complete graph with three vertices K3 is called triangle (Diestel, 2000). 
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The undirected graph can be represented using an adjacency matrix, where each row and 
column in the matrix represents one vertex (Figure 2.16 D). Each cell in the adjacency matrix 
takes a single value, which means the similarity (Sij) or distance (Dij) between the pair of 
vertices in the raw i and column j. Also, each raw in the matrix represents the relationship 
between a specific vertex and all other vertices in the graph. The degree of a vertex x 
(deg(x)) is the number that reflects the relation between the vertex x and all other vertices in 
the graph (Equation 2.28) (Diestel, 2000). 
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where, Sij is the similarity between the vertex i and vertex j.  
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Figure ‎2.16. Types of graph. A) Directed unweighted graph; the matrix on the right 
represents the adjacency matrix of the graph. Each cell takes an value in {0, 1}; one 
denoting presence and zero absence. B) Undirected unweighted graph; the matrix in the 
right represents the adjacency matrix of the graph. C) Directed weighted graph; the cells 
take the values that appear on the arrow. Note that (a,b)≠(b,a). D) Undirected weighted 
Graph; the adjacency matrix is a symmetric matrix, where (X,Y)=(Y,X). 
 
Spectral clustering: 
Graphs have been widely used in medical applications. For example, they have been used to 
study a public health database in order to identify geographic areas that have a high level of 
deprivation, diseases, and mortality rates (Bath, Craigs, Maheswaran, Raymond, & Willett, 
2005). Also, they have been used in several cancer diagnosis, prognosis and treatment 
applications (Canutescu, Shelenkov & Dunbrack, 2003; Kar, Gursoy & Keskin, 2009; Maxwell 
et al., 2008; Wang & Chen, 2011). The general idea of these studies is graph clustering.  
Graph clustering is a process of dividing the graph into sub-graphs that satisfy the following 
two conditions: firstly, the elements of each cluster are strongly related to each other, with 
high similarity within the cluster.  Secondly, the similarity between any pair of clusters is as 
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small as possible. There are several clustering algorithms used for graph clustering such as 
Markov Clustering (van Dongen, 2000), Iterative Conductance Cutting (Kannan, Vempala, & 
Vetta, 2004) and Spectral Clustering (Ng, Jordan & Weiss, 2001). The spectral algorithm is a 
simple and effective method for graph clustering, especially, in similarity based graphs. Also, 
it works well with a large amount of data (Auffarth, 2007). Therefore, in this study, we will 
focus on spectral clustering (Ng, Jordan & Weiss, 2001) (see Chapter 4 for more details on 
spectral clustering).  
2.6.4 Evaluation 
The aim of this step is to evaluate the performance of different CAD systems. As in most 
diagnostic systems, this research will use sensitivity, specificity, False Positive (FP) rate, False 
Negative (FN) rate and overall accuracy tests in evaluation (Equations 2.29-2.32) (Altman & 
Bland, 1994). Sensitivity is the percentage of true malignant patients that are correctly 
classified as malignant. On the other hand, specificity is the percentage of true normal 
patients that are correctly classified as normal. The FP rate is the percentage of benign cases 
in the malignant class and the FN rate is the percentage of malignant cases in the benign 
class. The last measure is the accuracy, which calculates the percentage of the samples that 
are correctly classified. For example, if the history of diagnostic accuracy of breast cancer for 
a doctor is 80%, sensitivity 70%, specificity 90%, FP rate 12.5% and FN rate 25%, according to 
these values, there is 80% chance that the doctor’s decision is correct. Furthermore, if the 
doctor diagnoses the patient as a cancer case, the likelihood that their decision is correct is 
87.5% and likelihood of a mistake is 12.5%. Also, it shows that 30% of cancer cases are 
misdiagnosed, while 10% of healthy cases are misdiagnosed, but, 25% of the cases that are 
classified as healthy have breast cancer. 
Sensitivity  = 
samplesmalignantofnumberTotal
samplesmalignantofNumber  classifiedcorrectly 
            (2.29) 
Specificity =
samplesbenignofnumberTotal
samplesbenignofNumber  classifiedcorrectly 
                                      (2.30) 
Accuracy =
samplesofnumberTotal
samplesofNumber  classifiedcorrectly 
                (2.31) 
FP  =
classmalignantinsamplesofnumberTotal
classifiedfalslysamplesbenignofNumber
                                     (2.32) 
FN  =
classbenigninsamplesofnumberTotal
classifiedfalslysamplesmalignantofNumber
             (2.33) 
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In summary, there are two types of breast cancer tests, clinical tests including ultrasound 
and mammography and biological tests including mRNA and miRNA tests. In this study, both 
clinical and biological tests are used for building a computational BC-CAD framework in order 
to enhance the diagnostic accuracy of current BC-CAD systems and give a doctor more 
alternatives for breast cancer diagnosis; specifically, a framework capable of diagnosing 
breast cancer using clinical data, biological data or both.  
Ultrasound images, the clinical part of the framework, are one of the most frequently used 
methods for breast cancer diagnosis. There are two types of ultrasound features used 
previously for building BC-CAD: morphological and texture features. The morphological 
features are system independent and there are few studies that used these features for 
building BC-CAD. Also, the accuracy of such systems still needs further enhancement. 
Accordingly, in this study the morphological features of mass are carefully investigated in 
Chapter 3 to extract a new effective morphological feature that enhances the accuracy of 
BC-CADs. Hierarchical clustering and SOM are strong methods for data clustering and 
visualization. Therefore, these methods are used in Chapter 3 for feature selection and data 
visualization.  
 
mRNA and miRNA microarrays, the biological part of the framework, are a rich source of 
molecular information at the genetic level in an organism. There are two main sources of cell 
samples used to design these microarrays: peripheral blood and mass lesion. Peripheral 
blood is readily available, easy to access and a rich source of genetic information for studying 
human diseases. Also, there are a few studies that used the peripheral blood based 
microarrays for breast cancer biomarker detection and classification. Therefore, this study 
used blood based microarrays datasets for building BC-CAD systems.  
Currently, the diagnostic accuracy of mRNA based BC-CAD is about 79% and needs further 
enhancement. Most current mRNA based CAD systems use wrapper or filter methods for 
gene selection and both methods do not consider the biological relations between genes. 
Accordingly, in Chapter 4 we develop a new gene selection method based on the biological 
relations between genes in order to define the breast cancer biomarkers in the blood and 
employ these biomarkers in a BC-CAD. The adjacency matrix of an undirected graph is used 
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to represent the Gene Co-expression Network (GCN). A spectral algorithm is a simple and 
effective method for graph clustering; especially, in similarity based graphs. Also, it works 
well with a large amount of data. Therefore, this study uses it for dividing GCN into 
functional groups. Also, we applied this new gene selection method to miRNA breast cancer 
dataset, especially collected from the blood of Jordanian females, to define the breast 
cancer miRNA biomarkers that enhance the diagnostic accuracy of miRNA based BC-CAD 
systems. 
There are several classifiers used for building BC-CAD systems including ANN, SVM, LDA and 
KNN. Each classifier has its advantages and disadvantages that produce variations in the 
classification accuracy on the same dataset. Therefore, each CAD used at least three 
different classifiers and compared their results to select the best classifier for each dataset. 
The results of all CADs are evaluated using the three most common measures: accuracy, 
sensitivity and specificity.  
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Chapter 3 
Ultrasound Based Computer Aided Diagnosis system: Evaluation of 
a new feature of mass Central Regularity Degree (CRD) 
As we mentioned in Chapter 2, two types of breast cancer tests, clinical and biological, are 
used in this work for building a computational BC-CAD framework in order to enhance the 
diagnostic accuracy of current BC-CAD systems and give a doctor more alternatives for 
breast cancer diagnosis. The framework is capable of diagnosing breast cancer using clinical 
data, biological data or both. In this chapter, we focus on the clinical part of the framework. 
Specifically, ultrasound based BC-CAD (Figure 3.1). Figure 3.1 shows the main components of 
the framework that includes ultrasound based CAD system based on clinical data and mRNA 
and miRNA CAD systems based on biological data. The orange colour represents the focus of 
this chapter- ultrasound based CAD system.  
  
Figure ‎3.1. The Breast Cancer Computer Aided Diagnosis (BC-CAD) Framework showing the 
three CAD systems; the CAD system for clinical data (ultrasound) and two systems for 
biological data (mRNA and miRNA) (The orange part, ultrasound BC-CAD, is the focus of 
this chapter) 
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3.1 Introduction 
Breast tumors including benign and malignant solid masses start with few cells and grow 
faster than the normal cells and form a mass inside the breast tissues. A growing solid 
benign mass pushes and compresses the surrounded tissues to create a space which makes 
well-defined boundary for the mass. Benign masses in most cases take an oval shape where 
the large axis of the oval is parallel to the skin line. Usually, the benign masses block the 
blood vessels which reduce the blood flow into the mass. Most of diagnosed benign masses 
are fibroadinoma. Another example of benign tumors is cysts which are a fluid-fill mass with 
a clear margin. On the other hand, malignant masses grow and invade the surrounded 
tissues and not restricted to a limited area resulting in an irregular shape and ill-defined 
margin (Mason, 2005).  
There are several changes in the breast anatomy during a female’s life. In some cases, 
calcium salt gets deposited in the soft tissues that makes them harder, this is called 
calcification. Several factors contribute to this including age, past trauma to breast and 
breast inflammation. Also, calcification in a few cases is a sign of breast carcinoma. There are 
two types of calcification: the first one is macrocalcification, where the size of calcium mass 
is big and probably benign. The second one is microcalcification, where the size of calcium 
deposit is very small, less than 0.5 mm and this type is probably malignant and requires 
further checking for microcalcification morphology and distribution (Panda, Panigrahi & 
Patro, 2009). 
Ultrasound is one of the most frequently used methods for early detection of breast cancer. 
As mentioned in Chapter 2, this method uses inaudible sound waves. The tumours are 
divided into four types according to their ability to return the sound waves (echogenicity). 
The first one is anechoic lesions, and has no internal echo. This type of lesion is a benign 
cyst. The second one is hypoechoic lesions and has low level echoes throughout the lesion 
and is probably malignant.  The third type is hyperechoic lesions with increased echogenicity 
compared to their surrounding fat, and are probably benign. The last type is isoechoic 
lesions with similar echogenicity compared to the fat echogenicity, and are probably benign 
(Popli, 2002; Rahbar et al., 1999).  
An ultrasound image is processed carefully to differentiate malignant from benign masses. 
The radiologist extracts a number of mass features from an ultrasound image such as, shape, 
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margin, orientation, echogenic pattern, posterior acoustic features, effect on surrounding 
parenchyma and Calcifications (Table 3.1) (Madjar & Mendelson, 2008; Popli, 2002). All 
these features are used to differentiate benign from malignant masses. 
 
Table ‎3.1. The ultrasound mass features and a brief description of each feature  
Feature Description 
shape The mass takes two main shapes, regular and irregular, the regular 
masses (or oval) are probably benign and irregular masses (speculated) 
are probably malignant. 
margin The border that separates the mass from the neighbouring normal 
tissue; it can be clear or well defined, which is suggestive of benign or 
it can be blurry or ill-defined which is probably malignant.  
orientation The long axis of the mass can be parallel to the skin line, which is 
suggestive of benign. 
posterior acoustic The shadow behind the mass usually caused by malignant lesion. 
Echogenic pattern  This feature reflects the internal mass Echogenicity (density of the 
mass); hypoechoic lesions are suggestive of malignant.  
Surrounding tissue The effect of the mass on the surrounding tissues; depends on the 
mass type, for example, solid mass may compact the neighbouring 
tissues. 
Calcification The presence of calcium inside the breast tissues; microcalcification is 
suggestive of malignant and macrocalcification is suggestive of benign. 
Blood flow  The speed of the blood inside the mass tissues; high speed is 
suggestive of malignant. 
Envelop  Most benign masses are enveloped or partially enveloped. 
 
There are two main types of mass features in the image; combined morphologic and 
geometric and texture features. The morphological features are related to the structure of 
the mass such as, shape, margin, blood flow and the pattern of mass (Huang et al., 2008). 
The geometrical features, such as, volumes, spaces and measurements, can also be used to 
study the morphological features of the mass to extract a new mass features. On the other 
hand, texture features are related to the arrangement of the colours in the ultrasound 
image. This type of feature is not easy to extract and needs image processing algorithms in 
order to analyse the image.  
Several studies used texture features of ultrasound images for building a BC-CAD. For 
example, 28 texture descriptors related to the intensities of the pixels in the Region Of 
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Interest  (ROI) including the Mean of Sum Average of intensities, Range of Sum Entropy of 
pixels, pixel correlation,…,etc. and two Posterior Acoustic Attenuation Descriptors (PAAD) 
including the difference between the average of gray level within (ROI) and within 32 X 32 
pixels under the  (ROI) and the difference between the gray level in 32 X 32 pixels under the  
(ROI) and the average of the average of gray levels in the two adjacent 32×32 pixel regions 
to the left and right of ROI, were extracted and used for differentiating cyst from solid mass 
(Sivaramakrishna et al., 2002). Stepwise logistic regression was used for feature selection 
and the study obtained 95.4% classification accuracy using Mean of Sum Average of 
intensities, Range of Sum Entropy of pixels and the second PAAD descriptor. In another 
study, the co-variance of pixel intensity in the Region Of Interest (ROI) and the pixel 
similarity were used to differentiate benign from malignant masses in ultrasound image with 
95.6% classification accuracy (Wen, Rueyg, Dar & Cheng, 2001).   
Another study (Zakeri et al., 2012) used the shape and texture features of the mass 
including: eccentricity, the eccentricity of the ellipse that has the same second moment as 
the mass region; solidity of the mass, ratio of the pixels in the mass to the convex including 
the mass; convex hull’s area minus convex rectangular area that contain the convex; Cross 
correlation left and cross correlation right, cross correlation value between the convex 
rectangular area that contain the convex and the left side and right side areas, respectively, 
to classify the masses into benign and malignant. These features were used as inputs to SVM 
to obtain 95% classification accuracy. Furthermore, texture features including auto-
covariance coefficients of the pixels, smoothness of the mass and block difference of inverse 
probabilities were used with Support Vector Machines (SVM) and produced 94.4% 
classification accuracy (Huang et al., 2006). Another study (Xiangjun, 2006) extracted eight 
texture features, three geometric features and two pixel histogram features, and used these 
features as input to a Fuzzy Support Vector Machine (FSVM), Artificial Neural Networks 
(ANN) and SVM to classify 87 lesions into benign and malignant. The FSVM obtained the best 
results where the accuracy was 94.2% followed by the ANN with 88.51% diagnostic accuracy.  
Compared with texture features, there are few studies that used the morphological features 
for building BC-CADs. For example, shape, orientation, margin, lesion boundary, echo 
pattern, and posterior acoustic features were used as inputs for a BC-CAD with 91.7% 
classification accuracy, 88.89% sensitivity and 92.5% specificity (Wei, Ruey, Kyung, Yi & 
Chiun, 2007). Also, another study (Chang, Wu, Moon & Chen, 2005) extracted 6 
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morphological features of the mass shape including: Form Factor, Roundness, Aspect Ratio, 
Convexity, Solidity and Extent; all of these features were based on a maximum and minimum 
diameters of the mass, mass area and convex and mass perimeter. These features were used 
with a Support Vector Machine and obtained 91.7% classification accuracy, 90.59% 
sensitivity and 92.22% specificity. Another study (Chen et al., 2003) extracted seven 
morphological features including the number of substantial protuberances and depressions, 
lobulation index, elliptic-normalized circumference, elliptic-normalized skeleton, long axis to 
short axis ratio, depth-to-width ratio, and size of the lesion. Multilayer Perceptron MLP 
neural networks was used for classification. The accuracy, sensitivity, specificity measures 
were 92.95±2%, 93.6±3% and 91.9±5.3%, respectively. 
Although texture features are good in differentiating benign from malignant, their values 
depend on the settings of the ultrasound machine. On the other hand, the morphological 
features are system independent (Chen et al., 2008). Therefore, in this research we use 
patient features such as, age, and morphological features of the mass for building a BC-CAD. 
Currently, the accuracy of CAD systems based on the morphological features of ultrasound 
images is about 90% and needs further enhancement in order to save the lives of the 
undetected. A meaningful approach to do this is to explore new and meaningful features 
with enhanced discriminating abilities and incorporate them into CAD systems. 
Mass shape is one of the most useful features in breast cancer CAD systems and has been 
used as an input for a classifier in several studies (Heinig, Witteler, Schmitz, Kiesel, & 
Steinhard, 2008; Hong, Rosen, Soo, & Baker, 2005; Lee et al., 2008; Shen et al., 2007). As 
mentioned in chapter 2, this feature takes two main values; regular or irregular shape. The 
irregular mass is an indication for malignancy but there are several benign masses that take 
irregular shape.  
The aim of this chapter is to enhance the diagnostic accuracy of ultrasound based CAD 
systems based on morphological features by a thorough investigation of the shape of the 
mass in ultrasound images in order to extract a new mass feature and employ this feature in 
a CAD system.   
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3.2 Materials and Methods 
This chapter evaluates 99 cases; 46 are malignant and 53 are benign. All cases were obtained 
from The Digital Database for Breast Ultrasound Image (DDBUI) (Tian et al., 2008). The 
Second Affiliated Hospital of Harbin Medical University collected all images from 2002 to 
2007. Each case in the database contains 1 to 6 images and a text file that lists important 
information of the patient and the lesions, such as, age, family history, shape, margin, size, 
blood flow, echo, microcalcification number and shape. All these features were obtained by 
five experts. 
3.2.1 Methods 
This step contains four main steps (Figure 3.2). In the first step all features are extracted and 
normalised. Then, the features that are strongly related to breast cancer have been selected 
for classification. Next, the selected features are used as inputs for multi-classifier systems. 
Finally, the individual classifier is evaluated using test datasets and the results of different 
CAD systems are compared. 
 
 
Figure ‎3.2. The components of the proposed ultrasound CAD system 
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Feature Extraction 
 As mentioned above, each case in the dataset has been described using a text file and 1 to 6 
images (Table 3.2). The text file contains 12 features and some of these features are 
described using linguistic variables such as shape: regular or irregular; envelop: enveloped, 
not filled or none. To use the features we converted the linguistic variables subjectively into 
numeric values as described in Table 3.3. 
Table ‎3.2.  The contents of the text file in the database 
 
 
 
 
 
 
 
 
Assessment:Malignant 
Ultrasound Doctor's Depictation: 
Assessment Sex: Female 
Age:32 
Family History Criterion: 
 Shape:Not Regular 
 Border:Blur 
 Echo:Unequable 
 Envelope:None 
 Side Echo:None 
 Microcalcification Shape:None, 
 Microcalcification Number:0--0 
 Reduction:Has 
 Lymph Transformation:None 
 Blood:II or III Level 
 Mass Maximal Diameter:More than 2 
Mammogram Total Number:0 
Radiologist Assessment:None 
Biopsy Result:None 
Biopsy Description: 
Operation Result:Benign 
Operation Description:breast fibroadenoma 
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Table ‎3.3. Description of the mass features and the numeric value for each description 
Feature Description Coding  
Shape Regular 
1 
Irregular 2 
Border Clear 
1 
Blur 2 
Echo 
Equable 1 
Unequable 2 
Envelope 
None 1 
Not filled 2 
Has 3 
Sides Echo (sides 
shadow) 
None 1 
Has 2 
Microcalcification 
shape 
Needle 3 
Cluster 2 
Big 4 
none 1 
Microcalcification 
number 
0 0 
1 1 
1--2 1.5 
2--3 2.5 
3--4 3.5 
3--5 4 
5--6 5.5 
Reduction (behind 
shadow) 
None 1 
Has 2 
Lymph 
Transformation 
None 1 
Has 2 
Blood 
Level 1 1 
level 2 or 3 2  
Mass Maximal 
Diameter 
<1 1 
>1 and <2 2 
>2 3 
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Also we used the case images to extract two mass geometric features; Depth Width ratio 
(DW) and a new feature called Central Regularity Degree (CRD). To compute the DW feature 
we applied the following steps: 
1- For each case edit the ultrasound image of the mass using any image editor. 
2-  Draw the smallest rectangle that contains the mass as shown in Figure 3.2. The X-
axis of the rectangle parallels the skin line and represents the width of the mass, 
whereas the Y-axis represents the depth of the mass. 
3- Compute the length of mass along X (W) and Y axes (in pixels). 
4- Compute DW = W/D = X/Y. 
A new feature- mass Central Regularity Degree (CRD). 
As we have mentioned above, mass shape is either regular or irregular. The irregular shape 
of mass is an indication of malignancy but there are several benign masses that take an 
irregular shape. Regular mass is suggestive of a benign mass but there are few malignant 
masses that have a regular mass shape. Thus there is a need for further investigation on the 
mass shape to differentiate irregular benign mass from irregular malignant mass. As the final 
results of a careful search for potential new features, we extracted a new geometric feature 
related to the mass shape called Central Regularity Degree (CRD). The CRD reflects the 
degree of regularity of the middle part of the mass. This was inspired by the fact that 
malignant masses have irregular shape the CRD is designed to capture this irregularity. As 
illustrated in Figure 3.3, the mass boundary in this image was defined previously by experts 
as the thin white line (Tian et al., 2008).  
To find CRD, we drew on ultrasound image in Figure 3.3, a small rectangle that contains the 
complete mass using image editor software. The rectangle lines X and Y represent the mass 
width and the mass depth, respectively. Then we divided the rectangle horizontally into 
three equal parts; upper, middle and lower (Figure 3.4). Next, for the middle part of the 
mass we found the length of the horizontal line that is parallel to the rectangle line (X) and 
connected the closest two points on the mass border (Z). Finally, we found the ratio of Z to 
the rectangle width (X) (Equation 3.1). The output value represents the Central Regularity 
Degree of the middle part of the mass. 
                               (3.1)           
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Figure ‎3.3. The smallest rectangle containing the mass where the thin line represents the 
mass boundary and the thick line represents the boundary of the rectangle. The X 
represents the width of the mass along X-axis and Y represents the depth of the mass 
along Y-axis 
 
Figure ‎3.4. New mass feature Central Regularity Degree (CRD). X is the rectangle width 
parallel to skin line, Y is the rectangle depth and Z is the shortest line in the middle part. 
After extracting and coding the mass features, there were 14 features (age, 11 features 
listed in Table 3.3 and the two geometric features) as inputs for the next step. But still there 
is a need for data normalization to speed up the classification process and to remove the 
effect of the large ranges of some features. To do so the Min-Max normalization method 
was applied (Equation 3.2). 
  nnn
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

                 (3.2) 
where X’, A, n are; normalised values of X, old range and new range, respectively. 
Feature Selection  
In this step, we used a wrapper method to select a subset of ultrasound features that are 
strongly related to breast cancer. Now each case in ultrasound dataset is represented as a 
vector of case features S = {S1,...,Sn}. The set of features that is strongly related to breast 
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cancer is selected by using Hierarchal clustering (Johnson, 1967) and a Self-Organizing Map 
(SOM) as follows: 
1- Build a state space starting from empty set in the root and add features one by one until 
we reach the set of all features. 
2- Use sequential search starting from the root to find the node that separates benign 
clusters from malignant clusters by applying the following steps: 
a. Apply Hierarchal clustering. 
b. Find the best cut off point that differentiates benign clusters from malignant clusters. 
c. Compute and save the accuracy and the node index. 
d. Repeat a-c until all nodes in the state space are visited 
3- Select the node with the highest accuracy.   
4- Validate the results using Self Organizing Map (SOM) clustering. 
 
Classification  
To evaluate the effect of the new ultrasound feature CRD on classification accuracy we 
applied four supervised classifiers: Multilayer Feed Forward Neural Network (MFFNN), 
Nearest Centroid (NC), K nearest neighbour (KNN) and Linear Discriminant Analysis (LDA). 
We divided the dataset randomly into two groups: training and testing, where, 77 cases 
were used for training and 22 for testing. Each classifier was trained and tested four times 
using different subsets. Each time the results were stored for the final evaluation.  
 
Multilayer Feed Forward Neural Network (MFFNN) 
Here, we used a Multilayer Feed Forward Neural Network an input layer, one hidden layer 
and one neuron in the output layer. The network was trained using Scaled Conjugate 
Gradient Back Propagation Algorithm (SCGBP) and Logistic function as the neuron activation 
function.  
Optimizing the number of hidden neurons in the network is still a challenge. Insufficient 
number of hidden neurons results in two problems:  the first is under fitting that results 
from selecting a small number of hidden neurons. The second problem is over fitting that 
results from selecting a large number of hidden neurons. To overcome these problems, this 
study used Self Organizing Map (SOM) to optimize the number of hidden neurons in the 
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network as described by Samarasinghe (2010). The algorithm starts with training a feed 
forward neural network with a relatively large number of neurons in the hidden layer. Then 
it reduces the number of hidden neurons by removing the redundant neurons that form 
correlated associations with other neurons. The net or weighted input ui to neuron i and the 
output yi of each neuron in the hidden layer is given by the following equations:                                
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 where x is an input vector, r is the number of inputs including bias inputs and wi is the 
weight vector between input vector x and neuron i. From Equation 3.3, the weighted input 
to the output neuron v and the final output of the neural network are:  
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 where, b0 is the bias input to the output neuron, b is the weight vector between hidden 
neurons and the output neuron.  
Form the above equations, the effect of hidden neurons in the classification result depends 
on the input-hidden layer weights and hidden-output layer weights so that we can describe 
each neuron in the hidden layer as:    
 iimiiii bwwwwNE ,, 210   (3.5) 
Now, we have a hidden neuron weight matrix NE where each row in the matrix represents 
one neuron. To reduce the complexity of the neural network, we removed the redundant 
neurons. To do this, we applied SOM to find the distribution of hidden neuron vectors over 
an SOM map and grouped similar neuron vectors into clusters. The number of different 
clusters on the SOM indicates the optimum number of hidden neurons. 
K-Nearest Neighbour (KNN) 
As described in the literature, the experimental samples are represented as marked points in 
the space where each mark denotes one class. For a new instance, the classifier represents 
the instance in the same space and calculates the distance between it and the experimental 
samples. The label of the new instance depends on the labels of the K closest points to the 
new instance. The instance is labelled with the class label that has the largest number of 
points within K closest points (Wu et al., 2007). To select the value of K we applied the 
following steps: 
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1- Set F = 0. 
2- For I=2 to N, where N is a large number.  
a- Set the value of K=I  
b- Classify the samples using KNN. 
c- Compute the overall accuracy.  
d- If accuracy ≥ F then set F = accuracy and Best = I. 
3- Set K = Best 
 
Nearest Centroid (NC) 
In this classifier, the classification is done by calculating the mean (centroid) of both classes, 
malignant and benign. For the new object x, the algorithm calculates the distance between 
the new object and the means of the classes; the object is then labelled with the label of the 
closest class centroid (Marcoulides, 2004). 
 
Linear Discriminant Analysis (LDA) 
This classifier uses a covariance matrix to build a hyperplane between the benign and 
malignant classes by maximizing between to within variance ratio for the classes (Equation 
3.6) (Balakrishnama & Ganapathiraju, 1998) such that.   
jixjpxiP  )|()|(  (3.6) 
The probability that x belongs to class i not easy to compute; therefore, the simplest 
mathematical formula of LDA is: 
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(3.7) 
where µi is the mean vector of class i,  C-1 is the inverse of covariance matrix of the dataset 
and pi is the probability of class i.  
xk belongs to class i if and only if: 
jixfxf kjki  )()(  
(3.8) 
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Evaluation 
The aim of this step is to evaluate the performance of the two CAD systems (with and 
without) using sensitivity, specificity, False Positive (FP) rate, False Negative (FN) rate and an 
overall accuracy (Altman & Bland, 1994).  
Sensitivity =
samplesmalignantofnumberTotal
samplesmalignantofNumber  classifiedcorrectly 
                              (3.9) 
Specificity =
samplesbenignofnumberTotal
samplesbenignofNumber  classifiedcorrectly 
                       (3.10) 
Accuracy =
samplesofnumberTotal
samplesofNumber  classifiedcorrectly 
                          (3.11) 
FP  =
classmalignantinsamplesofnumberTotal
classifiedfalslysamplesbenignofNumber
                               (3.12) 
FN  =
classbenigninsamplesofnumberTotal
classifiedfalslysamplesmalignantofNumber
           (3.13) 
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3.3 Results And Discussion 
3.3.1 Feature selection 
Frequencies of specific ultrasound features in both malignant and benign cases are shown in 
Table 3.4. The feature would be considered as a good feature if it clearly separated benign 
from malignant cases; for example, the margin was considered a good feature because most 
malignant cases (38 out of 46) were blurry and most benign cases (38 out of 53) were clear. 
On the other hand, the mass echo was not considered a good feature because most benign 
(34 out of 53) and malignant (42 out of 46) cases were not equable. 
Table 3.4 shows seven good features and these are: Age, Shape, Margin, Microcalcification, 
Blood level, WD ratio and CRD. In particular, it shows that the new feature CRD in on par 
with the most effective feature-margin. According to the good features a malignant mass 
has irregular shape, blurry margin, not equable echo pattern, potential microcalcification, 
higher blood speed or level, lower DW ratio (below 1.34) indicative of less elongated shape 
and smaller CRD (below 0.7) indicative more irregular shape.    
Hierarchical clustering (HC) and self-organizing maps were used for feature selection. We 
started with hierarchical clustering to find a set of features that separates benign cases and 
malignant cases into different clusters. Hierarchical clustering found age, shape, margin, 
blood level, DW and our new feature CRD as the features that strongly related to breast 
cancer. HC divided the dataset into 9 different clusters. The distribution of malignant 
samples was: 39 out of 46 cases were distributed over 2 different clusters (clusters X and Y) 
with 0.84 sensitivity (ratio of malignant cases in the 2 clusters to total malignant cases) 
(Figure 3.5). On the other hand, 42 out of 53 benign cases were distributed over 7 clusters 
with 0.793 specificity (ratio of benign cases in the 7 clusters to total benign cases) (Figure 
3.5). The Hierarchical clustering produced 81.8% accuracy.  
To confirm the above results, we used SOM to find the distribution of the 99 ultrasound 
samples over SOM map using the same features. The dataset was distributed over different 
regions on the SOM map where most of the malignant cases (41 out of 46) were distributed 
in the upper part of SOM and most benign cases (37 out of 53) were distributed in the lower 
part of SOM (Figure 3.6C). The SOM U-matrix clearly divided the upper part of SOM into 
three clusters that appear in the U-matrix as dark blue regions (Figure 3.6B). To clarify the 
boundary of each cluster in SOM map, we used K-mean clustering (k=9), same number of 
clusters in hierarchal clustering, to cluster the neurons of SOM (Figure 3.6A). By analysing 
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the 9 clusters we found 89% of malignant cases were distributed over 3 clusters (1, 2 and 3) 
and 70% of benign cases were distributed over the other 6 clusters. Both Hierarchical 
clustering and SOM found the above features strongly related to breast cancer. 
 
Table ‎3.4. Frequency of ultrasound features in 99 cases (46 are malignant (M) and 53 are 
benign (B)) 
Feature M B Quality  
Age mean 46.4 38 Good 
Shape    
   Regular 2 29 Good 
   Irregular 44 24  
Margin    
   Clear 8 38 Good 
    Blur 38 15  
Echo    
   Equable 4 19 Not good 
   Not equable 42 34  
Envelope     
   Enveloped 8 9  
   Partially  5 9 Not good 
   No  33 35  
Microcalcification    
   Big 2 0 Good 
   Cluster 2 1  
   Needle 21 6  
   None 21 46  
Blood level    
   Level 1 14 41 Good 
   > 1 32 12  
WD ratio    
   >=1.34 17 36 Good 
   <1.34 29 17  
CRD    
   >=0.7 10 39 Good 
   <0.7 36 14  
Diameter     
   <=1 2 8 Not  good 
   >1 and <=2 24 26  
   >2 20 19  
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Figure ‎3.5. The hierarchal clustering of the 99 cases using the 6 selected features. Each colour represents a cluster. The hierarchal clustering has 
spread the 99 cases over 9 different clusters. 
X 
Y 
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Figure ‎3.6. SOM clustering of ultrasound data: A) Clusters (colour coded). B) SOM U-matrix, 
the distance of a neuron to the neighboring nodes in the SOM lattice is represented by a 
colour according to the bar that appears on the right side of the figure, the distances range 
from dark blue (small distance) to dark red (large distance) large distances indicates 
potential clusters boundaries. C) The distribution of the benign (a) and malignant (m) cases 
over the SOM lattice. 
 
B A 
C 
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3.3.2 Classifications 
This step has been divided into two main stages: In the first stage, we applied the four 
classifiers; KNN, MFFNN, NC and LDA, on the dataset using all features including CRD. For 
KNN, firstly, we must determine the value of K, which represents the number of neighbours 
that controls the class label of the new instance. To do that, we started with large K=30 
down to K=1 (Figure 3.7). The best result was obtained when the value of k = 3.  
 
Figure ‎3.7. The accuracies of different k values for KNN clustering. Where the X-axis 
represents the value of K and Y-axis represents the accuracy 
The MFFNN is more complicated than KNN. In the MFFNN, we must take into account the 
optimal number of neurons in the hidden layer. To do this, firstly, we trained and tested 
MFFNN using a large number of hidden neurons and reduce the number gradually. Every 
time, we compared the results with the previous results until the best results were achieved. 
The best results were obtained using 15 hidden neurons. Secondly, despite the goodness of 
the results obtained with the 15 hidden neurons, we applied a network pruning method 
based on SOM clustering of correlated hidden neuron activations patterns (Samarasinghe, 
2010) to the MFFNN neuron network just achieved. The purpose was to determine whether 
there is a network less complicated than the 15 hidden neuron network still gives good 
results. As input into SOM, 8 attributes; weights of the 6 input-hidden connections, weight of 
the bias and hidden-output weight represent a hidden neuron in the hidden layer (see 
Chapter 2 for more details).  
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To build the SOM, we started from selecting the SOM topology; this study used hexagonal 
topology. Then, a 4x5 hexagon map was built and trained as described previously. The ward 
method was used to divide map neurons into clusters which resulting in 9 different clusters 
(Figure 3.8). According to Samarasinghe (2010), the number of different clusters represents 
the number of optimum hidden neurons. To verify the performance of the 9 hidden neurons 
instead of 15 neurons, we built an MFFNN using 9 neurons in the hidden layer. Then, the 
new MFFNN was trained and tested using the same dataset. The output results obtained 
from 9 hidden neurons neural network were compared with the results of MFFNN using 15 
hidden neurons and the values of accuracy, sensitivity and specificity were found equal in 
both networks. The classification accuracy was 95.5% with 100% sensitivity and 90.9% 
specificity. The results show that the SOM reduced the number of hidden neurons without 
any effect on the classification performance and reduced the complexity of the neural 
networks. 
 
Figure ‎3.8. SOM for 15 hidden neurons. A) The Distribution of 15 neurons over the map, 
groups of neurons (4, 7, 10), (6, 12) and (14, 15) shared the same Best Matching Unit 
(BMU) and formed three clusters. B) U-matrix for the 15 hidden neurons, neurons (9, 1, 8) 
were found close to each other (the blue colour on the top right of the matrix) and 
considered to be one cluster.  The SOM neurons were divided into 9 clusters. 
 
The outputs of different classifiers obtained from the first stage are shown in Table 3.5. The 
MFFNN was the superior classifier with 100% sensitivity, 90.9% specificity, 8.3% False 
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Positive (FP) rate, 100% True Negative (TN) rate and 95.5% classification accuracy. NC is the 
worst classifier. KNN and LDA had similar accuracies but LDA was a better discriminator of 
malignant cases. 
Table ‎3.5. The performance of different classifiers using all features.  (SN is sensitivity, SP 
specificity and Ac accuracy) 
classifier Training Testing 
SN SP Ac SN SP Ac 
KNN 85.7% 92.8% 89.6% 81.9% 90.9% 86.4% 
NC 82.8% 75.6% 80.5% 100% 63.6% 81.8% 
MFFNN 100% 100% 100% 100% 90.9% 95.4% 
LDA 82.8% 85.7% 84.4% 90.9% 81.8% 86.4% 
 
In the second stage, we applied the same classifiers (KNN, NC, MFFNN and LDA) on the same 
dataset using all features except CRD. The output results of different classifiers are shown in 
Table 3.6. By comparing the results of different classifiers obtained from the first and second 
stages we found that, the sensitivities of KNN and LDA in the training phase were improved 
by 5.7% and 2.8%, respectively, by adding CRD. Also, the specificity of LDA was increased 
from 83.3% to 85.7%; furthermore the overall accuracies of LDA and KNN have increased. In 
the testing phase the sensitivity of MFFNN and NC were improved by 18.2% and 9.1%, 
respectively, by adding CRD. Also the specificity of MFFNN and LDA were increased to 90.9% 
and 81.8% from 81.8% to 72.7%, respectively. Adding the CRD increased the overall accuracy 
of the three classifiers, MFFNN, NC and LDA. 
Only in the testing phase of KNN classifier we found adding CRD decreased the classification 
accuracy. This is because of the disadvantages KNN (see chapter 2) that leads to an increase in the 
number of missclassified cases in the testing phase. However, the overall accuracy of the classifier 
(training and testing) is increased by adding the new CRD feature where the overall accuracy of KNN 
using all features except CRD is ((22*90.9/100) + (77*85.7))/99)%=  86.9%;  on the other hand overall 
accuracy of KNN using all features is 88.8%. 
 
Table ‎3.6. The performance of different classifiers using all features except CRD 
Classifier Training Testing 
SN SP Ac SN SP Ac 
KNN 80% 92.8% 85.7% 90.9% 90.9% 90.9% 
NC 82.8% 75.6% 80.5% 90.9% 63.6% 77.3% 
MFFNN 100% 100% 100% 81.8% 81.8% 81.8% 
LDA 80% 83.3% 81.8% 90.9% 72.7% 81.4% 
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From the above comparison, we found that adding the new feature CRD enhanced the 
diagnostic accuracy of the BC-CAD. The best results were obtained by MFFNN with 95.4% 
accuracy, 90.9% specificity and 100% sensitivity. These results were compared with Wei et al 
(2007) study that used the same morphological features of masses except our new feature 
CRD as inputs to the CAD. The comparison found the accuracy of current system is 3.7% 
better than their system. The significant improvement of current BC-CAD over Wei et al 
(2007) system was in the sensitivity value where the current system obtained 100% 
sensitivity whereas their system obtained only 88.89% which means that there are 11.11% of 
cancer cases misdiagnosed in Wei et al. (2007) system that will be diagnosed correctly by the 
current system and hence more lives could be saved.  
Also, we compared results of the current system with Chang et al. (2005) results and we 
found that the current diagnostic system improved the accuracy by 3.7% and enhanced the 
sensitivity by 9%- a significant improvement. Furthermore, the results of the current system 
was slightly better than the results obtained by Chen et al. (2003)  where the best accuracy 
for this system was 94.8% compared with 95.4% classification accuracy of the current 
system. But Chen et al. (2003) system was more complicated than the current system 
because all the features used in their system were based on image processing algorithms 
that are computationally exhaustive and time consuming. Also, it is difficult for a radiologist 
to extract such features which make these features unusable in a direct diagnostic 
assessment made by the radiologist. In contrast, all the features used in the current system 
are extracted from the radiologist’s report except DW ratio and our new feature CRD that is 
easy to extract and use by a radiologist does not need any image processing algorithms. By 
these comparisons we found that the current system enhanced the diagnostic accuracy of 
previous ultrasound based BC-CAD systems.  
3.4  Summary  
We have presented in this chapter the ultrasound based CAD system for early detection of 
breast cancer, the clinical part of the current BC-CAD framework, and evaluated the effect of 
the new geometric mass feature (CRD) on the diagnostic accuracy of the CAD system. We 
started with the definitions of breast ultrasound findings. Then, from a thorough 
investigation of the images, we extracted a new geometric feature related to the shape of 
the mass in ultrasound images called Central Regularity Degree (CRD) and with inspired by 
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the fact that most of malignant masses are irregular. The CRD reflects the degree of 
regularity of the middle part of the mass. To demonstrate the effect of CRD on 
differentiating malignant from benign masses and the potential improvement of the 
diagnostic accuracy of breast cancer based on ultrasound images, this study evaluated the 
diagnostic accuracy of different classifiers when CRD was added to five known effective mass 
features: one geometric feature which is Depth-Width ratio (DW); two morphological 
features: shape and margin; and blood flow and age.  
Multilayer Feed Forward Neural Networks (MFFNN), K Nearest Neighbour (KNN), Nearest 
Centroid (NC) and Linear Discriminant Analysis (LDA) were used for classification and 
accuracy, sensitivity and specificity measures were used for evaluation. Ninety-nine breast 
sonograms - 46 of which were malignant and 53 benign were evaluated. The results revealed 
that CRD is an effective feature discriminating between malignant and benign cases leading 
to improved accuracy of diagnosing breast cancer. MFFNN obtained the best results, where 
the accuracies in the training and testing phase using all features except CRD were 100% and 
81.8%, respectively. On the other hand, adding CRD improves the accuracy of training and 
testing phases to 100% and 95.5%, respectively. Therefore, the overall improvement by 
adding CRD was about 14%, a significant improvement. Also, the new CRD feature makes the 
current system better than the previous CADs that used the morphological features of 
ultrasound images. 
By the end of this chapter the clinical part of the framework is completed and the framework 
can support the decision of a doctor using the morphological features of ultrasound images. 
In the next two chapters, we introduce the biological part of the framework including blood 
based mRNA BC-CAD system (Chapter 4) and circulating miRNA based BC-CAD system 
(Chapter 5).  
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Chapter 4: Gene expression based Computer Aided diagnosis 
system for Breast Cancer: A novel biological filter for biomarker 
detection 
In this chapter we focus on the biological part of the computational Breast Cancer Computer 
Aided Diagnosis (BC-CAD) framework. Specifically, we introduce a blood based gene 
expression BC-CAD system (Figure 4.1). Figure 4.1 show the three components of the current 
framework including the clinical part- ultrasound based BC-CAD, and the biological part- 
mRNA and miRNA based BC-CAD systems. The part highlighted in orange is the focus of this 
chapter.   
 
 
Figure ‎4.1. The Breast Cancer Computer Aided Diagnosis (BC-CAD) Framework showing the 
three CAD systems. (The orange part, mRNA BC-CAD, is the focus of this chapter) 
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4.1 Introduction 
Cancer is a complex disease because it makes complex cellular changes. Therefore, 
microarrays have become a powerful way to analyse cancer and identify what changes are 
produced within a cell. Through DNA microarrays, looking at the expression of thousands of 
genes in one sample has become possible and this is called gene expression profiling. Gene 
expression profiling is important to capture a set of expressed genes that determines a cell 
phenotype. 
Cell samples are required to design a microarray. There are two main sources of cell 
samples: tissues or blood cells. However, collecting tissue samples is not safe and such 
samples are not readily available, especially from healthy people (Marteau et al., 2005). On 
the other hand, peripheral blood is readily available, easy to access and is a rich source of 
genetic information for studying human diseases. These properties make blood a perfect 
source for measuring gene expression (Fang et al., 2006). Therefore, in this study, we used 
gene expression profiling of peripheral blood cells. 
Recently, gene expression profiling of peripheral blood cells has been used for early 
detection of breast cancer. However, analysing microarray data is challenged by the high-
dimensionality of the data compared with the number of samples. Most of the previous 
studies in this field have used either filters or wrappers to select a subset of genes that 
differentiate cancer from control cases (Aaroe et al., 2010; Fan et al., 2010; Kretschmer et 
al., 2011; Ma et al., 2011; Schrauder et al., 2012). However, as we discussed in Chapter 2, 
both of the above methods have disadvantages; for example, the wrapper methods are 
challenged by the dimensionality of the data whereas the filters ignore the relation between 
the features. For example, mRNA that is extracted from peripheral blood cells has been used 
by a Norwegian group for analysing the expression of 1,368 genes extracted from peripheral 
blood cells of 56 women: 24 breast cancer and 32 healthy, for early detection of breast 
cancer. The study used wrapper method for feature selection and correctly predicted 82% of 
the samples using 37 probes (29 genes) (Sharma et al., 2005).  
To confirm the results of Sharma et al., (2005) study, a larger sample of 11,217 genes 
extracted from 130 women was analysed (Aaroe et al., 2010). The study used Partial Least 
Square Regression (PLSR) and Jackknife testing (Wu, 1986) with dual leave one out cross 
validation for feature selection and classification. The PLSR with leave one out cross 
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validation was used to reduce the dimensionality of the data by selecting the optimum 
number of latent variables. This is a set of variables that are selected by analysing the 
covariance between the genes expression vectors and the class label. The regression returns 
also the regression coefficient for each gene. The Jackknife testing method is used to select 
the variables that have regression coefficient different from 0; p-value <0.05. The study 
obtained a set of 738 up and down regulated probes that differentiated healthy from cancer 
samples with 79.5% prediction accuracy, 80.6% sensitivity, and 78.3% specificity. The study 
compared the 738 genes with the 37 probes (29 unique genes) obtained from the previous 
study (Sharma  et al., 2005) and found that 20 out of the 29 genes were not significant in 
relation to the disease status in the present study (Aaroe et al., 2010). The hypothesis that a 
larger sample could increase prediction accuracy was not proved in this case. However, this 
study used filtering methods for feature selection that ignored the biological relation 
between genes and selected the genes based on the ability of individual genes to 
differentiate cancer from control cases. In addition, the method selected a large number of 
genes compared with the number of samples, as inputs for the classifier which can 
negatively affect the outcomes. Furthermore, the accuracy of current CAD systems based on 
mRNA is about 79% and needs further enhancement in order to save the lives of the 
undetected. 
Gene co-expression provides key information to understand living systems, where the co-
expressed genes are often involved in the same biological pathway (Obayashi et al., 2008). 
Given that, the similarity between genes may reflect the biological relation between them, 
where the genes with high similarity may have similar biological function or may be a part of 
the same pathway (Yip & Horvath, 2007; Zhang & Horvath, 2005). There are several ways to 
compute the similarity between genes. The most common one for gene expression data is 
Pearson Correlation Coefficient (PCC) and it is a perfect measure that reflects the linear 
relationship between a pair of genes. The PCC takes values in the range from +1 to -1. A 
correlation of +1 means that there is a perfect positive linear relationship between variables 
(features) and -1 means that there is a perfect negative linear relationship between 
variables. However, PCC considers each pair of variables in isolation to other variables. From 
a biological perspective, the relationships with other variables, genes or proteins, should be 
taken into account. This is because if a pair of genes shares relations with other genes, they 
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all may be similar and may belong to the same pathway or may have similar biological 
functions (Yip & Horvath, 2007; Zhang & Horvath, 2005).  
A meaningful approach to increase the diagnostic accuracy of mRNA CAD systems that 
incorporates biological relations in genes is to explore novel gene selection methods that 
considers biologically-significant relations between the genes. Then, incorporate the 
selected genes into a CAD system. In this chapter, we aim to introduce a novel feature 
selection method called Bi-biological filter and Best First Search with SVM (BFS-SVM). 
4.2 Materials 
In this study we used 121 samples (67 malignant and 54 benign) that were collected by 
(Ullevål University Hospital and Haukeland University Hospital) between 2002-2004. The 
malignant group contains 10 samples with ductal carcinoma in situ and 57 invasive 
carcinoma samples spread across a number of severity Grades, from I to III. Invasive 
carcinoma samples include 49 Ductal, 4 Lobular and 4 another invasive types. The dataset 
also contains 12 benign cases and 42 normal cases with neither benign nor malignant 
findings (Table 4.1). Each sample contains 11,217 genes (7351 known genes and 3866 
unknown genes). The known genes are genes that have gene symbols and gene IDs whereas 
the unknown genes are the genes with no symbols and IDs at this stage. In this study, we 
only used the 7351 known genes. The samples are publicly available in the NCBI's Gene 
Expression Omnibus through GEO:GSE16443 accession number.  
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Table ‎4.1. Clinical characteristics of the 121 samples 
Diagnosis  Number  Grade  
Ductal Carcinoma in situ DCIS 10 I:1 
II:2 
III:7 
Invasive Ductal Carcinoma (IDC) 49 I:  11 
II: 17 
III: 16 
Unknown: 5 
Invasive Lobular Carcinoma (ILC)  
 
4 I: 2 
II: 2 
Other invasive  
 
4 Invasive Tubular Carcinoma: 
2  
Medullary Carcinoma: 1 
Other/mixed cases:1 
 
Benign changes   12 Fibroadenoma: 1. 
Fibroadenoma and 
Haematoma: 1. 
Cyst: 6. 
Unspecified findings:6 
No finding  42  
4.3 Methods 
4.3.1 Data pre-processing 
The microarray data used in this work was downloaded from the Gene Expression Omnibus 
through GEO:GSE16443 accession number. The data is already pre-processed, where the 
effect of the background has been removed, normalised and summarised. As we mentioned 
earlier, the dataset contains 11,217 genes. But there are 3866 currently unknown genes so 
we exclude these genes and only use the 7351 known genes for building the CAD system. 
4.3.2 Feature selection 
Learning tasks, such as classification and clustering are challenged by high dimensional data. 
Such data may have a lot of noisy features which make the learning task very complex. The 
process of removing noisy data (irrelevant and redundant) or choosing a sub set of features 
(relevant) from a given set of features is called feature selection (Blum & Langley, 1997; 
Gilad-Bachrach et al., 2004). In this research we used a new method of feature selection 
called Bi-Biological Filter and Best First Search with SVM wrapper (BiBio-BFSS). This method 
contains two main steps; bi-biological filter and Best First Search with SVM wrapper (Figure 
4.2). The bi-biological filter also contains two steps: neither cancer nor healthy biomarker 
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elimination and healthy biomarker removal. The output genes from Bi-Biological filter are 
used as inputs to BFS-SVM wrapper to select a smaller set of genes for classification.  
 
Figure ‎4.2. Bi-Biological filter and Best First Search with SVM wrapper (BiBio-BFSS) feature 
selection flow chart. The dataset is divided into two subsets; cancer and healthy and 
entered to the Bi-biological filter. In the first step, the cancer dataset is used to remove 
neither cancer nor healthy biomarkers. Then, the healthy dataset and the output from the 
first step are used for removing healthy biomarkers. The outputs of Bi-Biological are used 
as input for BFS-SVM wrapper that selects a subset of features for classification    
 
Bi-biological filter 
The biomarkers of breast cancer should satisfy two conditions: firstly,  it should be shared 
between any cancer sets. Secondly, it should be absent from any healthy sets. All previous 
studies perform a direct comparison between the cancer set and healthy set and selected 
the biomarkers that are absent from the healthy set which is the second condition. But still 
there is a need to remove the biomarkers that are not shared between cancer sets. These 
biomarkers maybe related to any non-cancer condition –for example “influenza”- or noise in 
the gene expression data– for example noise that results from anxiety, temperature, etc. 
Bi-biological filter is responsible for selecting a group of genes that are strongly related to 
breast cancer by using gene co-expression networks as described by Zhang and Horvath 
(2005). The first step is designed for removing the biomarkers or modules, groups of genes 
that are not shared between the cancer cases (neither cancer nor healthy groups). This type 
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of groups may result from the noise in the dataset or other disease biomarkers shared 
between some cancer cases. The second step is to filter out the healthy biomarkers from the 
selected biomarkers found in the first step. 
Neither cancer nor healthy biomarker filtering 
This is to remove the modules that are not shared between all cancer cases. To do this, we 
randomly divided the malignant dataset into two sub-datasets, 33 samples assigned to M1 
and 34 samples to M2. Then, the genes of each subset were divided into functional groups 
as follows: 
1- Build Co-expression Network described by Zhang and Horvath (2005) as follows : 
a. Find the correlation matrix S (similarity matrix) using Pearson Correlation Coefficient 
(PCC) (Equation 4.1). The output matrix is an adjacency matrix of 7351 X 7351 
PCCij=
          
 
             
 
   
 
   
       
  
           
 
   
 
       
  
           
 
   
 
 (4.1) 
 
where n is the number of samples and xju represents the expression value of gene j in sample 
u. 
Now, we compute the connectivity value for each gene (Ki=∑ PCCij). The connectivity value 
reflects the strength of the correlation between the gene and other genes; a high value 
means that there are a lot of genes strongly correlated to that gene, and a small value 
means that there is only a small number of genes strongly correlated to that gene. To 
highlight strong relations, dampen weak correlations and to convert the network to scale-
free topology we powered the absolute value of PCC to β (Equation 4.2).  
As described by Zhang and Horvath (2005), network satisfies scale-free topology if the 
number of hubs with strong connections to other genes is small compared with the number 
of genes that have a small connection strength to other genes. In other words, the 
frequencies of high connectivity are small compared with frequencies of low connectivity 
values. Mathematically, the network is supposed to have scale free topology, if the 
distribution of the nodes degrees (connectivity values) follow a power law, P(K) =cK-p, where 
p(K) is the frequency of the connectivity value K, c is normalisation constant and p is a value 
between 1 and 2. Accordingly, log-log plot, log(K) and log(p(K)), should approximately follow 
a straight line with a slope between 1 and 2. To make meaningful comparisons across 
datasets the value of β is chosen to be 6 as used previously by Zhang and Horvath (2005). 
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Wij =       
 
  
(4.2) 
2- The above output matrix (W) represents the similarity between one pair of genes only. 
To involve other genes in the similarity consideration, we will recompute the similarity 
using the above matrix and topology overlap between all pairs of genes as follows: 
a. For each gene in the dataset find the degree or the connectivity value of the gene using 
wij instead of PCCij (Equation 4.3).  
       
 
   
   
  (4.3) 
 
where ci is the connectivity of gene i and wij is the similarity value between gene i and j 
from step 1. The resulting vector C represents the connectivity of all genes where C is an 
nx1 vector.                 
b. Now, for each pair of genes we find the number of shared genes. Assume the 
correlation between any pair of genes i and j is represented by aij {0,1}, where, 0 
means that there is a weak correlation between the pair of genes, correlation value < 
threshold, and 1 means that there is a perfect correlation between the pair of genes, 
correlation value ≥ threshold. To find the number of shared genes between a pair of 
genes, we compute the inner product of genes’ vectors (Equation 4.4); 
        
 
   
     
     (4.4) 
where, Iij is the number of shared genes between gene i and gene j and aui is the 
correlation value between gene i and gene u. For example, assume the dataset contains 
19 genes x1,...,x19; the correlation for this case will be 19X19 adjacency matrix (Table 
4.2). From the Table, the number of shared genes between genes 1 and 4 is 3. 
However, Equation 4.4 leads to some information loss, due to discretisation of the 
correlation values (similarity values). To overcome this problem we use wui instead of 
aui (Equation 4.5).  
        
 
   
     
     (4.5) 
where lij is a number between 0 and n and wui is the similarity value; a high value of Iij means 
that there is a high number of shared genes between i and j and low value means that there 
is no or few shared genes between i and j. 
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Table ‎4.2. The adjacency or similarity matrix between 19 genes, where the first row and 
the first column represents the gene ID. The matrix is symmetric (aui = aiu) so the values 
along the diagonal are 0 (auu=0)  
 1 2  3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
2 1 0 0 1 1 0 0 0 0 0 0 0 0 0 1 0 0 1 0 
3 1 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 1 0 
4 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 1 
5 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
6 0 0 1 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 
7 0 0 0 0 0 1 0 1 1 0 0 0 0 0 1 0 0 0 0 
8 0 0 0 0 0 1 1 0 1 0 1 0 0 0 0 0 0 0 0 
9 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 
19 0 0 0 0 0 0 0 0 0 0 1 1 0 0 1 0 0 0 0 
11 0 0 0 0 0 0 0 1 0 1 0 1 0 1 0 0 0 0 0 
12 0 0 0 0 0 0 0 0 0 1 1 0 1 0 1 0 0 0 0 
13 0 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 
14 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 0 0 0 0 
15 0 1 0 0 0 0 1 0 0 1 0 1 0 1 0 0 0 0 1 
16 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
17 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 
18 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 
19 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 
 
c. Now, we use the topological overlap similarity between each gene pair (Equation 4.6). To 
get this equation, the value of Iij (see Equation 4.5) is added to the numerator so that the 
high value of Iij increases the similarity between the pair of genes. Assume, the 
connectivity values of i, j, e genes are 20, 700 and 600, respectively, and the values lij , lje 
are 15 and 30. By comparing the values of lij and lje, we find that lij is smaller than lje 
which makes the numerator of tje greater than the numerator of tij (Equation 4.6) and 
makes tje better than tij. However, in fact, lij is better than lje because most genes strongly 
correlated to i gene are also strongly correlated to j gene and few genes correlated to j 
are correlated to e. To overcome this, the minimum connectivity value between the pair 
of genes min(ci,cj) is added to the denominator where a small connectivity value 
increases the topological overlap similarity. Also,       is used to prevent dividing by 0 
when          = 0. 
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  (4.6) 
The above output matrix tij called Topological Overlap Matrix (TOM) -the ratio of the number 
of the pairwise connections between genes i and j to the smaller of the number of 
connections to all genes of one of them, so is a “local link to global link” comparison-  is 
plotted in a weighted undirected graph (see Chapter 2 for more details), where each gene is 
represented as a vertex and the edge between the pair of genes is weighted by the 
topological overlap similarity tij value. For example, the simpler case of the above {0,1} 
adjacency matrix (Table 4.2) can be represented by the network shown in Figure 4.3. With tij 
values a network based TOM will has not only edges but also strength of the edges tij.  
Module extraction 
Clustering plays an important role in data analysis. In biology, especially with high 
dimensional data, clustering has been used to reduce the dimensionality of data by grouping 
the similar dimensions. The module is a group of genes working together to do a specific 
biological function. From the above definition, the genes that are strongly correlated to each 
other may belong to one pathway or do similar functions. To find the clusters of genes, this 
work will use Spectral Clustering. The spectral clustering is easy to implement and a 
powerful clustering method for similarity based graphs.  
  
Figure ‎4.3. The graph that represents the adjacency matrix in Table 4.2. The square 
represents the node and the existence of an edge means that there is a relation between 
the pair of genes 
 
 
Spectral clustering algorithm 
Spectral clustering is a clustering method that divides the Laplacian matrix (L) of the 
adjacency matrix using spectral (eigenvalues) analysis. The Laplacian matrix holds 
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information about the structure of the graph and its sub-graphs. It is a symmetric and 
positive semidefinite (all its eigenvalues are positive [0,2]) matrix. The number of times 2 
appears as an eigenvalue is the number of connected components in the graph. The 
connected components are a set of vertices in a graph where all vertices in the set are 
connected to each other directly or indirectly and are isolated from the other graph vertices.  
The TOM matrix can be represented as an undirected graph G={V,E}, where V is the set of 
vertices {g1,g2,…,gn}, n is the number of genes in the data set, and E= { t11, t12,..,tnn}, tij is the 
topological overlap similarity between genes i and j. To apply spectral clustering on TOM 
graph we follow the following steps as described by Ng, Jordan and Weiss (2001): 
1. Find the  degree of each vertex in the graph (Equation 4.7):  
       
 
     (4.7) 
2. From the vertex degree we can define a new matrix called the degree matrix (D) 
(Equation 4.8). The degree matrix is a diagonal matrix where the diagonal is the vertex 
degrees and the off diagonal entries are zeros. 
   
     
      
    (4.8) 
 
3. This step is to find the graph’s Laplacian matrix (L). There are two types of spectral 
clustering, normalised (Equation 4.10) and non-normalised (Equation 4.9) Laplacian, 
respectively, based on the Laplacian matrix used for clustering. 
A- Non- normalised Laplacian: 
L= D-TOM (4.9) 
  Where TOM is the Topological Overlap Matrix (Equation 4.6) 
B- Normalised Laplacian: 
     
                     
   
      
             
  (4.10) 
The normalised spectral clustering is known to outperform the non-normalised version in 
high dimensional data (Ng, Jordan & Weiss, 2001). So, we will use normalised spectral 
clustering. 
Now we perform spectral clustering as follows:  
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a- Find all eigenvalues and eigenvectors for the normalised Laplacian matrix. An 
eigenvector v of a symmetric matrix (X) is a nonzero vector that satisfies Xv=λv, where λ 
is a scalar by which the eigenvector changes when multiplied by the matrix and called 
eigenvalue. To find the eigenvalues and eigenvectors of the symmetric matrix X, we use 
Equation 4.11. Any n-by-n symmetric matrix has n eigenvalues λ1< λ2<...< λn and n 
eigenvectors {v1, v2,…, vn} corresponding to the eigenvalues where eigenvectors of 
different eigenvalues are orthogonal to each other. 
Det(X-λ.I)v=0   (4.11) 
where I is the identity matrix of X and Det(z) is the determinant of matrix of z. 
 
b- Next step is to determine the number of sub-graphs or clusters in the gene co-expression 
graph. This is done by selecting K representative eigenvectors from the n eigenvectors of 
the graph, where K is much smaller than n, in order to reduce the dimensionality of the 
data and to select the number of clusters. According to spectral clustering, the number 
of representative eigenvectors is equal to the number of clusters. However, the difficulty 
lies in determining the number of representative eigenvectors. Typically, the value of K is 
chosen based on the largest K eigenvalues. In order to find this value, the gaps between 
all adjacent pairs of eigenvalues are computed and then the value of K is determined on 
the basis of the largest gap, so that the gap between k and k-1 is much less than the gap 
between k and k +1.  
c- Let V є RnX k be the matrix containing the selected eigenvectors v1, v2, v3, …, vk as 
columns. Form the matrix U by normalizing the row sums to 1 (Equation 4.12). Now, 
genes of the original adjacency matrix is represented by lower dimensional matrix U, 
where row i in U represents gene i in original matrix: 
    
   
     
  
    
 
 
  (4.12) 
d- Gene clustering: for i=1, …, n , let yi є R
k be the vector corresponding to ith row of U. 
Cluster the points yi with k-means algorithm into clusters C1,…,Ck. 
 
Despite the simplicity of the gap method in selecting the value of K, this method suffers from 
inadequacy if the graph contains a large number of edges compared to the number of 
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vertices (dense graph). In this case, the largest eigenvalue will be 2 and much larger than the 
second largest eigenvalue- the graph is non-dividable and the differences between the other 
eigenvalues are relatively small; and it is difficult to find values for K that demonstrate a 
clear distinction between (K, K-1) and (K, K +1) gaps.  
To overcome this problem, we use a clustering fitness function for determining the value of 
K in spectral clustering. The algorithm contains the following steps:  
1- Assume the value of K is a small number; for example, 2. 
2- Apply the spectral clustering to cut the graph into K sub-graphs. 
3- Compute the clustering quality using cluster fitness measure (see next section). 
4- Increase the value K of by 1. 
5- Repeat steps 2-4 until N, where N is a relatively large number. 
6- Select the clustering with best fitness value. 
 
Clustering Fitness Function 
The goal of using spectral clustering is to divide the graph into sub-graphs that satisfy the 
following two conditions: firstly, the elements of each cluster are strongly related to each 
other, i.e. high similarity within the cluster. Secondly, the similarity between a pair of 
clusters is as small as possible. To do this, most of the previous studies have used the 
following fitness measures to select the best clustering from a set of alternatives:    
1- Cut Based Measures: the focus of these measures is to minimise the number of cut 
off edges in the graph (He, Zha, Ding, & Simon, 2002; Kannan et al., 2004; Shi & 
Malik, 2000). These methods seek to divide the graph into sub-graph with little or no 
cohesion between them so that they fall easily from each other.  
2- Density Based Measures: the focus of this measures it to maximise the densities of 
sub-graphs (Rianne & Nico, 2010). This method seeks to divide the graph into dense, 
heavy, clusters that fall down easily from the graph. 
 
 To clarify the meaning of cut off and density measures:  
Assume G= {V,E}  is a graph with a set of vertices V and a set of edges 
E that connects the vertices and the graph A={v,e}  is a sub graph of G 
where     and    . In our case V is the set genes and E is a set 
of topological overlap similarities tij (Equation 4.6). 
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To compute the cut off between sub-graphs A and V\A, we compute the number of edges 
that are deleted by dividing G into two clusters A and V\A (Equation 4.13):  
Cut(A,V\A)=              
(4.13) 
 
The goal is to minimize the total cut off value (equation 4.14): 
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where m is the number of sub-graphs. The sum is divided by 2 because the edge is counted 
twice. Also, there are some studies that normalise the above formula to the minimum 
cluster connectivity (Kao et al., 2011) as in equation 4.15: 
          
              
                     
   
where deg(A)=          
(4.15) 
where deg(A) is the total connectivity values of the cluster.   
On the other hand, using the same assumption as above, the density of the sub-graph A, 
)(A , is given by Equation 4.16: 
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where n is the number of vertices in the sub-graph A and 

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n
 is the maximum possible 
degree for the sub-graph A. 
 
From the above formulae, the cut off fitness measure search for clustering with minimum 
relations between the pair of clusters; in other words, minimum similarity between the pair 
of clusters. On the other hand, the density measure searches for clustering with maximum 
number of strong relations between cluster members, which means that there is a high 
similarity within the cluster. Thus, using a fitness function that integrates both measures can 
lead to achieving the goal of clustering more efficiently. In this work we have combined both 
measures (density and cut off) in one fitness function as follow: 
1- Form density vector XMD1 , where D(i)= )(i   and M is the number of clusters.    
2- Form a cut off matrix 
MXMC , where C(i,j)=NC(i,j). 
3- Form the cut off density matrix 
MXMCD as in Equation 4.17: 
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4- Find the overall quality of the clustering graph or matrix A, Q(A), by computing the 
mean of the CD matrix of A. In this measure, we have used the mean instead of 
summation to remove the effect of the number of clusters on the clustering quality 
(Equation 4.18). 
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where m is the number of clusters in A. 
In some cases, the high quality of the selected clustering is a result of only one or few high 
quality clusters. This means, one or few clusters have a very high quality compared to all 
other clusters. For example, if we have two clustering exercises where both of them divide 
the graph into 10 clusters. From Equation 4.18, quality of cluster i , CD(i), is the summation 
of the ith row values of the CD matrix; in the first clustering, 9 out of 10 clusters have poor 
quality between each other (assume 10) and only one cluster has high quality with the other 
9 clusters (for example 500). From Equation 4.18, the overall quality will be 
((10*9*8)+500*9) /90)= 5220/90= 58). On the other hand, in the second clustering, assuming 
the quality between all clusters CDij= 50 (which is relatively good), the overall quality of the 
clustering will be ((50*10*9)/ 90= 4500/90= 50). By comparing the quality measure of the 
first and second clustering, we find that the first one is better. But in reality, the second one 
is better because the quality of all clusters in the second one were better than the first 
clustering except for one cluster. Thus, there is a need to measure the consistency of the 
quality of each clustering and select the clustering based on the quality and consistency. To 
do so, beside the fitness function, we introduce a new measure to check the consistency of 
clusters for each clustering using the Average Standard Deviation of cluster quality (Equation 
4.19), where the clustering with high quality and low ASTD values is selected.   
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where CD(i) is the quality vector of cluster i.  
Example:  
In this example we demonstrate spectral clustering with the gap method and the proposed 
method. Specifically, for the graph represented by the adjacency matrix in Table 4.2 we 
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compare the selected number of clusters using the gap method and the proposed method. 
First we find the normalised Laplacian matrix of the graph. Then, we find the eigenvectors 
and eigenvalue for the Laplacian matrix. The number of clusters is then selected using the 
largest gap between the eigenvalues (Figure 4.4). From this figure, it is easy to determine the 
number of clusters in the graph. The gap between eigenvalues 4 and 5 is much higher 
compared with 3 and 4; therefore, the number of clusters based on the gap is 4. 
 
Figure ‎4.4. The 14 largest eigenvectors for the Laplation matrix in the example in Table 4.2. 
The gap between eigenvalues 4 and 5 is very large compared to the gap between 
eigenvalues 3 and 4 
Now, by applying the proposed method for selecting the number of clusters with the new 
fitness function, we found that the highest value of the quality is 6.5 with 1.9 ASTD and the 
number of clusters for this point is also 4 (Figure 4.5). This means, the new algorithm works 
very well with spectral clustering and it can be successfully used to select the number of 
clusters. More importantly, the new method provides an improved cluster quality measure 
that enhances the confidence in the clustering results. The output clusters from the spectral 
clustering using k=4 is shown in (Figure 4.6). 
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Figure ‎4.5.  Quality and Consistency of the clustering. The red line represents the internal 
consistency measure for clustering and the blue line is the quality measure. The largest 
value for the quality is 6.5 where the number of clusters is 4. The value of ASTD is also 
small (1.9) for 4 clusters which means that the internal consistency of the clusters is good 
 
  
Figure ‎4.6. The four output clusters from spectral clustering. The nodes of the same cluster 
take the same colour   
 
 
 
 
Shared clusters selection. 
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Now, by the end of the above step, the genes of M1 and M2 datasets have been divided into 
functional groups. This step is responsible for selecting the shared groups of genes between 
M1 and M2 (Figure 4.7).  
 
Figure ‎4.7. The shared clusters between M1 and M2 cancer subsets. Red colour represents 
the clusters that were in M1 only, blue represents the clusters that were in M2 only and 
yellow represents the shared clusters between M1 and M2    
A direct comparison between all genes in the groups is difficult so that we select the hub 
genes for each clusters and the comparison takes place on hub gene level instead of all 
genes. To select the hub genes of a cluster, we find the within cluster connectivity for each 
gene (Equation 4.20) and select the m highest genes, m is relatively a small number, as hub 
genes. Selecting more than one hub gene allows partial similarity between the pair of 
clusters where the cluster is considered to be shared, if one or more hub genes shared 
between two clusters.  

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where i and j are genes in cluster A and r is the number of genes in the cluster.  
By the end of this step, neither cancer nor healthy clusters are removed and we keep only 
the shared groups that represent cancer and healthy biomarkers.  
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Removal of healthy biomarkers 
As we mentioned above, Bi-biological filter is divided into two main steps; neither cancer nor 
healthy biomarker filter and healthy biomarker filter (Figure 4.8). From Figure 4.8, in the first 
step, the shared clusters between two cancer dataset (M1 and M2) are selected. Then, in 
the second step, the healthy clusters are removed from the shared clusters between cancer1 
and cancer2.   
 
Figure ‎4.8. Bi-biological Filter. The first step is neither cancer nor healthy biomarker filter 
and the second step is healthy biomarker filter.   
This step (step 2) is for filtering out the healthy biomarkers from the selected biomarkers 
and to keep only the probable cancer biomarkers by applying the following steps: 
1- Build the co-expression gene network for the healthy dataset using Zhang and 
Horvath (2005) method. 
2- Apply the spectral clustering to extract the healthy biomarkers as described above. 
3- Extract the hub genes for the healthy clusters. 
4- Find the shared clusters between the healthy clusters and the previously selected 
clusters containing cancer and healthy biomarkers. 
5- Delete the shared clusters found in step 4. 
In summary, the bi-biological filter starts by removing neither cancer nor healthy groups by 
dividing the cancer dataset randomly into two datasets and taking the shared clusters 
between them. Then, the selected clusters containing cancer and healthy genes are 
compared with the healthy clusters and the shared clusters are deleted. However, the 
remaining number of genes is still large compared with the number of samples and needs 
further filtering to select a set with a fewer number of genes for classification. To address 
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this problem, we use a wrapper method to select a subset of genes from the selected genes 
for classification. 
Best First Search and SVM K-fold out cross validation wrapper 
Wrapper methods search through the space of all features using a learning algorithm, to find 
the features that produce the highest classification accuracy. Wrappers may start with an 
empty set and then add features from unselected ones and calculate the accuracy, searching 
for the group of genes that provides the highest accuracy. This method is called forward 
selection. In contrast, the backward elimination starts with all the features and removes 
features incrementally, to find the feature set that provides the highest accuracy (Das, 
2001). The advantages of wrappers are that they interact with the classification algorithm, 
and model feature dependency. Several searching algorithms have been used for finding the 
best subset of features such as; Genetic algorithm (GA) (Zhuo et al., 2008), Simulated 
Annealing ( Li & Liu, 2008), Best First Search (BFS) (Kohavi, 1996; Kohavi & John, 1997) and 
Greedy search (Geng et al., 2007).  
In this work we use the forward BFS and the accuracy of SVM with K-fold out cross validation 
to find the subset of genes that strongly related to breast cancer. K-fold out cross validation 
is a training and testing technique that is widely used when the size of the dataset is 
relatively small. This technique divides the dataset into K subsets of approximately same 
size. Then the classifier (SVM) is trained and tested K times, each time K-1 subsets are used 
for training and one subset is used for testing. 
Best first search (BFS) is a simple and robust search engine method that searches for the 
optimum solution by expanding the node in the state space with the best value for the 
heuristic function H(f) and allowing backtracking (Russell & Norvig, 2009). However, BFS 
search for the best node in the state space of the problem and stops only if all nodes are 
visited or the goal is reached, which makes the algorithm very slow with large number of 
nodes. To overcome this problem, Kohavi & John (1997) developed a new stopping criteria 
based on k number of consequant faliure of enhancement. So that the algorithm stops if 
there is no enhancement in the last K expantions, reaches the goal or there are no further 
unvisited nodes. To do that we will apply the following steps:  
1- Set best= small number; initialise the best value for classification accuracy with a small 
number.  
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2- Set goal= target accuracy value; this is to stop the algorithm when the algorithm reaches 
the target. 
3- Set Index=empty, the index of the node with the highest classification accuracy. 
4- Set m= max number of fails; this is to stop the algorithm if there is no enhancement in 
the last m expansions. 
5- Set OpenList= Root; the list that contains all unvisited children of the visited nodes. 
6- Set CloseList=empty; the list that contains all visited nodes. 
7- Set f= the node with max H(v), where vopen and H(v) is the classification accuracy of 
SVM when the genes of node v are used as inputs.  
8- Add f to the close list; now the node is considered to be visited and added to the visited 
node list.  
9- Remove f from open; remove the node from the unvisited list. 
10- Expand f, (but all children of f in open list) 
11- If H(f)>best then set best=H(f), set index=f and set fail=0; if the classification accuracy is 
enhanced by f then the new best value become H(f), the index is f and fail counter 
become 0.       
else set fail=fail+1, this is to increase the fail counter by 1 if there is no enhancement 
by f.  
12- if fail < m and H(v)<goal and OpenList not empty then go to 5, this is to stop running the 
algorithm if there is no enhancement in the last m expansions, or the goal has been 
reached or there are no further unvisited nodes. 
13- Return best and index. 
 
4.3.3 Classification and Evaluation 
In this Chapter we use three classifiers; Multilayer Feed Foreword Neural Networks 
(MFFNN), linear Discriminant Analysis (LDA) and Support Vector Machine (SVM), as 
described in Chapter 2, to evaluate the classification accuracy of the selected genes. Also, 
sensitivity, specificity, FN rate, FP rate and accuracy are used for evaluation (see Chapter 2 
for more details). 
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4.4 Results and Discussion 
4.4.1 Feature selection 
As we mentioned earlier, this step is divided into two main steps; Bi-biological filter and 
SVM-5-fold out cross validation wrapper method. 
Neither cancer nor healthy biomarker filter: The cancer dataset is divided randomly into 
two subsets; cancer1 and cancer2. The cancer1 subset contains 33 samples and cancer2 
contains 34 samples; both subsets contain 7351 mRNA genes.  
For cancer1 subset, we first built the gene co-expression network and then we used the 
network to find the groups of genes using spectral clustering. Then, to find the number of 
clusters in the network using the gap between the adjacent eigenvalues, we extracted the 
first 100 eigenvalues of the graph in order to find the maximum gap. We found the 
eigenvalues were close to each other and maximum gap was found between the first and 
the second eigenvalue. This means that the graph was not divisible and there was no clear 
gap to select the number of clusters (Figure 4.9). 
 
Figure ‎4.9. The first 100 eigenvalues of cancer1 subset. The X axis represents the index of 
the eigenvalues, Y axis represents the corresponding eigenvalues 
To overcome this problem, we used the density-cutoff quality measure to find the number 
of clusters. We started by k=2 and increased the value of k gradually up to k=30 (Figure 
4.10). The best quality of the clustering was found to be 31 and the number of clusters was 
17. Also, we noted that the value of ASTD was much smaller than the quality measure when 
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the number of clusters was 17, which means that the quality value of individual cluster in the 
clustering was consistent around the obtained quality value.  
  
Figure ‎4.10. The quality and consistency of different number of clusters for cancer1 subset 
using k= [2 to 30]. The blue line represents the ASTD for different number of clusters and 
the red line represents the corresponding Quality  
Now, for the cancer2 subset we applied the same steps and also we found the gap criteria 
was insufficient for determining the number of clusters (Figure 4.11). On the other hand, by 
applying the density-cutoff measure, the highest quality value was found to be 9.6 with 8.5 
ASTD when the number of clusters was 16.  This means that the clusters’ quality values were 
around the overall quality value and the clustering was consistent (Figure 4.12). 
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Figure ‎4.11. The gap between the adjacent eigenvalues of cancer2 subset. The X axis 
represents the index of the eigenvalues and Y axis represents the corresponding 
eigenvalues 
 
Figure ‎4.12. The quality and consistency of different number of clusters for cancer1 subset 
using k= [2 to 30]. The blue line represents the ASTD for different number of clusters and 
the red line represents the corresponding Quality 
Next, we found the hub genes for each cluster. To make the comparison more flexible and to 
allow a partial similarity between cancer1 and cancer2 clusters, we selected two hub genes 
for each cluster (Table 4.3).  
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Table ‎4.3. The hub genes of the two subsets (cancer1 and cancer2), where the number of 
hub genes for each cluster is 2 
Cancer1 Cancer2 
Cluster Id Gene Id Gene Symbol Cluster Id Gene Id Gene Symbol 
1 3437 IFIT3 1 22827 SIAHBP1 
1 9246 UBE2L6 1 8241 RBM10 
2 65005 MRPL9 2 6139 RPL17 
2 6636 SNRPF 2 170622 COMMD6 
3 5791 PTPRE 3 6434 SFRS10 
3 3920 LAMP2 3 5501 PPP1CC 
4 95606 G22P1 4 2253 FGF8 
4 6749 SSRP1 4 8786 RGS11 
5 6143 RPL19 5 10921 RNPS1 
5 8409 UXT 5 3326 HSPCB 
6 8786 RGS11 6 150372 NFAM1 
6 1634 DCN 6 386757 FLJ43855 
7 5361 PLXNA1 7 366 AQP9 
7 3972 LHB 7 5894 RAF1 
8 6535 SLC6A8 8 2314 FLII 
8 150372 NFAM1 8 9343 U5-116KD 
9 10006 ABI1 9 409 ARRB2 
9 4170 MCL1 9 3868 KRT16 
10 4818 NKG7 10 54106 TLR9 
10 30009 TBX21 10 22936 ELL2 
11 22827 SIAHBP1 11 5058 PAK1 
11 10768 AHCYL1 11 23214 XPO6 
12 374872 C19orf35 12 57645 POGK 
12 26539 OR10H1 12 25814 ATXN10 
13 6139 RPL17 13 113 ADCY7 
13 6201 RPS7 13 54940 OCIAD1 
14 22862 FNDC3A 14 55339 WDR33 
14 10772 FUSIP1 14 5653 KLK6 
15 79143 LENG4 15 79143 LENG4 
15 9260 PDLIM7 15 79042 LENG5 
16 6726 SRP9 16 989 7-Sep 
16 55745 C14orf108 16 10443 PFAAP5 
17 10313 RTN3 
17 29855 UBN1 
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The clusters are said to be shared if there is at least one hub gene shared between the pair 
of clusters. The comparison of the hub genes revealed that cancer1 and cancer2 shared 5 
clusters (Table 4.4). During this step, 12 clusters were excluded from cancer1 and 11 clusters 
were excluded from cancer2. These clusters may be found due to other diseases or disorders 
but not breast cancer. 
Table ‎4.4. The shared clusters between cancer1 and cancer2 datasets. For simplicity, each 
shared pair was given a new Id, i.e., shared cluster 1 will be used instead of the pair (11, 1)    
Shared 
Clusters  
Cancer1 
Cluster Id 
Cancer2 
Cluster Id 
Gene Id Gene Symbol 
1 11 1 22827 SIAHBP1 
2 13 2 6139 RPL17 
3 6 4 8786 RGS11 
4 8 6 150372 NFAM1 
5 15 15 79143 LENG4 
Removal of healthy biomarkers: From the above step we excluded all biomarkers which 
were not shared between cancer1 and cancer2. Now, the resulting clusters will be carried to 
the next step of biomarker filtering. In this step, we analysed the healthy dataset to find all 
healthy biomarkers. The analysis revealed that there are four options for the number of 
clusters based on the density-cutoff quality measure; 15, 21, 24 and 26. However, the values 
of ASTD for all options were high compared with the quality value except, 15 clusters option 
where the quality and STD values were 7.4 and 8.03, respectively (Figure 4.13). 
 
Figure ‎4.13. The quality and consistency of the clusters for the healthy dataset. The blue 
line represents the STD and the red line represents Quality. The highest values of quality 
are at 15, 21, 24 and 26 clusters and the lowest value of STD is at 15 clusters 
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As such, the genes of the healthy dataset were divided over 15 different biomarkers 
(clusters). Then, for each healthy cluster we also extracted two representative hub gene sets 
(Table 4.5). By comparing the healthy hub genes and the hub genes that were shared 
between cancer1 and cancer2 datasets (Table 4.4), we found that 2 out of 5 clusters (2 and 
5) were found in the healthy dataset and considered to be healthy biomarkers (Table 4.6). 
Thus, the remaining three clusters (1, 3 and 4) in Table 4.4 are considered to be the breast 
cancer biomarkers.   
Table ‎4.5.  The hub genes of the healthy dataset 
Healthy 
Cluster Id 
Gene Id Gene Symbol 
Healthy 
Cluster Id 
Gene Id Gene Symbol 
1 3430 IFI35 9 10728 TEBP 
1 9246 UBE2L6 9 865 CBFB 
2 3326 HSPCB 10 7528 YY1 
2 57645 POGK 10 51621 KLF13 
3 79143 LENG4 11 3050 HBZ 
3 6888 TALDO1 11 29121 CLEC2D 
4 22913 RALY 12 57580 PREX1 
4 1460 CSNK2B 12 3920 LAMP2 
5 3868 KRT16 13 8991 SELENBP1 
5 409 ARRB2 13 5305 PIP5K2A 
6 10053 AP1M2 14 6139 RPL17 
6 56146 PCDHA2 14 51637 C14orf166 
7 64844 7-Mar 15 6349 CCL3L1 
7 139818 DOCK11 15 63946 DMRTC2 
8 22818 COPZ1 
8 114049 WBSCR22 
Table ‎4.6. Shared genes between the healthy and the shared clusters of the cancer 
datasets (Table 4.4). Two clusters (5 and 2) were found in the healthy dataset and 
considered to be healthy biomarkers 
 
 
 
By the end of this step, the bi-biological filter found 3 clusters (1, 3 and 4 in Table 4.4) as 
breast cancer biomarkers. Because we allowed partial similarity, the shared genes between 
Healthy 
Cluster Id 
Shared 
Cluster Id 
Gene 
Id 
Gene 
Symbol 
 3 5 79143 LENG4 
14 2 6139 RPL17 
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the pairs of clusters (cancer1-cancer2) were selected and considered to be breast cancer 
biomarkers. The total number of selected genes was 415 (Table 6.7). 
Table ‎4.7. The 415 genes selected by the filter and the distribution of the genes over the 
three selected clusters 1, 3 and 4 shown in Table 4.4   
Shared 
Cluster 
Gene symbol 
1 
MAN2B1,RUFY1,TETRAN,GOSR1,CTDSP1,MICAL1,PABPC3,ILK,RBM10,TRAF7,ADAM1
5,TBC1D13,CNDP2,DAPK3,TUBB2,RDBP,TGFB1,STIM1,DIA1,SYTL1,CD37,FLJ35827,M
YO1G,STX5A,U1SNRNPBP,MGC10433,CGI51,ZNF289,DNCL2A,CORO1B,PFN1,BCAS3,
ARID1A,AHCYL1,YWHAB,FLJ22301,AP1G2,GAK,DHPS,ACTR1A,CAPNS1,FIBP,HIF1AN,
TGB4BP,TRAPPC1,P4HB,UQCRC1,GSTP1,IDH3G,PTOV1SLC35A4,CXX1,VPS4A,BRE,TRI
AD3,IRF2BP1,FLJ20014,CENTB1,BAP1,HA1,SIAHBP1,DOC1R,DCTN1,ENO1,EIF4EBP3,
MASK_BP3,FLJ14154,POU2F1,VKORC1,CAPG,SNX17,PRKCSH,PRAF2,DAXX,SRISNF2L,
CSNK2B,DNCL2A,MAP4K2,NPL4,SF4, TPI1,SLC25A1,CLN3,COASY 
3 
APTX,GMEB2,SPRR2B,SPRR2A,GPR133,EGFL3,NDUFB4,CCT4,UQCRC2,SLC35E1,STK3
6,METRN,MGC4825,ZNF358,BTC,GPR7,C11orf10,CCL1,VMD2L2,TSGA14,RTN4R,GPR
78,P2RY6,SNX26,MGC3047,RGS11,MGC52010,ZG16,AKNA,ALG5,GGPS1,MGC10540,
E2IG5,GPR27,SLC6A18,ACAT2,FLJ22028,TIMM9,SPRR1A,PRKRIP1,RIN1,MEF2B,PCSK
1N,CHGA,CCNF,EXO1,TNFRSF25,DYRK4,VAT1,LCE2B,EVX1,KRT15,CTF1,GCNT1,HCRT,
P2RY11,TIMM23,FLJ38792,COL2A1,PLAC8,FLJ32884,TYSND1,NRM,TMEM4,PSARL,P
DCD1,FAM3A,DUSP3,SPOCD1,STAP2,TMEPAI,MGC2744,ABCD1,MRPS14,FLJ39155,C
ABIN1,C20orf102,MADP1,IL17R,HSPC171,VDAC3,NRG2,HRBL,ATP13A2,LOC200205,
MT1G,PTGIR,CD151,GGTLA1,CGI128,HSPC135,PFDN2,MGC40499,TRPM3,C20orf141
,CMA1,FLJ21736,HES5,SLC6A3,NDUFA7,LAPTM4B,SLC16A8,FLJ31547,PPY,PTCRA,AT
F4,MGC17791,CRMP1,FGD2,DTNA,GPR92,Ufc1,RTEL1,T3JAM,SARM1,CYP2D6,CYP2
D7P1,TRIP4,LDOC1,VPS18,PDZK4,PARK2,GZMK,MARK4,,GFI1B,EPHA2,DMRTC2,PFKF
B2,SSTR5,FLJ12517,KRTHA8,GPR31,HOXB3,,PN1,LAMA5,DTX3NDUFAB1,ZNF406,DK
FZP564M082,TRIM15,R30953_1,MAP4,KIAA0971,KIAA1115,NIT2,ETFA,MGC23244,
DKKL1,LOC57168,PRSS3,NRXN2,C18orf21MDH1,DNCL1,MGC52423,ANKRD16,KRT3,,
CDH23,RASEF,MSX2,SRP72,ARMC7,KIAA0152,SKP1A,SERHL,dJ222E13.1,MRGX3,NFX
1,MSL3L1,LOC205251,TSAP6,na,ENPP7,PKD1L1,LOC149830,LCE3C,LCE5A,,CTXN1,HS
3ST4,DCN,P4HA3 
4 
UBE2I,ANXA2,FLJ14775,ZNF207,EIF2C1,THRAP3,PRO2730,FLJ12998 
HBD,TRIM56,C9orf90,ZNF297,DKFZP434I116,RAB9P40,ABCC13,LOC57117,TBX3,TFA
P2E,TTC7A,CCR9,KLF3,DHX16,QPCTL,MSX1,MGC59937,RPIA,DKFZp434I1117,FAM22
A,C10orf137,RNF34,Ells1,ZBTB3,DPM3,ADAMTS10,ALS2CR2,na,HBLD2,MARS,GPR10
3,OXSR1,PKM2,EIF3S9,GNG7,BNIP3L,GNPTG,GYPC,HSPBP1,SCRIB,BTBD4,TBXA2R,DY
M,C20orf128,HSCARG,CRB3,OR2B11,SLC30A3,KCNK4,FBXO9,GBE1,JAK3,TRIM46,HO
MER3,APOE,RPL3L,TREX1,UGT2A1,PIWIL3,C22orf18,WNT3,RCOR3,LOC401316,GAR
PBTK,TK1,RABEP2,GOLGB1,FLJ12788,OR56B4,OR10H3,ZNF366,TNK2,BTBD2,FLJ345
12,MYL4,PPP1R7,MAP17,EPPK1,MGC70857,NUDT4P1,NUDT4,EDG8,CRHR1,ARL10A,
PP3856,DSCR8,MGC13057,CAPN12,SLC39A1,SLC26A6,ZNF2,C10orf95,GORASP1,MC
FD2,BPGM,PABPN1,NLGN2,FGF1,AD023,GRIPAP1,TPM4,RDS,PGAM1,TP53AP1,C18o
rf10,ARL11,NYD_SP20,RBPMS,DKFZp434K1815,SCGB1A1,LOC388962,CSNK1E,GOLG
A1,C8B,BMP8A,TP53BP1,HLADQA2,LILRB4,PBX4,BAG1,PRR7,SORD,SDS,COPB2,DKFZ
P564G2022,LOC220070,OR3A4,GNB1,ANXA2,MKRN1,POLR3B,LLGL1,NTN2L,ALS2CR
2,MFAP1,S100A10,UMOD,SLC6A18,GPR158,LOC51234,FAM33A,LJ39647,OR1J2,FAD
S6,DKFZp564N2472,MKL1,NFAM1,VTI1B,MGC42630 
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Now, for genes in each cluster, we investigated the biological processes related to the genes 
of that cluster. We used The Database for Annotation, Visualization and Integrated Discovery 
(DAVID) (Dennis et al., 2003) to find the biological processes and we selected the processes 
that had False Discovery Rate (FDR) less than 20% and (p-value<0.05). 
For the first cluster (1) in Table 4.8, we found the apoptosis process (GO:0006915) and the 
regulation of apoptosis process (GO:0042981) were the most important processes that 
differentiated normal and cancer cells (Table 4.8). Apoptosis is a mechanism of cell death 
and is responsible for killing unwanted or unnecessary body cells, and therefore, is the most 
important process to protect our bodies from cancer (Lodish, Arnold Berk, Zipursky, 
Matsudaira & Darnell, 1995). The rate of cell death by apoptosis is controlled by regulation 
of the apoptosis process. Several previous studies found apoptosis in relation to breast 
cancer where the apoptosis process in cancer patients was decreased compared with 
healthy ones (Haldar, Negrini, Monne, Sabbioni & Croce, 1994; Parton et al., 2001). Also, the 
apoptosis of cells has been widely studied in trying to find a breast cancer treatment that 
target the cell death process and there are many reports that have suggested steroidogenic 
hormones, progesterone and oestradiol as a complex (all 3 together) produce a strong effect 
on the regulation of cell death (Feng et al, 1995; Graham & Clarke, 1997).  
For the second cluster (3) in Table 4.9, we found that, cellular respiration process 
(GO:0045333), which is the enzymatic release of energy from organic compounds that either 
requires oxygen (aerobic respiration) or does not (anaerobic respiration) (European 
Molecular Biology Laboratory, 2011), was found in several studies in relation to breast 
cancer (Simonnet et al., 2002; Warburg, 1956). These studies found the cellular respiration 
was injured in the cancer cells. Another process related to the genes of the cluster (3), 
epithelial cell differentiation process (GO:0030855), the process in which a relatively 
unspecialised cell acquires specialised features of an epithelial cell (European Molecular 
Biology Laboratory, 2011), was found in relation to breast cancer in Beitsch and Clifford 
(2000) study. In this study, blood samples of healthy patients as well as breast cancer 
patients were compared and found the number of epithelial cells in the blood of breast 
cancer patients was greater than the healthy ones. Also the study found that the number of 
epithelial cells was increased by the stage of cancer. Also, in the same cluster we found three 
processes related to developmental processes including system development, 
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developmental process and epidermis development (Table 4.9). But we found no previous 
study that mentioned the relationship of the system development processes and breast 
cancer. 
In the last cluster (4), we found the processes were in relation to producing energy necessary 
for cellular processes (Table 4.10). Glucose is an important source of energy in the body and 
it is considered as fuel for a cell. Without energy, cells cannot perform their natural 
processes. Cancer cells are characterised by uncontrolled and rapid division so there is a 
need for providing cancer cells with a larger amount of glucose and speed up the process of 
producing energy from it (Annibaldi & Widmann, 2010). 
By the end of this investigation we found that genes in the same cluster work together to 
carry out the same biological processes which provides support for the biological relation 
between the genes. Furthermore, we find the relationship between the biological processes 
of the groups and breast cancer are strong which also provides support for the selected 
group of biomarkers. 
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Table ‎4.8. The biological processes from the DAVID database for the genes of cluster 1 in Table 4.7 
Process ID Term Genes P-value FDR 
GO:0016192 
vesicle-mediated 
transport 
STX5, rufy1, MAP4K2, SYTL1, vps4a, APOE, LOC100129500, ARFGAP2, CLN3, ap1g2, GOSR1, 
TRAPPC1, ACTR1A, snx17 
3E-05 0.05 
GO:0015031 protein transport 
STX5, rufy1, YWHAB, BID, SYTL1, vps4a, ACAP1, TGFB1, ARFGAP2, ap1g2, GOSR1, PRAF2, 
snx17 
4E-04 0.7 
GO:0046907 
intracellular 
transport 
STX5, TGFB1, YWHAB, , ID, ap1g2, GOSR1, vps4a, SYTL1, TRAPPC1, snx17, slc25a1, APOE, 
LOC100129500 
4.63E-04 0.74 
GO:0008219 cell death DAXX, TGFB1, YWHAB, DCTN1, PUF60, BID, MFSD10, rnf216, , CLN3, dapk3, BRE, TRAF7 9 E-4 1.5 
GO:0016265 death DAXX,TGFB1,YWHAB,DCTN1,PUF60,BID,MFSD10,rnf216,CLN3,dapk3,BRE,TRAF7 0.001 1.6 
GO:0033036 
macromolecule 
localisation 
STX5,rufy1,YWHAB,BID,SYTL1,vps4a,APOE,LOC100129500,ACAP1,TGFB1,ARFGAP2,ap1g2,GO
SR1,PRAF2,snx17 
0.002 4.4 
GO:0006886 
intracellular protein 
transport 
STX5, TGFB1, YWHAB, BID, ap1g2, GOSR1, SYTL1, snx17 0.0029 4.6 
GO:0006810 transport 
STX5, SLC35A4, rufy1, MAP4K2, YWHAB, BID, MFSD10, STIM1, vps4a, SYTL1, APOE, 
LOC100129500, ACAP1, TGFB1, ARFGAP2, ap1g2, CLN3, GOSR1, PRAF2, snrnp35, Abcb5, 
TRAPPC1, ACTR1A, nx17, slc25a1, Uqcrc1 
0.004 7.2 
GO:0042981 
regulation of 
apoptosis 
TUBB2C, DAXX, TGFB1 , YWHAB, GSTP1, BID, CLN3, ILK,dapk3 ,TRAF7 ,APOE , LOC100129500 0.0073 11.3 
GO:0043067 
regulation of 
programmed cell 
death 
TUBB2C, DAXX, TGFB1 , YWHAB, GSTP1, BID, CLN3, ILK,dapk3 ,TRAF7 ,APOE , LOC100129500 0.0078 12.0 
GO:0010941 
regulation of cell 
death 
TUBB2C, DAXX, TGFB1 , YWHAB, GSTP1, BID, CLN3, ILK,dapk3 ,TRAF7 ,APOE , LOC100129500 0.008 12.3 
GO:0006915 apoptosis DAXX, YWHAB, PUF60, BID,MFSD10, rnf216, dapk3, BRE, TRAF7 0.011 16.8 
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Table ‎4.9. The biological processes from the DAVID database for the genes of cluster 2 in Table 4.7 
Process ID Term Genes P-Value FDR 
GO:0031424 keratinisation  LCE2B,LCE3C,LCE5A,SPRR1A, SPRR2A,SPRR2B 2.3E-5 3.6E-2 
GO:0030855 epithelial cell differentiation  KRT3,LAMA5,LCE2B,LCE3C,LCE5A,SPRR1A,SPRR2A,SPRR2B 1.1E-4 1.8E-1 
GO:0009913 epidermal cell differentiation  LCE2B,LCE3C,LCE5A,SPRR1A, SPRR2A,SPRR2B 2.7E-4 4.3E-1 
GO:0008544 epidermis development  KRT3,LAMA5,LCE2B,LCE3C, LCE5A,SPRR1A,SPRR2A,SPRR2B 6.9E-4 1.1E0 
GO:0045333 cellular respiration  NDUFA7,NDUFAB1,NDUFB4, MDH1,UQCRC2 7.6E-3 1.1E1 
GO:0048731 system development  
EPHA2,MEF2B,MARK4,PARK2,CDH23,CTF1,COL2A1,CRMP1,CCNF,DCN,EVX1,EXO1,HES5,HOX
B3,KRT15,KRT3,LAMA5,LCE2B,LCE3C,LCE5A,METRN,SX2,PCSK1N,RTN4R,SPRR1A, 
SPRR2A,SPRR2B,SLC6A3, TRIM15,ZNF358 
8.5E-3 1.3E1 
GO:0032502 developmental process  
DMRTC2,EPHA2,MEF2B,MARK4,PARK2,ALG5,CDH23,CTF1,COL2A1,CRMP1,CCNF,DCN, 
DKKL1,EVX1,EXO1,GFI1B,HES5,HOXB3,KRT15,KRT3,LAMA5,LCE2B,LCE3C,LCE5A,METRN, 
MSX2,NRG2,PDCD1,PCSK1N,RTN4R,STK36,SPRR1A,SPRR2A,SPRR2B,SLC6A3,TRIM15,ZNF358 
1.2E-2 1.7E1 
GO:0022900 electron transport chain  NDUFA7,NDUFAB1,ETFA, NDUFB4,UQCRC2 1.3E-2 1.9E1 
Table ‎4.10. The biological processes from the DAVID database for the genes of cluster 1 in Table 4.7 
Process ID Term Genes P-value FDR 
GO:0006006 glucose metabolic process GBE1, SORD, SDS, PKM2, PGAM1, BPGM, RPIA 5.16E-04 0.8 
GO:0044262 
cellular carbohydrate metabolic 
process 
GNPTG, GYPC, GBE1, SORD, SDS, PKM2, PGAM1, BPGM, DPM3, RPIA 0.0010 1.5 
GO:0019318 hexose metabolic process GBE1, SORD, SDS, PKM2, PGAM1, BPGM, RPIA 0.0016 2.6 
GO:0046164 alcohol catabolic process SORD, PKM2, PGAM1, BPGM, RPIA 0.0019 3.1 
GO:0044275 cellular carbohydrate catabolic process SORD, PKM2, PGAM1, BPGM, RPIA 0.0023 3.7 
GO:0005996 monosaccharide metabolic process GBE1, SORD, SDS, PKM2, PGAM1, BPGM, RPIA 0.0034 5.3 
GO:0016052 carbohydrate catabolic process SORD, PKM2, PGAM1, BPGM, RPIA 0.0058 8.8 
GO:0006007 glucose catabolic process PKM2, PGAM1, BPGM, RPIA 0.0065 9.9 
GO:0005975 carbohydrate metabolic process GNPTG, GYPC, GBE1, SORD, SDS, PKM2, PGAM1, BPGM, DPM3, RPIA 0.0081 12.1 
GO:0019320 hexose catabolic process PKM2, PGAM1, BPGM, RPIA 0.0106 15.5 
GO:0046365 monosaccharide catabolic process PKM2, PGAM1, BPGM, RPIA 0.0114 16.7 
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Best First Search and SVM with 5-fold out cross validation wrapper  
The Bi-Biological filter selected 415 genes that were divided over 3 clusters; these clusters 
were probably breast cancer biomarkers. But we still needed to reduce the dimensionality of 
the data and select a subset of genes from 415 genes for classification. To do that, we 
applied the BFS and SVM with 5-fold out cross validation wrapper for gene selection as 
described previously in Section 4.3.2. After 16 iterations, the algorithm stopped because 
there are no improvements in iterations 14, 15 and 16 (number of fails m= 3). The highest 
accuracy that was obtained by the wrapper was at iteration number 13 with 85.1% 
classification accuracy; 88.05% sensitivity and 81.4% specificity (Figure 4.14 and Table 4.11).  
Also, we found DAPK3 (Death-Associated Protein Kinase 3) obtained the highest individual 
classification accuracy (iteration1) (Table 4.11). 
 
Figure ‎4.14. The output accuracies from the Best First Search and SVM with 5-fold out 
cross validation wrapper for 16 iterations. The X-axis represents the iteration number and 
the Y-axis represents the corresponding accuracy value. The highest accuracy was 85.1% at 
iteration number 13  
4.4.2 Classification and evaluation 
The thirteen selected genes have been used as input for the three classifiers, Multilayer Feed 
Forward Neural Network (MFFNN) with 5-fold out cross validation, SVM with Leave One Out 
Cross Validation (LOOCV) and Linear Discriminant Analysis (LDA) with LOOCV. 
We used a Multilayer Feed forward Neural Network with an input layer, one hidden layer 
and one neuron in the output layer. The network was trained using Scaled Conjugate 
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Gradient Back Propagation Algorithm (SCGBP) and Logistic function as the neuron activation 
function. For training and testing, we divided the dataset randomly into five subsets. 
Table ‎4.11. The set of genes, sensitivity, specificity and the accuracy of the first 13 iteration 
of the BFS and SVM with 5-fold out cross validation wrapper  
Then the network is trained and tested five times; each time, four subsets are used for 
training and one subset for testing. Next, the outputs of each subset are stored for 
evaluation. For LDA and SVM training and testing we used Leave One Out Cross Validation 
(LOOCV) where, the classifiers are trained and tested 121 times. Each time, all samples 
except one are used for training and the remaining sample is used for testing and the output 
result for the testing sample is stored for evaluation. 
 The output results of each classifier were evaluated using the sensitivity, specificity, FP, FN 
and accuracy measures (Table 4.12). From the outputs of different classifiers we found the 
Iteration 
number 
Set members  Specificity Sensitivity Accuracy 
1 DAPK3 0.537037 0.731343 0.644628 
2 DAPK3,CTDSP1 0.62963 0.791045 0.719008 
3 DAPK3,CTDSP1,CXX1 0.685185 0.791045 0.743802 
4 DAPK3,CTDSP1,CXX1,RCOR3 0.703704 0.80597 0.760331 
5 DAPK3,CTDSP1,CXX1,RCOR3,MYL4 0.703704 0.80597 0.760331 
6 DAPK3,CTDSP1,CXX1,RCOR3,MYL4,YWHAB 0.722222 0.791045 0.760331 
7 
DAPK3,CTDSP1,CXX1,RCOR3,MYL4,YWHAB 
GMEB2 
0.703704 0.820896 0.768595 
8 
DAPK3,CTDSP1,CXX1,RCOR3,MYL4,YWHAB 
GMEB2,GPR78 
0.722222 0.835821 0.785124 
9 
DAPK3,CTDSP1,CXX1,RCOR3,MYL4,YWHAB 
GMEB2,GPR78,ILK 
0.777778 0.865672 0.826446 
10 
DAPK3,CTDSP1,CXX1,RCOR3,MYL4,YWHAB 
GMEB2,GPR78,ILK HSPC171 
0.796296 0.835821 0.818182 
11 
DAPK3,CTDSP1,CXX1,RCOR3,MYL4,YWHAB 
GMEB2,GPR78,ILK HSPC171,ACAT2 
0.777778 0.835821 0.809917 
12 
DAPK3,CTDSP1,CXX1,RCOR3,MYL4,YWHAB 
GMEB2,GPR78,ILK,HSPC171,ACAT2, 
PRKRIP1 
0.814815 0.835821 0.826446 
13 
DAPK3,CTDSP1,CXX1,RCOR3,MYL4,YWHAB
GMEB2,GPR78,ILK, HSPC171,ACAT2, 
PRKRIP1,PP3856 
0.814815 0.880597 0.85124 
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MFFNN was the superior classifier with 94.02% sensitivity, 92.6% specificity and 93.4 % 
accuracy.  
Table ‎4.12. The performance of different classifiers using the thirteen selected genes 
Classifier Sensitivity  Specificity  FN rate FP rate Accuracy  
SVM 86.6% 81.5% 16.98% 14.7% 84.3% 
LDA 82.1% 79.6% 21.8% 16.7% 80.9% 
MFFNN 94.02% 92.6% 7.4% 5.97% 93.4% 
Now, reviewing the FP and FN cases of the best classifier, MFFNN, we found 2 out of 4 FP 
cases had a cyst or benign tumour which means that the presence of benign findings in the 
breast may reduce the specificity of the current system. The grades of FN cases were: one 
case grade one, two cases grade two and one case not classified. From these FN cases we 
found that the current system correctly classified 92.8% of grade one cases and 90.9% of 
grade two cases and the local sensitivity values of both grades are close to the overall 
sensitivity of the system. This means that the current system successfully predicts breast 
cancer in early stages.      
From the literature review we found that, there is only one blood based mRNA CAD for early 
detection of breast cancer (Aaroe  et al., 2010). This CAD system extracted 738 mRNA probes 
as breast cancer biomarkers using a filtering method. These biomarkers were used for 
classifying the samples into healthy and cancer cases. The accuracy, sensitivity and specificity 
value for Aaroe et al. (2010) CAD system were 79.5%, 80.6%, 78.3%, respectively. By 
comparing the current CAD system results with their system we found that the accuracies of 
all classifiers in the current CAD systems are better. Specifically, the diagnostic accuracy of 
LDA classifier was enhanced by 2% and the SVM improved the diagnostic accuracy by 5.5%. 
The significant improvement of the current BC-CAD over Aaroe et al. (2010) system was in 
the accuracy, sensitivity and specificity values of MFFNN where the current system obtained 
93.4%, 94.02% and 92.6%, respectively, whereas their system obtained only 79.5%, 80.6%, 
78.3%, respectively, which means that there are about 14% of cancer cases misdiagnosed in 
Aaroe et al. (2010) system that were diagnosed correctly in the current system and hence 
more lives could be saved. Also, about 14% of healthy cases wrongly diagnosed in their 
system were diagnosed correctly in the current system hence the burden of further 
examinations will be reduced. Furthermore, using 738 probes for classification reduces the 
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performance of classifiers due to high dimensionality of the data compared with 13 genes in 
the current study, 56 times less than their study. 
By the end of this chapter, the first component of the biological part of the framework was 
successfully completed. The framework is now capable of supporting the decision of a  
doctor using three alternatives of input data: (i) ultrasound data with 95.4% diagnostic 
accuracy, 8.3% false Positive (FP) rate and 0 False Negative rate; (ii) mRNA data with 93.4% 
diagnostic accuracy, 5.6% FP rate and 7.4% FN rate or (iii) both ultrasound and mRNA data. 
The third choice gives more confidence for decision if both CAD systems diagnosed a case as 
cancer or healthy. Assume, one system diagnosed a case as cancer and the other diagnosed 
it as healthy. In this case, the current framework provides doctor with the False Positive (FP) 
rate of the positive CAD system and the False Negative (FN) rate of the negative CAD 
systems which allow the doctor to select the system with lower value. For example, if the 
decision of the ultrasound CAD system was positive, diagnosing a case as cancer, and the 
decision of mRNA CAD system was negative, diagnosing the same case as healthy, then, the 
framework provides the doctor with FP rate of the ultrasound CAD system (8.3%) and the FN 
rate of mRNA CAD system (7.4%) and the decision can made using these values.  The mRNA 
CAD system has a lower error rate and therefore can be considered more reliable for this 
case. 
4.5 Summary 
The aim of this chapter is to build the first component of the biological part of the BC-CAD 
framework and enhance the diagnostic accuracy of breast cancer CAD systems that used 
gene expression profiling of peripheral blood cells. To do that, we introduced a novel feature 
selection method called Bi-biological filter and Best First Search with SVM (BFS-SVM). The bi-
biological filter contains two biological filters; the first one is to find the shared biomarkers 
between randomly divided cancer datasets and the second one is to eliminate the healthy 
biomarkers from the shared ones. Then, BFS-SVM used the output of the bi-biological filter 
to select a subset of genes for classification. Specifically, Topological Overlap Matrix (TOM) 
and spectral clustering were used for building Gene Co-expression Network (GCN) and 
dividing the network into clusters (biomarkers), respectively.  
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The gaps between the adjacent eigenvalues in the dense graph were relatively scaled and 
were not helpful for determining the number of clusters. Therefore, we introduced a new 
fitness criterion for determining the number of clusters, cut of and density measures with 
average STD. This method successfully determined the number of clusters. Also, we used BFS 
with 5 fold out cross validation to select a subset of genes for classification.  
To demonstrate the effect of the selected genes on differentiating benign from malignant 
cases and the potential improvement to the diagnostic accuracy of previous CAD systems, 
this study evaluated the diagnostic accuracies of three classifiers; Artificial Neural Networks 
(ANN) with 5-fold out cross validation, SVM with Leave One Out Cross Validation (SVM-
LOOCV) and Linear Discriminant Analysis with LOOCV (LDA-LOOCV). Also, sensitivity, 
specificity and accuracy measures were used for evaluation.   
The study used 121 samples – 67 malignant and 54 benign cases- as input for the system. 
The bi-biological filters revealed that three functional groups of genes exist in the cancer 
datasets and not found in the healthy dataset and were suggestive of breast cancer 
biomarkers. The total number of biomarker genes in the three groups was 415. The BFS-SVM 
selected 13 out of the 415 genes for classification. The superior classifier was MFFNN with 
93.4% classification accuracy. Therefore, the overall improvement was a significant 14% over 
the results from the previous blood based mRNA BC-CAD (Aaroe et al., 2010). Also, we 
successfully completed the mRNA part of the BC-CAD framework which now provides three 
alternatives for decision making based on ultrasound data, mRNA data or both ultrasound 
and mRNA.   
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Chapter 5: Circulating miRNA gene expression in the serum for 
breast cancer biomarker detection and classification for Jordanian 
women 
In the last two chapters, the first and the second component of the BC-CAD framework were 
successfully completed. In this chapter, we focus on the second component of the biological 
part of the computational Breast Cancer Computer Aided Diagnosis (BC-CAD) framework. 
Specifically, we introduce a circulating miRNA based BC-CAD system (Figure 5.1). Figure 5.1 
shows the three components of the current framework including the clinical part- ultrasound 
based BC-CAD, and the biological part- mRNA and miRNA based BC-CAD systems. The part 
highlighted in orange is the focus of this chapter – the miRNA based BC-CAD system. 
 
Figure ‎5.1. The Breast Cancer Computer Aided Diagnosis (BC-CAD) Framework showing the 
three CAD systems. (The orange part, miRNA BC-CAD, is the focus of this chapter) 
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5.1 Introduction 
Cancer is the number one cause of death in the world. In low income countries, such as 
Jordan, the frequency of death by cancer is much higher than that in rich countries.  About 
70% of the total deaths in the world from cancer occur in low to middle income countries. 
Breast cancer is considered to be the most common type of cancer among Jordanian 
women, which contributes to about 32% of the total cancer incidence (Al-Tarawneh et al., 
2010). 
MiRNAs (microRNAs) are involved in crucial biological processes, including apoptosis 
(Brennecke et al., 2003); haematopoietic differentiation ( Chen et al., 2004), metabolism 
(Poy et al., 2004), skin morphogenesis (Yi, et al., 2006) and neural development (Schratt et 
al., 2006) through imperfect pairing with target messenger RNAs (mRNAs) of protein-coding 
genes and the transcriptional or post-transcriptional regulation of their expressions. 
In humans, aberrant expression of miRNAs contributes to carcinogenesis by promoting the 
expression of proto-oncogenes or by inhibiting the expression of tumour suppressor genes 
(Iorio et al., 2005). For example, miRNA-15 and miRNA-16 are miRNAs frequently deleted 
and down-regulated in chronic lymphocytic leukaemias and thus act as tumour suppressor 
genes (Calin et al., 2002), whereas miRNAs (miRNAs-17-92) on chromosome 13 are over-
expressed in some lymphomas (Calin et al., 2004) and act as oncogenes.  
Many tumour types have been analysed by miRNA profiling and each has shown differing 
miRNA profiles when compared with normal cells from the same tissue. In one of the 
profiling studies, genome-wide miRNA expression was done in a systematic analysis of 334 
leukaemias and solid cancers using miRNA expression profiling. This study has shown that 
not only some miRNA levels were higher in normal tissues compared to tumours, but also 
they could classify human cancers according to the developmental lineage and 
differentiation state of the tumours using miRNA expression profile clustering (Narod & 
Foulkes, 2004). 
A more recent link between miRNA function and breast cancer pathogenesis is supported by 
studies examining the expression of miRNA in breast cancer clinical samples and breast 
cancer cell lines (Zhao et al., 2008). The study defined a set of miRNAs, which were 
specifically elevated in ERα-negative breast cancer compared to ERα-positive and primary 
tumours cell lines. Of the elevated miRNAs in ERα-negative cells, miRNA-221 and miRNA-222   
were found to be directly interacting with 3’UTR of ERα. More importantly, the knockdown 
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of miRNA-221 or/and miRNA-222 sensitises breast cancer cells to tamoxifen and induces cell 
growth arrest and apoptosis of these cells. These findings indicate that the miRNA-221 and 
miRNA-222 play a significant role in regulation of ERα expression at protein level and could 
be target candidates for future drug developments.  
The potential use of miRNA biomarkers in breast cancer detection has also been discussed 
by Fu, Chen & Man (2011) who summarised previous works on 24 miRNAs (miR-206, miR-17-
5p, miR-125a/b, miR-200c,let-7, miR-34a,miR-31, miR-335, miR-27b, miR-126, miR-101, miR-
145, miR-146a/b, miR-205, miR-21, miR-155, miR-10b, miR-373/520c, miR-27a, miR221/222) 
and their roles in breast cancer detection. 
A few years ago, studies started the use of blood samples to find circulating miRNA 
biomarkers that differentiate breast cancer cases from healthy cases. For example, 
circulating miRNAs have been used to define the miRNA biomarkers in early stages of breast 
cancer (Zhao et al., 2010).  In this study, 20 breast cancer cases (10 Caucasian American (CA) 
and 10 African American (AA)) and 20 control samples (10 Caucasian American (CA) and 10 
African American (AA)) were used. Ranking based feature selection method (R-square 
Bioconductor) has been used to find up and down regulated genes (p-value<=0.05) by 
comparing (AA vs. AA) and (CA vs. CA). Then, hierarchical clustering has been used to group 
the cases into case/control groups and the accuracy of each gene was computed using ROC 
curve. For AA group, the study found a set of 18 genes that was differentially expressed (9 
up-regulated and 9 dawn regulated). On the other hand, a group of 31 genes was 
differentially expressed in CA samples. Only two genes were common to the two groups. The 
best result has been obtained using hsa-let-7c miRNA, where the area under the ROC curve 
was 0.85.  
In another study, the expressions of 4 genes (miR10b, miR34a, miR141 and miR155) were 
extracted from the blood of 89 breast cancer patients (59 primary breast cancer (M0) and 30 
metastatic (M1)) and 29 control samples. The p value of each gene was computed for three 
groups; (M0 and healthy), (M1 and healthy) and (M1 and M0). SPSS was used to compute 
the p value of each gene in the above three groups. The study found the level of RNA (P = 
0.0001) and miR155 (P = 0.0001) differentiating M0 from healthy. In the second group, 
miR10b (P = 0.005), miR34a (P = 0.001) and miR155 (P =0.008) were differentiating M1 from 
healthy. And finally, the study found the levels of RNA (P = 0.0001), miR10b (P = 0.01), 
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miR34a (P = 0.003) and miR155 (P = 0.002) were changed in M1 samples from M0 samples 
(Roth et al., 2010).  
Also, the circulating miRNA has been used to define a chemotherapy resistance biomarker 
(Wang et al., 2012). The study compared the level of mir-125b gene expression in 56 women 
(30 responsive and 26 non-responsive) in order to find the biomarker related to breast 
cancer chemotherapy resistance. The study found the level of mir-125b is higher in non-
responsive compared to responsive patients.  
Also in a recent study, miRNA has been used for early detection of breast cancer (Schrauder 
et al., 2012), where, 1100 miRNAs have been analysed to identify miRNA biomarkers for 
breast cancer. The study analysed 48 cancer cases and 57 healthy cases to find the up and 
down regulated genes using p value under p<=0.05. The study obtained 59 differentially 
expressed genes; 13 up-regulated with the highest ten genes being: mir-4306, mir-202, mir-
4257, mir-1323, mir-335, mir-497, mir-106b, mir-922, mir-516b, let7a* and 46 down 
regulated genes with the highest fifteen genes being: mir-718, mir-625*, mir-1471, mir-
193a-3p, mir-182, mir-1915, mir-564, mir-107, mir-2355, mir-3186-3p, mir-24, mir-3130-3p, 
mir-526a, mir-1469, mir-874). Then, the accuracy of individual genes has been computed in 
order to find a single biomarker for breast cancer. The highest classification accuracy 
obtained using single gene, mir-718, was 77%. To find a pattern of genes instead of single 
gene biomarker, SVM with 10 fold out cross validation has been used to discriminate cancer 
from control cases using different subsets of genes. The values of accuracy, sensitivity and 
specificity were over 80% using a subset of 30 miRNAs extracted from the 59 differentially 
expressed genes but the optimum values for the three measures have been found using a 
subset of 240 miRNA genes including the 59 differentially expressed genes. The overall 
accuracy using 240 genes was 85.6% with 78.8% specificity and 92.5% sensitivity. 
Another study (Hu et al., 2012) started by finding the Endogenous Control miRNAs (ECMs) 
using different cancer traits and controls. Then, the miRNA genes of 48 breast cancer 
samples and 48 control samples were normalised to the ECMs genes and used in discovery 
stage to find the differentially expressed genes (P<0.001). Next, in the validation stage, 76 
breast cancer samples and 76 control samples were validated using the genes that were 
obtained from the discovery stage. Four miRNA genes were differentially expressed between 
cancer and control samples (miR-16, miR-25, miR-222 and miR-324-3p) and used with linear 
regression to classify the samples in the discovery and validation stages. The values of 
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accuracy, sensitivity and specificity in the discovery stage were 90.65%, 91.7% and 89.6%, 
respectively, and for the validation stage were 92.75%, 92.1% and 93.4%, respectively. The 
overall accuracy of the system using all samples, 248 samples, was 91.9%.  
Most miRNA microarray based breast cancer research, such as Hu et al. (2012) used the p 
value for feature ranking and selection. This method is a statistical method and it ignores the 
biological relations between the genes. Also, ranking method is a filtering method that has 
several disadvantages as described in literature. Briefly, the filtering methods ignore the 
relation between features and the relation between the features and classifier.  
Comparing filtering methods, there are few miRNA studies that have used wrapper methods 
for feature selection. For example, Schrauder et al., (2012) selected a subset of 240 genes, 
using SVM with 10-fold out cross validation; this wrapper method has the same 
disadvantages of the other wrapper methods (see Chapter 2 for more details). However, the 
number of selected genes used for classification was still huge compared with the number of 
samples and may cause classifier overfitting. 
Currently, the diagnostic accuracy of breast cancer Computer Aided Diagnosis systems using 
circulating miRNA is about 91%. Thus, there is a need for enhancing the diagnostic accuracy 
of breast cancer CAD systems in order to save the lives of undetected.  
The aim of this chapter is to enhance the diagnostic accuracy of circulating miRNA based 
breast cancer CADs (detect the circulating breast cancer miRNA biomarkers in Jordanian 
women) and to do that, this chapter applied Bi-Biological filter and BFS-SVM wrapper, as 
described in the previous chapter using 56 samples, specially collected from the serums of 
Jordanian women. 
5.2 Materials 
A total of 56 Jordanian females, 32 clinically diagnosed with breast cancer after a "triple 
test" of clinical breast examination, breast examination by a trained medical practitioner, 
mammography, and fine needle aspiration cytology, and 24 control samples were used in 
this study. The patients were referred to the surgery clinic in Queen Alia Hospital, Alhussien 
Medical City and King Abdullah University Hospital. To preserve confidentiality, clinical and 
social information were obtained and recorded in a medical form (Questionnaire), especially 
designed for this purpose. All the samples, the microarray data and the final normalised 
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genes expressions, used in this work were collected and extracted by a specialist Jordanian 
medical group at Prince Haya Biotechnology Centre.   
5.2.1 Sample collection 
A total of 50 ml whole blood samples were collected aseptically into Z serum clot activator 
from the patients before and after the surgery; additionally, fresh malignant tissue sample 
were taken during the operation which were submerged in a sufficient volume of RNAlater 
RNA stabilization reagent (Qiagen, Germany) to protect the RNA because once it is harvested 
it becomes extremely unstable and prone to degradation. Immediate stabilization of the 
RNA and preservation of the RNA expression pattern is a prerequisite for accurate gene 
expression analysis. This ensures that the downstream analyses truly reflect the expression 
profile of the intact tissues. The reagent preserves RNA for up to 1 day at 37°C, 7 days at 18–
25°C, or 4 weeks at 2–8°C, allowing processing, transportation, storage, and shipping of 
samples without liquid nitrogen or dry ice. Alternatively, the samples can also be placed at –
20°C or –80°C for archival storage as in our case. In this study we use the samples that are 
collected before the surgery. 
5.2.2 Extraction of the Circulating miRNA from serum 
 The circulating miRNA was extracted from the serum using QIAamp Circulating Nucleic Acid 
Kit (QIAGEN, 2003) and procedure (QIAGEN, 2011), which enable efficient purification of 
these circulating nucleic acids. Elution step is performed using Buffer AVE where, the elution 
volume can be as low as 50 µl.  If higher nucleic acid concentrations are required, the elution 
volume can be reduced to as low as 20 µl. Low elution volume leads to highly concentrated 
nucleic acid elutes. For downstream applications that require small starting volumes (e.g., 
some PCR and RT-PCR assays), a more concentrated eluate may increase assay sensitivity. 
For downstream applications that require a larger starting volume, the elution volume can 
be increased up to 150 µl. However, any increase in elution volume will decrease the 
concentration of nucleic acids in the eluate. To accurately determine the concentration of 
the RNA sample, the NanoDrop® ND-2000 Spectrophotometer was used. The concentration 
of the miRNA samples were adjusted to be used for the downstream analysis. 
5.2.3 miRNA microarray. 
miRNA profiling was performed by using GeneChipR miRNA Array (Affymetrix, Santa Clara, 
CA, USA). The array comprised 7815 probe sets. Specifically, this microarray contains: 6703 
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encoded miRNA coverage of 71 organisms including human, mouse, rat, canine and rhesus 
macaque, 922 encompassed human snoRNAs and scaRNAs. Also, 190 control targets were 
included in the array that including 95 background probe sets, 63 hybridisation control probe 
sets, 22 oligonucleotide spike-in control probe sets and 10 identical probes. The Probe 
feature size in these arrays was 11µm. Microarray experiments were conducted with 
malignant and normal samples according to the manufacturer's instructions of miRNA 
arrays. Briefly, after miRNA extraction, they were labelled using Biotin FlashTag Biotin 
Labeling kit (Affymetrix). The labelling reaction was hybridised on the miRNA Array in 
Affymetrix Hybridisation Oven 640 (Affymetrix) at 48 °C for 16 hours. The arrays were 
stained with Fluidics Station 450 using fluidics script FS450_0003 (Affymetrix). Then they 
were scanned by microarray scanner (Affymetrix). The Microarray data is still in the form of 
raw data (text file) and needs further processing steps that makes the data ready for further 
analysis. To do that, they used Robust Multichip Average (RAM) method for background 
detection and correction, normalisation and summarisation (see Chapter 2 for more details).  
The miRNA microarray contains a set of 847 human miRNA probes. In this study we used 
only these genes for further analysis.  So, as a first step we generated a new dataset from 
the original one by removing the other miRNA from the original samples and keeping only 
the 847 miRNA human genes.  
5.3 Methods. 
In this chapter we applied the same methods described in the previous Chapter. We started 
by feature selection and then classification and evaluation. The feature selection step 
started with Bi-Biological filter that divided the malignant samples into two groups in order 
to remove neither cancer nor healthy group of genes. Then, the filter removed the healthy 
genes from the remaining set. The output from the Bi-Biological filter was considered to be 
miRNA biomarkers in the serum of Jordanian women. Then we used these biomarkers as 
inputs to Best First Search with SVM-5-fold out cross validation to select a set of small 
number of miRNA genes that gives the highest classification accuracy. Also, in this chapter 
we used MFFNN, SVM, KNN and LDA for classification using 5 fold out cross validation. The 
sensitivity, specificity and accuracy measures were used for evaluation (Figure 5.2). 
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Figure ‎5.2. The methods that are used for miRNA biomarker detection and classification 
for breast cancer in Jordanian women  
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5.4 Results and discussion 
5.4.1 miRNA biomarker detection (Bi-biological filter) 
As we mentioned in Chapter 2, Bi-biological filter is divided into two main steps; neither 
cancer nor healthy biomarker filter and healthy biomarker filter (Figure 5.3). From Figure 
5.3, in the first step, the shared clusters between two cancer dataset (cancer1 and cancer2) 
are selected. Then, in the second step, the healthy clusters are removed from the shared 
clusters between cancer1 and cancer2.   
 
Figure ‎5.3. Bi-biological filter. The first step is neither cancer nor healthy biomarker filter 
and the second step is healthy biomarker filter   
 
Neither cancer nor healthy biomarker filter: The cancer dataset was divided randomly into 
two subsets; cancer1 and cancer2. Each subset contains 16 samples and 847 miRNA genes. 
For the first subset (cancer1) we built the genes co-expression network using the Topological 
Overlap Matrix (TOM) method and applied spectral clustering to cluster the graph (see 
Chapter 4). Then, we used Eigen-gap criterion to find the number of clusters in the network. 
We also found that the maximum gap was between the first and the second eigenvalues 
(Figure 5.4). This means that the graph is not divisible and there is no clear gap to select the 
number of clusters.  
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Figure ‎5.4. The gap between the adjacent eigenvalues of cancer1 subset. The X axis 
represents the index of the eigenvalues and Y axis represents the corresponding 
eigenvalues 
 
As we described in the methods discussion, we proposed an alternative approach involving   
the cut-off and the density measures to select the optimum number of clusters in the 
network. To do that we started by k=2 and increased the value gradually up to k=38 (Figure 
5.5). The best quality of the clustering was found to be 0.85 and the number of clusters was 
24. Also we found that the value of Average Standard Deviation (ASTD) was much smaller 
than the quality measure when the number of clusters was 24, which means that the quality 
values of the clusters are consistent. Therefore, the graph was divided into 24 sub-graphs 
(Figure 5.6).  
The left heat map in Figure 5.6 represents the original 847 X 847 TOM similarity matrix of 
miRNA genes. The points with high brightness, strong similarity, were randomly distributed 
and there were no clear boundaries for the clusters in the matrix. The right heat map in 
Figure 5.5 also represents the 847 X 847 TOM but this time after applying the spectral 
clustering and rearranging the genes to the corresponding clusters. The 24 clusters came 
into sight clearly on the diagonal of the heat map. Each bright square on the diagonal 
represents one cluster with high similarity values within clusters.  
 136 
 
 
Figure ‎5.5. The quality and consistency of different clusters in the cancer1 subset using k= 
[2 38]. Blue line represents the quality of different clusters and the red line represents the 
corresponding consistency 
 
Figure ‎5.6. The heat maps of the cancer1 adjacency matrix before and after clustering. The 
image on the left represents the adjacency TOM matrix of the graph before clustering and 
the image on the right represents the adjacency matrix after rearranging the original graph 
based on the resulting clusters. Each square in the diagonal represents one cluster. The 
brightness of the points reflects the strength of the relationship between a pair of genes; 
the brighter the stronger 
Next and for the cancer2 dataset, we applied the same steps and also found the gap criteria 
not working for the dataset (Figure 5.7). Therefore, we applied the density-cutoff measure 
and found 23 clusters (Figure 5.8). The highest quality value of 0.78 was for this number of 
clusters with 0.45 ASTD, indicating that the cluster quality values were around the overall 
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quality value and the clustering was consistent. Therefore, the cancer 2 dataset was divided 
into 23 clusters (Figure 5.9). 
 
Figure ‎5.7 The gap between the adjacent eigenvalues of cancer2 subset. The X axis 
represents the index of the eigenvalues and Y axis represents the corresponding 
eigenvalues 
 
 
Figure ‎5.8. The quality and consistency of different clusters in the cancer2 subset using k= 
[2 38]. Blue line represents the quality of different clustering and the red line represents 
the corresponding consistency  
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Figure ‎5.9. The heat maps for the cancer2 adjacency matrix before and after clustering. 
The image on the left represents the adjacency matrix of the graph before clustering and 
the image on the right represents the adjacency matrix after rearranged the original graph 
based on the resulting clusters.  Each square in the diagonal represents one cluster. The 
brightness of the point reflects the strength of the relationship between the pair of genes; 
the brighter the stronger 
Then, we found the hub genes of each cluster. To make the comparison more fixable and to 
allow a partial similarity between cancer1 and cancer2 clusters we selected three hub genes 
for each cluster (Table 5.1). 
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Table ‎5.1. The hub genes of cancer1 and cancer2 subsets. The gene index represents the 
unique number given for each probe in the dataset (see Appendix A) 
Cancer1 Cancer2 
Cluster Index Gene Index Cluster index Gene Index 
1 256,335,154 1 240, 667, 161 
2 551,102,168 2 87,337,455 
3 131,68,592 3 128,483,670 
4 773,553,167 4 583,430,684 
5 4,735,153 5 728,834,824 
6 825,210,521 6 143,453,325 
7 157,120,741 7 98,20,509 
8 164,299,452 8 133,666,823 
9 123,826,94 9 422,168,802 
10 298,224,330 10 42,260,104 
11 618,10,666 11 461,55,605 
12 420,399,603 12 717,212,144 
13 654,315,460 13 394,41,446 
14 250,85,800 14 419,282,93 
15 282,295,454 15 74,691,372 
16 63,320,747 16 94,541,424 
17 268,89,169 17 844,284,801 
18 290,376,700 18 533,406,819 
19 695,676,287 19 124,44,827 
20 135,595,614 20 312,342,82 
21 769,348,179 21 379,638,618 
22 341,429,41 22 228,66,596 
23 659,581,191 23 268,68,710 
24 314,404,239 
 
Now, to remove neither cancer nor healthy biomarkers, we compared the hub genes of 
cancer1 and cancer2 to select only the shared clusters between the two subsets. The cluster 
is said to be shared if there is at least one hub gene shared between a pair of clusters. The 
comparison found 8 shared hub genes between cancer1 and cancer2. Because we allowed a 
partial similarity, sometimes, one cluster can match two or three clusters (Table 5.2).  
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Table ‎5.2. The shared hub genes between cancer 1 and cancer 2. Cluster 23 from cancer2 
matches cluster 3 and 17 from cancer1. This is because we allowed partial similarity.  
Shared cluster Index Cluster index 
Cancer1 
Cluster Index 
Cancer2 
Hub Gene Index Gene Name 
1 11 8 666 'hsa-miR-576-3p_st' 
2 2 9 168 'hsa-miR-135a_st' 
3 22 13 41 'hsa-miR-1185_st' 
4 15 14 282 'hsa-miR-200c-star_st' 
5 9 16 94 'hsa-miR-125b-2-star_st' 
6 11 21 618 'hsa-miR-548b-3p_st' 
7 3 23 68 'hsa-miR-1236_st' 
8 17 23 268 'hsa-miR-199a-3p_st' 
By the end of this step, 17 out of 24 clusters were excluded from cancer1 clusters and 16 out 
of 23 clusters were excluded from cancer2. These clusters may be found due to other 
diseases or disorders but not breast cancer. 
Removal of healthy biomarkers: From the above step we excluded all biomarkers which 
were not shared between cancer1 and cancer2. Now, the resulting clusters will be carried to 
the next step of biomarker filtering. In this step, we analysed the healthy dataset to find all 
healthy clusters in order to remove the healthy clusters from the shared clusters between 
cancer1 and cancer2 subsets. Accordingly, we built the gene co-expression network for the 
healthy dataset and we divided the genes into potential functional groups using TOM and 
spectral clustering, respectively (Chapter 4). The density-cutoff measure found the healthy 
dataset contains 22 clusters, for which the quality was the highest quality (1.19) with 0.65 
ASTD (Figure 5.10). Therefore, the genes of the healthy dataset have been divided into 22 
clusters (Figure 5.11). 
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Figure ‎5.10. The quality and consistency of different clusters in the healthy dataset using 
k= [2 35]. Blue line represents the quality of different clusters, the red line represents the 
corresponding consistency  
 
Figure ‎5.11. The heat map for the healthy adjacency matrix after clustering. The brighter 
points means stronger relations 
Then, we found the healthy cluster hub genes (Table 5.3) and compared these genes with 
the hub genes shared between cancer1 and cancer2 (Table 5.2).  We found that the hub 
gene of cluster 6, hsa-miR-548b-3p, from Table 5.2 is shared with the healthy cluster 1. 
Therefore, cluster 6 was considered to be a healthy cluster and was excluded from the 
shared clusters between cancer1 and cancer2 (Table 5.2). 
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Table ‎5.3. The hub genes of the healthy dataset. The gene index represents a unique 
number given for each probe in the dataset (appendix A) 
Cluster Index Gene  Index Cluster Index Gene  Index 
1 668, 379, 618 12 683,839,377 
2 615, 621, 651 13 306,28,795 
3 505, 645, 116 14 163,347,334 
4 508, 736, 353 15 388,257,800 
5 838,605,64 16 657,189,390 
6 231,504,396 17 514,330,212 
7 105,661,152 18 269,122,227 
8 296,86,686 19  238,614,758 
9 534,730,449 20 38,258,159 
10 52,528,544 21 207,404,156 
11 43,276,560 22 442,781,824 
 
By the end of this step, the bi-biological filter found 7 clusters as breast cancer biomarkers. 
Specifically, only 1 hub gene from the healthy cluster 1 overlapped with the shared cancer1 
and cancer2 in Table 5.2. This was the gene with index 618. Therefore, the cluster containing 
this gene (cluster 6 Table 5.2) was removed from the shared cancer1 and cancer2 clusters 
leaving 7 clusters representing cancer. These contained 74 genes as shown in Table 5.4. 
Table ‎5.4. Shared clusters (selected from Table 5.2) containing cancer biomarkers and 
corresponding genes that overlapped between cancer1 and cancer2 
Shared cluster index 
(Table 5.2) 
Gene Name 
1 miR-1224-3p, miR-1273,miR-129-5p,miR-138,miR-182, miR-185-star 
miR-221-star,miR-376b,miR-499-3p,miR-502-5p,miR-516a-5p,miR-576-3p, 
MiR-770-5p, miR-922, miR-923, miR-99b-star. 
2 hsa-miR-135a,miR-324-5p,miR-34a,miR-423-5p,miR-449a,miR-490-5p,  
Hsa-miR-548g, miR-561, miR-616-star, miR-720, miR-885-5p. 
3 miR-1185, miR-137,miR-187,miR-30c,miR-32-star,miR-374b,miR-375,  
miR-379-star, miR-527 
4 let-7c-star,miR-1226,miR-1258,miR-1282,miR-15b,miR-200b,  miR-200c, 
miR-320c,miR-33a,miR-346,miR-515-3p,miR-590-3p,miR-613,miR-629 
miR-643,miR-766 
5 miR-1181,miR-1243,miR-125b-2-star, miR-145-star, miR-146b-3p,miR-18b-
star,miR-22-star,miR-27b-star,miR-342-5p,miR-491-5p 
MiR-509-5p, miR-567, miR-663, miR-769-5p. 
7 MiR-1225-3p, miR-1236, miR-501-3p, miR-548f. 
8 MiR-199a-3p, miR-199a-5p, miR-611, miR-615-5p. 
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Now, for each gene in Table 5.4, we investigated the relation of the gene with breast cancer 
or other cancers in the previous studies and found, 31 out of the 74  selected were related to 
cancer (miR-1224-3p, miR-129-5p,miR-138, mir-590-3p, miR-182, miR-185, miR-221, miR-
376b, miR-499-3p, mir-576-3p, miR-99b, miR-135a, miR-34a, miR-449a, miR-885-5p, mir-
502-5p, miR-137, miR-30c, miR-375, let-7c, miR-1226, miR-1258, mir-1181, miR-200b/c, miR-
125b-2, miR-146b-3p ,miR-342-5p ,miR-663, miR-199a-3p, miR-199a-5p) and 22 out of 31 
genes were in direct relation with breast cancer (Afanasyeva et al., 2011; Boyerinas, Park, 
Hau, Murmann & Peter, 2010; Brest et al., 2011; Y. Chen et al., 2012; Cittelly et al., 2010; 
Dykxhoorn et al., 2009; Fassan et al., 2009; Giricz et al., 2012; Guttilla & White, 2009; Hao, 
Xing, & He, 2012; Imam et al., 2010; Jin, Rajabi, &  Kufe, 2010; Johnson et al., 2007; 
Lambertini et al., 2012; Li et al., 2012; Lowery et al., 2009; Moskwa et al., 2011; Nugent, 
Miller, & Kerin, 2012; Park, Gaur, Lengyel, & Peter, 2008; Peurala et al., 2011; Radisky, 2011; 
Romero-Cordoba et al., 2012; Shah & Calin, 2011; Shatseva, Lee, Deng, & Yang, 2011; 
Stinson et al., 2011; Tanic et al., 2012; Turcatel, Rubin, El-Hashash, & Warburton, 2012; 
Wang et al., 2012; Yang et al., 2012; Yu et al., 2007; Zhao et al., 2011; Zhao et al., 2012) (see 
Appendix A.3). 
By this investigation we found that more than 40% of the 74 miRNA genes (31 genes) 
overlapped with other cancer studies. This finding provided further evidence of the 
relationship between these genes and breast cancer. Also, we introduced a new group of 
genes, 43 genes, strongly related to the 31 known cancer genes and may belong to the same 
pathway.  
To validate the biological relations between the genes in the same cluster, firstly, we used 
miRBase database (Griffiths-Jones, Saini, van Dongen & Enright, 2008) to find the verified 
target mRNA genes for each member in the group in Table 5.4 (Table 5.5). From this table 
we found the target mRNA genes of the miRNA genes in cluster 7 (in Table 5.4) were not 
discovered yet. Therefore, this cluster was excluded from the next step. Then, we used 
DAVID (v6.7) database (Dennis et al., 2003) to find the biological processes for the mRNA 
groups (Tables 5.6-5.10). 
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Table ‎5.5.  The miRNA target genes. The gene symbols were grouped based on the miRNA groups in Table 5.4 
Shred cluster Index 
(Table 5.4) 
Target genes 
1 
CAMTA1, BMPR2, SOX4, ZFP91, TP53INP1, FNDC3B, GALNT1, PDS5A, ETV6, TNPO1, EZH2, VIM, RHOC, ZEB2, ROCK2, SERPINE1, EID1, ARHGEF3, MITF, EP300 , RARG, 
FOXO3 , CLOCK, ADCY6, ALK7, SOX6, SET8, KLK10 
2 
JAK2, APC, NR3C2, SIRT1, BCL2, YY1,MYC,CDK6,CCND1,FOXP1,E2F3,ACSL4,AXL,MTA2,LDHA , LEF1, ACSL1, MYCN, ARHGAP1, RTN4, TPD52, RDH11, WNT1, NOTCH1, 
GRM7, JAG1 , RTN4,  CAMTA1, POU2F1, PHF19 , CDON , UBP1, SOCS4, TPD52, HOXB8, BCL2L13, TXNIP , REEP3, SATB2, PPP3R1, 10ORF22, MTMR9 , KIAA0196, 
VPS37B, FAM104A , SLC4A7, POGZ , MYC, TATDN2 , SENP1, XRN1 , FAM76A , FIGN, B4GALT3, TNRC18B, TSPAN14, C13ORF23, PUM2, AC121493.1 , NCBP2, ZNF644, 
SNX12, SGPP1, ZC3H4, MAP3K7, GAS1, MTDH, RRAS, ERLIN1, EMP1, MET, MYB, HNF4A , VPS45, ATXN2L, NT5C2 , TMOD2, CFL1 , TTLL12 , SORT1, HUWE1, GTF3C1, 
CDC5L, STAG2, HIST4H4 , NOTCH2, VCL , RPIA , DDX21 , RNF40 , GYG1 , TES , LARP1 , RSU1 , CTNNB1 , RAE1 ,CCNE2 , AXIN2 , E2F5 , GIGYF2, KTN1 , TXNRD1 , DLL1 , 
KPNA1 , WASF2 , HIST1H4H , FAM3C , PEA15 , SURF4 , CALD1 , MDM4 , CDC23 , PLCG1 , EFNB1 , GAPVD1 , G3BP2 , ZFR , CYB5B , AKR1A1 , QDPR , MAP2K1 , ARF6 , 
OGFOD1 , RRM2 , GORASP2 , TSN , HNRNPUL1 , HIST1H2AC , LRRC40 , MCM3 , CCND3 , UBR4 , CDC25A, WISP2, CDK2, MCM5 
3 
E2F6, CDK6, NCOA2, MUC17, GLI1, SMO, PELI1, IRS2 , STCH, KIAA0494, GALNT7, C5ORF32, TACC1, ATF2, KBTBD8 , NUP153, AFTPH, REEP3 , SEMA3C, AFF4, MINPP1, 
RHOU, TRA2A, ZBTB41 , DEK, ADD3, SFRS7, ZSWIM6, MAPK1IP1L, CCND1 , NRXN3 , CA13, HOXA5, SON, SLC11A2, PARG, ZNF175 , SPTLC1, FAM76A , OSTM1, C9ORF5, 
PAPD4, ATP6V1C1, BAMBI, NARG1L, PARD6B , MRPL19, RAPH1, CMPK1, MIER3, MEX3C, YAP1, YWHAZ  
4 
MUC1, HPSE, BCL2, CCNE1, RECK, CCND1, EIF4A1, ZEB1, BAP1, ERBB2IP, SHC1, PTPRD, KLHL20, ELMO2, KLF11, RIN2, ZEB2, PTPN12, ETS1, WASF3, GATA4, RERE, 
EP300, FN1, MATR3, ZFPM2, BMI1, RTN4, PCGF2, YWHAH, BSDC1, SH3PXD2A, PPP1R9A, FBXO30, SAMD8 , LRRC8A , CSNK1G3 , HOXA9 , KLF9, PAPOLG, BCL10, 
ANKRD29, STYX, DCBLD2, HMGB2, SHCBP1, GLT8D3, TMEM65, IER5, C19ORF43, EXOC4, SGMS1, TSG101, RAB5A, FOXP1, AC099524.5, VTI1B, CRY2, STRBP, NUFIP2, 
HIF1A, MAPK8, PIM3, BTBD2, ZC3H12C, NCOA6, LDHA, ZFYVE20, LIMA1, SERTAD2, BRWD1, ERO1LB, AKAP11, SLC39A14, GPR137C, NPC1, ABCA1, LIF, CDKN1A, STCH, 
KIAA0494, MED13L, ANGEL2, PGAP1, RDH11, EXOC5, GPATCH8, FBXW7, SETD7,  EEP3, MYST4, SCDC2, ID4, USP6NL, NARG1, C4ORF15, 
TMEM123, PPP2R5A, LIMS1,SNO25,CSNK1D, KHSRP, PNN, FAM108B1,R3C1, NUFIP2, CSTF1, FOXG1B, ATXN1, FAM49B, NEO1, SKI, NAT12, C19ORF6, UBXN2A, SERTA
D4, CITED2, SUV420H1, TERF2IP, NEDD4, PAPD4, C18ORF19, PDIK1L, IL6ST, PLEKHA1, GATAD2B, RBM12B, ZNF238, SESN3, HIPK1, NRIP1, PRKAR2B, SPATS2, VPS35, S
GCB, MRPL19, CMPK1, MTF1, KCTD20, KCTD20, ERALPHA. 
5 
ERALPHA, PDGFB, PAX3, CYP1B1, ADORA2B, MMP13, BCL2L1, CHD4, TAF10, ERROR, FAM126B, SCP2, TAOK2, RGMB. 
8 
MTOR, FLAP, KRT. 
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Table ‎5.6.  The biological processes for the genes in cluster 1 
ID Name Genes FDR P-value 
 
GO:0006355 
Transcription  EP300, EID1, SOX4,CAMTA1, CLOCK,EZH2,ETV6, FOXO3, MITF,RARG,ZEB2 8.6E-2 7.7E-5 
 
GO:0042981 
 
Regulation of apoptosis 
ARHGEF3,SOX4,FOXO3,MITF, RARG,TP53INP1,ZFP91 3.3 2.3E-3 
GO:0043067 Regulation of 
programmed cell death 
ARHGEF3,SOX4,FOXO3,MITF,RARG,TP53INP1,ZFP91 3.5 2.4E-3 
Table ‎5.7. The biological processes for the genes in cluster 2 
ID Name Genes FDR P-value 
 
GO:0070013 
Intracellular organelle 
lumen 
CDC5L,E2F3,HUWE1,JAK2,POU2F1,SATB2,YY1,CCND1,CDK2,FIGN,FOXP1,GTF3C1,LEF1,
MTDH,MTA2,MCM5,NCBP2,SIRT1,MYB,MYC 
8.2E-2 6.9E-5 
GO:0043233 Organelle lumen CDC5L,E2F3,HUWE1,JAK2,POU2F1,SATB2,YY1,CCND1,CDK2,FIGN,FOXP1, 
GTF3C1,LEF1,MTDH,MTA2,MCM5,NCBP2,SIRT1,MYB,MYC 
2.7E-1 9.4E-5 
GO:0042981 Regulation of apoptosis BCL2,BCL2L13,JAK2,NOTCH1,NOTCH2,APC,GAS1,MAP3K7,PPP3R1,RTN4,SIRT1,SORT1,
MYC 
2.4E-1 1.5E-4 
GO:0043067 Regulation of 
programmed cell death 
BCL2,BCL2L13,JAK2,NOTCH1,NOTCH2,APC,GAS1,MAP3K7,PPP3R1,RTN4,SIRT1,SORT1,
MYC 
2.7E-1 1.6E-4 
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Table ‎5.8. The biological processes for the genes in cluster 3 
ID Name Genes P-
value 
FDR 
GO:0051329 Interphase of mitotic cell cycle E2F6, CCND1, CDK6, RHOU 0.003 4.3 
GO:0000082 G1/S transition of mitotic cell 
cycle 
E2F6, CCND1,  RHOU 0.01 15 
Table ‎5.9. The biological processes for the genes in cluster 4 
ID Name Genes FDR P-value 
GO:0051252 Regulation of  RNA 
metabolic process 
BCL10,EP300,GATA4,KLF11,KLF9,MYST4,SERTAD2,SETD7,RERE,BRWD1,CCNE1,FOXP1
,HMGB2,HIF1A,ID4,LIF,MED13L,NCOA6,PCGF2,TSG101,ETS1,ZEB1,ZEB2 
9.4E-2 
5.9E-5 
 
 p53 Signalling Pathway BLC2,CCD1,CCNE1,CDKNIA 2.1 2.1E-3 
GO:0030308 Negative regulation of 
cell growth BCL2,SERTAD2,CDKNIA,DCBLD2,RTNT 2 
1.2E-3 
 
Table ‎5.10. The biological processes for the genes in cluster 5 
ID Name Genes FDR P-value 
 
GO:0045935 
Positive regulation of nucleobase-containing compound metabolic 
process 
RGMB,ADORA2B,PAX3,PDGFB 12 9.2E-3 
 
GO:0051173 
Positive regulation of nitrogen compound metabolic process RGMB,ADORA2B,PAX3,PDGFB 13 1.0E-2 
GO:0070482 Response to oxygen levels. BCL2L1,MMP13,PDGFB 6.3 4.6E-3 
0016477 Cell migration TAOK2,PAX3,PDGFB 21 1.7E-2 
GO:0045860 Positive regulation of protein kinase activity TAOK2,ADORA2B,PDGFB 15 1.1E-2 
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The first cluster contains two main biological processes, transcription (GO:0006351) and 
apoptosis (GO:0042981) (Table 5.6). Transcription is a process in which the parts of the DNA 
that code for a specific protein are converted to ribonucleic acid (RNA). Also, this process is 
responsible for regulating the level of gene expression in the cells. The cancer cells result 
from a failure of regulation of the expression of genes that are a part of cell growth and 
differentiation (Cox & Goding, 1991; Shen et al., 2007). The second biological process, 
Apoptosis, also called programmed cell death, is responsible for killing the cells that are 
sufficiently damaged. Apoptosis is controlled by extracellular signals (i.e., heat and radiation) 
or intracellular signals (i.e., hormones and growth factors).  Several studies have found that 
breast cancer cells are developed due to loss of control between apoptosis and proliferation, 
and suggested breast cancer treatments by inhibiting proliferation and inducing apoptosis of 
cancer cells (Dowsett et al., 1999; Ghavami et al., 2009; Parton et al., 2001; Vakkala, 
Lähteenmäki, Raunio, Pääkkö & Soini, 1999).  
Cluster two contains four biological processes (Table 5.7). The first two biological processes 
(GO:0070013, GO:0043233) are about the organelle lumen. The lumen represents the 
volume of the space that is enclosed by the membranes of an organelle. For example, the 
lumen of the breast duct is the empty space inside the duct that is surrounded by epithelial 
cells (Figure 5.12) that is reduced by the cancer cell proliferation and accumulation inside the 
duct. Intracellular organelle lumen process contains two genes (BRCA1 and BRCA2) that are 
strongly related to breast cancer (Babaei, Akker, Ridder, & Reinders, 2011). Mutations in 
BRCA1 and BRCA2 have been found to be the most common cause of breast cancer (Welcsh 
& King, 2001). Even though these genes were not found within the verified targets of the 
miRNA genes in cluster 2 (Table 5.5), it could be good evidence that may be one or more 
miRNA genes control the expression of BRCA1 and BRCA2 but they have not yet been 
discovered. The other two biological processes are about cell death (GO:0042981: regulation 
of apoptosis and GO:0043067: regulation of programmed cell death which were discussed 
before. 
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Figure ‎5.12. Enlarged image of the breast duct where A is the ductal cells and B is the 
lumen of the duct 
 
Cluster 3 contains two biological processes: interphase of mitotic cell cycle (GO:0051329) 
and G1/S transition of mitotic cell cycle (GO:0000082). Interphase of mitotic cell cycle is a 
preparation step of cell division that proceeds into three stages G1, S, G2. During this stage 
the cells grow but not divide. G1 is the first stage of interphase which produces a large 
number of proteins and enzymes that are required by S stage to replicate DNA. Transition 
from G1 to S is a critical decision made for the cell to divide and controlled by a group of 
genes such as CDK family (Alberts et al., 2008). Several studies found the transition between 
G1 and S in breast cancer cells different from normal breast cells (Sahin et al., 2009; Nielsen, 
Loden, Cajander, Emdin & Landberg, 1999). For example, Nielsen et al. (1999) studied the 
G1/S transition and found that 90% of breast cancer cell were different from normal cells in 
the level of the proteins that control G1/S transition process.  
For the cluster number four, we found p53 signalling pathway as the most important 
process. The relationship of these pathways to cancer is well known as p53 is crucial for the 
decision whether a DNA damaged cell survives or dies (Kang et al., 2009; Mirzayans, Andrais, 
Scott & Murray, 2012). Also, in breast cancer, p53 signalling pathway has been found in 
relation to aggressive breast cancer cases (Gasco et al., 2002). Recently, p53 pathway has 
been studied in order to develop a target therapy for cancer (Stegh, 2012).    
In cluster five, the most important process is cell migration (GO:0016477), in which the 
cancer cells are moved from one side to another. The movement of cancer cells from one 
side to another in breast cancer results in Metastasis Breast Cancer. This type of cancer is 
considered to be an aggressive stage of breast cancer (Imaginis, 2012). Also, several studies 
have been done on cell migration process in breast cancer in order to find a targeted 
treatment that stops or prevents the spread of cancer (Chen et al., 2012; Kim et al., 2012; 
Rodrigues-Ferreira et al., 2012). 
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The above investigation indicates that genes in the same cluster work together to carry out 
the same biological processes which provides support for the biological relations between 
the genes of the same cluster. Furthermore, we find the relationship between the biological 
processes of the groups and breast cancer are strong which also provides support for the 
selected group of biomarkers. Only one cluster, clusters 8, was found to have no biological 
processes. This is because the cluster has a small number of target mRNA genes. However, 
still there is a need for reducing the number of genes to improve the performance of the 
classification step. Therefore, the next step is to select a smaller set of genes from the 74 
genes for classification. 
5.4.2 Best First Search and SVM with 5-fold out cross validation 
This is an iterative algorithm that search for the optimum set of genes by expanding the set 
of genes, in the state space, with the best value for the heuristic function H(f), the diagnostic 
accuracy obtained by using the set of genes f as input to SVM with 5-fold out cross 
validation, and allowing backtracking. In each iteration, each gene is added to the optimum 
set of genes. Then the algorithm computes the accuracies of the resulting sets and selects 
the set with the highest accuracy. The algorithm stops running if there is no enhancement in 
the last 3 steps, the goal has been achieved or the optimum set contains all genes (see 
Chapter 4 for more details). By applying the BFS-SVM, we found the algorithm has stopped 
running after 10 iterations. For the first iteration involving single genes, the best results were 
obtained for miR-129-5p gene, where the values of specificity, sensitivity and accuracy were 
0.75, 0.78 and 0.76, respectively (Table 5.11). 
Table ‎5.11. Results for the top 10 genes in the first iteration involving a single gene  
Gene name Specificity    % Sensitivity % Accuracy % FN rate % FP rate % 
miR-129-5p 75 78.125 76.78 19.35 28 
miR-643 62.5 87.5 76.78 24.32 21.05 
miR-923 54.16 87.5 73.21 28.20 23.52 
miR-922 58.33 81.25 71.42 27.77 30 
miR-182 62.5 75 69.64 27.27 34.78 
miR-145* 58.33 75 67.85 29.41 36.36 
miR-1236 54.16 78.12 67.85 30.55 35 
miR-320c 54.16 78.12 67.85 30.55 35 
miR-342-5p 54.16 78.12 67.85 30.55 35 
miR-885-5p 54.16 78.12 67.85 30.55 35 
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The highest accuracy was found to be 98.2% at iteration number 7 with 100% specificity and 
95.83% sensitivity using 7 miRNA genes (miR-548f, miR-502-5p, miR-1236, miR-590-3p, miR-
1181, miR-145*, miR-129-5p) (Figure 5.13). The algorithm returned the accuracy values and 
the gene sets of the first seven iterations (Table 5.12). In the whole gene list in Table 5.12 
there were 7 unique miRNA genes that are shown for iteration 7. These were selected to 
build the classifiers.  
Four out the seven genes (miR-129-5p, miR-1181, miR-590-3p and miR-502-5p) were related 
to cancer in previous studies (Liu et al., 2012; Zhai et. al., 2012; Brest et al., 2011; Zhang et 
al., 2011; Backes et.al. 2010). Thus, the current method identified three new breast cancer 
biomarkers (miR-548f, miR-1236, miR-145*). Also, the seven selected genes were distributed 
over 5 clusters (clusters 1, 2, 4, 5, 7 in Table 5.4) containing 64 out of 74. Therefore, about 
89% of the 74 genes were represented by the 7 selected genes. Furthermore, the biological 
processes of clusters 1, 2, 4, 5 were found strongly related to breast cancer such as, 
Apoptosis, Organelle lumen, p53 signalling pathway and cell migration.     
 
 
Figure ‎5.13. The accuracies of the first 7 iteration of the wrapper, the X-axis represents the 
iteration number and the Y-axis represents the accuracy  
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Table ‎5.12. The sets of genes used in each iteration of the wrapper 
Iteration 
Number 
Set members Accuracy 
1 miR-129-5p 76.78 
2 miR-145-star,miR-129-5p 85.71 
3 miR-1181,miR-145-star,miR-129-5p 89.28 
4 miR-590-3p,miR-1181,miR-145-star,miR-129-5p. 94.64 
5 miR-1236,miR-590-3p,miR-1181,miR-145-star,miR-129-5p. 94.64 
6 miR-502-5p,miR-1236,miR-590-3p,miR-1181,miR-145-star,miR-
129-5p. 
96.42 
7 miR-548f,miR-502-5p,miR-1236,miR-590-3p,miR-1181,miR-145*, 
miR-129-5p 
98.21 
  
5.4.3 Classification 
To validate the accuracy of the seven selected genes we applied 5-fold out cross validation 
with four different classifiers: Multilayer Feed Forward Neural Network (FFNN), SVM, K 
Nearest Neighbour (KNN) and Linear Discriminant Analysis (LDA). The 5-fold out cross 
validation was used because of the small number of samples. To evaluate the performance 
of different classifiers, accuracy, sensitivity, specificity, false positive and false negative rates 
have been used. For the KNN classifier the best value for K has been found at K=13 (Figure 
5.14). 
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Figure ‎5.14. The accuracies of different number of neighbor nodes (K). The best result was 
obtained for k=13 
 
From the outputs of different classifiers we found that SVM was the superior classifier with 
100% sensitivity, 95.3 % specificity and 98.2 % accuracy (Table 5.13). 
Table ‎5.13.  The performance of different classifiers using the seven selected biomarkers 
Classifier Sensitivity  Specificity  FN rate FP rate Accuracy  
SVM 100% 95.3% 0 3% 98.2% 
LDA 96.9% 87.5% 4.5% 8.8% 92.9% 
MFFNN 96.9% 95.8 4.2% 3.1% 96.4% 
KNN 100% 79.2% 0 13.5% 91.1% 
  
There are only two published circulating miRNA based BC-CAD systems (Schrauder et al., 
2012 and Hu et al., 2012) with which to compare the results of the current system. 
Schrauder et al., (2012) CAD used a wrapper method, SVM with 10 fold out cross validation, 
to discriminate cancer from control cases using different subsets of genes. The optimum 
values of accuracy, sensitivity and specificity measures were 85.6%, 78.8% and 92.5%, 
respectively, using a subset of 240 miRNA genes. Thus, the accuracy, sensitivity and 
specificity measures of the four classifiers used in the current study were better than the 
results of Schrauder et al. (2012) study. Specifically, improvement in accuracy is 12% by 
using SVM classifier. Also, the number of selected genes for classification in the current 
study was 7 genes compared to 240 genes in their study. Therefore, the classifier developed 
in this study has achieved higher accuracy with a very small but effective set of biomarkers.  
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Hu et al., (2012) CAD system extracted 4 mRNA genes (miR-16, miR-25, miR-222 and miR-
324-3p) as breast cancer biomarkers using a filtering method. These biomarkers were used 
for classifying the samples into healthy and cancer cases. The accuracy, sensitivity and 
specificity values were 91.9%, 91.9%, 91.9%, respectively. By comparing the current CAD 
system results with their results we found that accuracy, sensitivity and specificity measures 
of SVM and MFFNN in the current system were better than the results of their system. 
Specifically, improvement in accuracy, sensitivity and specificity measures is 6.3%, 8.1% and 
3.4%, respectively, by using SVM.   
By the end of this chapter, the current Computational BC-CAD Framework was successfully 
completed (Figure 5.15). The framework is now capable of supporting the decision of a  
doctor using seven alternatives: (i) ultrasound data with 95.4% diagnostic accuracy, 8.3 % 
false Positive (FP) rate and 0 False Negative rate; (ii) mRNA data with 93.4% diagnostic 
accuracy, 5.6% FP rate and 7.4% FN rate; (iii) miRNA data with 98.2% diagnostic accuracy, 0 
FP rate and 3% FN rate; (iv) ultrasound and mRNA datasets; (v) ultrasound and miRNA 
datasets; (vi) mRNA and miRNA datasets; and (vii) mRNA, miRNA and ultrasound. In the last 
choice the framework supplements the doctor’s decision with three BC-CADs with two 
possibilities: same decision from all CADs, or two with the same decision and one being 
different in which case the decision from the two similar CADs is more reliable. If we have 
only two input datasets with conflicting decisions, the framework returns FP and FN rates of 
the CADs for comparison and resolving the conflict to make a final decision (see Chapter 4 
for more details).   
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Figure ‎5.15. The Breast Cancer Computer Aided Diagnosis (BC-CAD) Framework showing 
the three CAD systems. The orange colour means that all the framework component were 
successfully completed 
 
5.5 Summary 
We have presented in this chapter an miRNA based CAD system for early detection of breast 
cancer and defined some effective breast cancer biomarkers for Jordanian women. We 
started with a brief introduction about breast cancer in Jordan. Then we introduced an 
overview to miRNA and current accuracy of the miRNA based CADs for early detection of 
breast cancer. A total of 56 Jordanian females, of whom, 32 were clinically diagnosed with 
breast cancer after a "triple test" of clinical breast examination (breast examination by a 
trained medical practitioner), mammography, and fine needle aspiration cytology, and 24 
control samples, were included in this study. 
By applying the Bi-biological filter for feature selection, 8 groups of genes were found to be 
shared  between the groups of the two cancer subsets and only one out of the 8 clusters 
were shared with the healthy groups. Thus, 7 groups of genes were considered to be breast 
cancer biomarkers for Jordanian women. The total number of genes in the selected seven 
groups was 74 genes. By investigating the relation of individual genes with cancer, we found 
31 out of 74 have been previously found to be related to cancer (miR-1224-3p, miR-129-5p, 
miR-138, miR-182, miR-185, miR-221, miR-376b, miR-499-3p, miR-576-3p, miR-99b, miR-
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135a, miR-34a, miR-449a, miR-885-5p, miR-137, miR-30c, miR-375, let-7c, miR-1226, miR-
1258, miR-200b/c, miR-125b-2, miR-146b-3p, miR-342-5p, miR-663, miR-199a-3p, miR-199a-
5p) and 22 out of 31 genes were found directly related to breast cancer.  
Next, for each of the seven groups we used the miRBase and DAVID databases to find the 
target mRNA genes and validate the biological relations between the genes within a group, 
respectively. We found the genes in the same cluster work together to do same biological 
processes (transcription, apoptosis, regulation of programmed cell death, lumen process and 
p53 Signalling Pathway) which provides a support for the biological relation between the 
genes of the same cluster. Furthermore, we find the relationship between the biological 
processes of the groups and breast cancer are strong which also provides a support for the 
selected group of biomarkers.  
Then, we used Best First Search and SVM with 5-fold out cross validation wrapper to select a 
subset of genes from the 74 previously selected genes for classification. A subset of seven 
genes were selected as input for the classifiers (miR-548f, miR-502-5p, miR-1236, miR-590-
3p, miR-1181, miR-145*, miR-129-5p). These genes were distributed over 5 clusters and 
successfully represented 89% of the 74 genes. Three out of the seven genes (miR-548f, miR-
1236, miR-145*) were not found previously to be related to breast cancer and therefore 
were defined as new breast cancer biomarkers.  
Four classifiers, MFFNN, SVM, LDA and KNN with 5-fold out cross validation, have been used 
to validate the accuracy of the selected genes. Sensitivity, specificity, FP, FN and accuracy 
measures have been used for validation. The SVM was the superior classifier with 98.2% 
classification accuracy. Therefore, the overall improvement by using the Novel feature 
selection method was about 7%, which is a significant improvement compared with the 
current best circulating miRNA based BC-CAD systems. Also, in this chapter, the current 
Computational BC-CAD Framework was successfully completed and it provided a set of 
alternatives involving clinical and biological data that aid doctors in making accurate   
decisions. 
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Chapter 6 
Conclusions and Future Work 
The overall goal of this thesis was to integrate data mining and biology to study, model and 
enhance the diagnostic accuracy of Breast Cancer Computer Aided Diagnosis systems. The 
main objective of this research was to better understand and to acquire more insight into 
Breast Cancer Computer Aided Diagnosis Systems (BC-CADs) in order to develop a 
Computational Breast Cancer Computer Aided Framework that enhances the current 
accuracy of breast cancer CAD systems. Different CAD systems are developed for early 
detection of breast cancer, depending on the type of the breast cancer examination and the 
particular research questions asked. The results from the current framework indicated that it 
was successful in enhancing the diagnostic accuracy of breast cancer and providing doctors 
with a set of alternatives for detecting breast cancer in early stage using clinical or biological 
data or combination of both. We now give a general overview of what we have achieved and 
the contribution of these achievements and future directions that can follow from the 
current work. 
6.1 General overview 
The first focus of the current work, clinical part of the framework, was to enhance the 
diagnostic accuracy of breast cancer CAD systems using the morphological features in clinical 
datasets (Ultrasound) (Chapter 3). To fulfil this goal, we first extracted the morphological 
findings from the breast ultrasound images. Then, we converted the linguistic values of the 
features into numerical values and found the frequencies of different features in both 
malignant and benign cases to classify the features into good and bad features. Importantly, 
we investigated the shape of the mass in ultrasound images and extract a new mass feature 
called Central Regularity Degree (CRD) of the mass. This feature was inspired by the fact that 
malignant masses typically have an irregular shape and current CADs do not make use of this 
morphological feature.  
Then, we used hierarchical clustering and SOM to select a subset of features for 
classification. To demonstrate the effect of CRD on differentiating malignant from benign 
masses and its potential to improve the diagnostic accuracy of breast cancer using 
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ultrasound images, we evaluated the diagnostic accuracy of different classifiers when the 
CRD was added to five known powerful mass features.  
We summarised the findings of the chapter in the following five aspects: (1) The frequencies 
of the features show that the mass shape, margin, microcalsification, blood level, DW ratio, 
CRD and age can differentiate cancer from malignant cases, (2) Both clustering methods: 
hierarchical clustering and SOM, selected the age, shape, margin, DW ratio, blood level and 
CRD features for classification with about 81% classification accuracy. (3) The comparison 
between the accuracies of different classifiers when the CRD was added to the feature list 
revealed that CRD is an effective feature discriminating between malignant and benign cases 
leading to improved accuracy of diagnosing breast cancer. MFFNN obtained the best results; 
the accuracy in the training and testing phase using all features except CRD was 100% and 
81.8%, respectively. Adding CRD, these results were: 100% and 95.5%. Therefore, the overall 
improvement by adding CRD was about 14%; a significant improvement. (4) The comparison 
between the results of the current BC-CAD system and the previous ultrasound based BC-
CADs found that the results of the current system are better than the results of the previous 
best CAD systems (Wei et al., 2007; Chang et al., 2005; Chen et al., 2003). (5) The clinical part 
of the framework was successfully completed and it is capable of classifying the cases using 
the morphological features of ultrasound images with improved accuracy.  
  
The second focus of this research, biological part of the framework, was to provide a 
biological based gene selection method to find the mRNA biomarkers in peripheral blood of 
breast cancer patients and enhance the diagnostic accuracy of the mRNA based BC-CAD 
systems (Chapter 4). For this purpose, we introduced a novel gene selection method called 
Bi-Biological filter. This filter started by dividing the cancer datasets randomly into two 
subsets. Next, for each subset we built the co-expression network using TOM approach and 
divided the network into functional groups in order to find the biomarkers shared between 
the cancer subsets and exclude the non-shared ones. These shared groups contain breast 
cancer and healthy biomarkers. Then, we built the co-expression network for the whole 
healthy dataset and divided the network into functional groups. Next, we compared the 
‘shared groups between the cancer subsets’ and the healthy groups in order to remove the 
healthy groups from the shared groups between cancer subsets. Subsequently, we 
investigated the biological relation between genes of each selected group by searching for 
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the biological processes that are related to the genes of the same cluster using the DAVID 
database.  
Finally, we evaluated the diagnostic accuracy of the selected gene biomarkers by using them 
as input for a CAD system. To increase the performance of the classifiers, we selected a small 
subset of genes using BFS and SVM with 5-fold out cross validation. Three classifiers were 
used for classification and the results of different classifiers were evaluated using sensitivity, 
specificity and accuracy measures.  
The findings of the mRNA CAD system are summarised in the following aspects: (1) The gap 
criteria that have been used for finding the number of clusters in the graph or network 
suffered from the density of the graph where the resulting eigenvalues of the graph were 
uniformly spread and there was no clear gap between the adjacent values. To overcome this 
problem, we combined the Density and Cut-off graph clustering criteria to select the 
optimum number of clusters. Also, we introduced a new criterion called the Average 
Standard Deviation (ASTD) to assess the internal consistency of the quality value of each 
cluster. (2) One of the cancer subsets was divided into 17 functional groups and the other 
one was divided into 16. The comparison between the functional groups of the two subsets 
found 5 shared groups between the cancer subsets. A further filtering was done by dividing 
the genes of the healthy dataset into 15 functional groups and comparing the 5 groups with 
the 15 healthy groups. This step kept only three out of the five clusters as breast cancer 
biomarkers. The total number of genes in the three clusters was 415 genes. (3) By 
investigating the biological relations between the genes of each cluster we found the genes 
in the same cluster are involved in the same biological processes, which provides support for 
the biological relations between the genes. Furthermore, we find that the relationship 
between the biological processes of the groups and breast cancer are strong which also 
provides support for the selected group of biomarkers. (4) The BFS-SVM selected 13 out of 
415 genes for classification. The superior classifier was MFFNN with 93.2% classification 
accuracy. Therefore, the overall improvement was about 13% significant improvement 
compared to the one and only previous study (Aaroe  et al., 2010). (5) The first component 
of the biological part of the framework was successfully completed. This part provided 
another two alternatives of input data to the BC-CAD framework: mRAN data and mRNA and 
ultrasound. 
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The final focus of this research, the second component of the biological part of the 
framework, was to determine the miRNA biomarkers in the serum of the breast cancer in 
Jordanian women and enhance the diagnostic accuracy of circulating miRNA based CAD 
systems (Chapter 5). We started by identifying the miRNA biomarkers. This was done by 
using 56 samples (32 cancers 24 controls) that were collected from the serum of Jordanian 
women. Furthermore, the Bi-Biological filter was used as described in the previous chapter. 
Then, we evaluated the diagnostic accuracy of the selected biomarkers by using them as 
input for a CAD system. To increase the performance of the classifiers, we selected a small 
subset of genes from the total using BFS and SVM with 5-fold out cross validation. Four 
classifiers were used for classification and the results of different classifiers were evaluated 
using sensitivity, specificity and accuracy measures.  
The findings of this chapter are summarised as follows: (1) Eight groups of genes were found 
to be shared  between the groups of the two cancer subsets and only one out of the eight  
clusters was found in the healthy groups. Seven groups of genes thus were considered to be 
breast cancer biomarkers for Jordanian women. The total number of genes in the selected 
groups was 74, (2) By investigating the relation of individual genes with cancer, we found 31 
out of 74 have been previously found to be related to cancer and 22 out of 31 genes were 
found in direct relationship to breast cancer. This finding provided further evidence of the 
relationship between the 31 genes and breast cancer. Also, we introduced a new group of 
genes, 43 genes, strongly related to the 31 genes and may belong to the same pathway, (3) 
By using DAVID database we found genes in the same cluster work together in the same 
biological processes, which provides support for the biological relations between the genes. 
Furthermore, we find the relationship between the biological processes of the groups and 
breast cancer are strong which also provides support for the selected group of biomarkers, 
(4) A subset of seven genes (miR-548f, miR-502-5p, miR-1236, miR-590-3p, miR-1181, miR-
145*, miR-129-5p) was selected as input for the classifiers. Four out the seven genes (miR-
129-5p, miR-1181, miR-590-3p and miR-502-5p) were related to breast cancer in previous 
studies (Liu et al., 2012; Zhai et al., 2012; Brest et al., 2011; Zhang et al., 2011; Backes et al., 
2010). Thus, the current method identified three new breast cancer biomarkers (miR-548f, 
miR-1236, miR-145*). Also, the seven selected genes were distributed over 5 clusters 
(clusters 1, 2, 4, 5, 7 in Table 5.4) containing 64 out of 74 genes. Therefore, about 89% of the 
74 genes were represented by the 7 selected genes. Furthermore, the biological processes of 
clusters 1, 2, 4, 5 were found strongly related to breast cancer such as, apoptosis, organelle 
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lumen, p53 signalling pathway and cell migration, (5) Four classifiers, MFFNN, SVM, LDA and 
KNN with 5-fold out cross validation, were used to validate the accuracy of the 7 selected 
genes in the improving the breast cancer diagnosis. The SVM was the superior classifier with 
98.2% classification accuracy. The overall improvement by using the novel feature selection 
method was about 7%, a significant improvement compared with the performance of the 
best previous circulating miRNA based BC-CAD system (Hu et al., 2012). 
6.2 Conclusions.  
Early detection of breast cancer is the key to a patient survival.  In low income countries, 
such as Jordan, the frequency of death by cancer is much higher than in wealthy countries. 
There are two main types of data that have been used for building CAD systems, clinical, i.e. 
ultrasound, and biological, i.e. mRNA and miRNA. The diagnostic accuracy of breast cancer 
CAD system needs further enhancement to save the lives of the undetected. In this work we 
successfully developed a computational BC-CAD framework that used both clinical and 
biological data and enhanced the diagnostic accuracy of breast cancer. Where, in the clinical 
part (ultrasound), we introduced a new mass feature (CRD) that enhanced the diagnostic 
accuracy of the CAD system by 14%, when it was added to five known powerful mass 
features, which is a significant improvement. Also, the current ultrasound based CAD 
outperformed the diagnostic accuracies of the best three previous CADs (Wei et al., 2007; 
Chang et al., 2005; Chen et al., 2003). Furthermore, by using the novel gene selection (Bi-
Biological filter), the diagnostic accuracy of blood based mRNA CADs has been enhanced in 
comparison to the previous studies (Aaroe et al., 2010), by 13%, which is a significant 
improvement. Furthermore, from miRNA data, we identified 74 genes divided over 7 
functional groups as possible biomarkers for breast cancer in Jordanian women using the Bi-
Biological filter. The seven out of 74 genes selected as breast cancer biomarkers enhanced 
the diagnostic accuracy of the only two known circulating miRNA based CAD systems by 
about 7%  (Hu et al., 2012) and 12% (Schrauder et al., 2012), which are significant 
improvements.  
6.3 Contributions 
In this thesis, we addressed three BC-CAD systems; one clinical and two biological. The 
following summarises the contributions of the thesis: 
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 Developed a computational framework for early detection of breast cancer using both 
biological and clinical datasets.  
 Introduced a new morphological feature of mass in ultrasound image called Central 
Regularity Degree (CRD) that accounts for the irregularity of malignant masses. 
 Enhanced breast cancer diagnostic accuracy using the new feature CRD: 14% significant 
improvement.    
 Enhanced the diagnostic accuracy of BC-CADs that use the mRNA of peripheral blood 
cells by exploring a novel gene selection method that starts from the biologically-
significant relations between the genes. Then, the selected genes were incorporated into 
the CAD system. 
 Identified the circulating miRNA biomarkers of breast cancer in Jordanian women. 
Developed a CAD system incorporating these biomarkers and achieved an enhanced 
diagnostic accuracy of breast cancer. 
 
6.4 Future work 
The work described in this thesis suggests several directions for future work. 
 The main goal of any CAD system is support a doctor in making the correct decision. The 
current system takes either clinical or biological datasets as input but not both. This is 
because there is no dataset found in the public databases that contains both types of 
examination for the same patient. Therefore, in future, we can evolve the framework by 
collecting a dataset containing both types of examination and integrating the decision of 
the clinical and biological subsystem in order to enhance the diagnostic accuracy of the 
framework.  
 
 As well as the ultrasound, mammography too is considered an important examination in 
the early detection of breast cancer. Both share some morphological features such as 
shape and margin. Therefore, we would suggest the inclusion of the new feature, CRD, in 
mammography based CAD systems in order to enhance their effectiveness in 
differentiating cancer from benign cases. 
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 Microarray technology has been widely used for diagnosing several other diseases such 
as, leukaemia, lymphoma and ovarian cancers. We would suggest the use of the 
methodology developed in this study to identify biomarkers for enhancing the diagnostic 
accuracy of these diseases too. 
 
 Microarrays have been used not only for diagnosis but also for prognosis. This method 
could identify biological biomarkers to be utilized for stratification of cancer patients as 
well as to identify patients at higher risks that might require differential therapeutic 
interventions. 
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Appendix A 
Analysis of miRNA Data 
A.1 Hub genes in cancer1 and cancer2 subsets 
Cancer1 Cancer2 
Cluster Index Gene  Index Gene Name Cluster index Gene Index Gene Name 
1 256 'hsa-miR-193a-5p_st' 1 240 'hsa-miR-186_st' 
1 335 'hsa-miR-26a-2-star_st' 1 667 'hsa-miR-576-5p_st' 
1 154 'hsa-miR-130a-star_st' 1 161 'hsa-miR-1323_st' 
2 551 'hsa-miR-515-3p_st' 2 87 'hsa-miR-1256_st' 
2 102 'hsa-miR-1265_st' 2 337 'hsa-miR-26b-star_st' 
2 168 'hsa-miR-135a_st' 2 455 'hsa-miR-378_st' 
3 131 'hsa-miR-128_st' 3 128 'hsa-miR-1287_st' 
3 68 'hsa-miR-1236_st' 3 483 'hsa-miR-433_st' 
3 592 'hsa-miR-521_st' 3 670 'hsa-miR-579_st' 
4 773 'hsa-miR-7-1-star_st' 4 583 'hsa-miR-520b_st' 
4 553 'hsa-miR-516a-3p_st' 4 430 'hsa-miR-363-star_st' 
4 167 'hsa-miR-135a-star_st' 4 684 'hsa-miR-590-5p_st' 
5 4 'hsa-let-7b_st' 5 728 'hsa-miR-629-star_st' 
5 735 'hsa-miR-635_st' 5 834 'hsa-miR-940_st' 
5 153 'hsa-miR-1308_st' 5 824 'hsa-miR-92b_st' 
6 825 'hsa-miR-93-star_st' 6 143 'hsa-miR-1298_st' 
6 210 'hsa-miR-154_st' 6 453 'hsa-miR-377_st' 
6 521 'hsa-miR-497_st' 6 325 'hsa-miR-23a-star_st' 
7 157 'hsa-miR-130b_st' 7 98 'hsa-miR-1261_st' 
7 120 'hsa-miR-1279_st' 7 20 'hsa-miR-101-star_st' 
7 741 'hsa-miR-641_st' 7 509 'hsa-miR-489_st' 
8 164 'hsa-miR-133a_st' 8 133 'hsa-miR-129-5p_st' 
8 299 'hsa-miR-212_st' 8 666 'hsa-miR-576-3p_st' 
8 452 'hsa-miR-377-star_st' 8 823 'hsa-miR-92b-star_st' 
9 123 'hsa-miR-1282_st' 9 422 'hsa-miR-34b-star_st' 
9 826 'hsa-miR-933_st' 9 168 'hsa-miR-135a_st' 
9 94 'hsa-miR-125b-2-star_st' 9 802 'hsa-miR-885-5p_st' 
10 298 'hsa-miR-211_st' 10 42 'hsa-miR-1197_st' 
10 224 'hsa-miR-181a_st' 10 260 'hsa-miR-194_st' 
10 330 'hsa-miR-24-2-star_st' 10 104 'hsa-miR-1267_st' 
11 618 'hsa-miR-548b-3p_st' 11 461 'hsa-miR-382_st' 
11 10 'hsa-let-7e_st' 11 55 'hsa-miR-1224-5p_st' 
11 666 'hsa-miR-576-3p_st' 11 605 'hsa-miR-532-3p_st' 
12 420 'hsa-miR-34a-star_st' 12 717 'hsa-miR-621_st' 
12 399 'hsa-miR-330-5p_st' 12 212 'hsa-miR-155_st' 
12 603 'hsa-miR-526b_st' 12 144 'hsa-miR-1299_st' 
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Cancer1 Cancer2 
Cluster Index Gene  Index Gene Name Cluster index Gene Index Gene Name 
13 654 'hsa-miR-564_st' 13 394 'hsa-miR-326_st' 
13 315 'hsa-miR-220b_st' 13 41 'hsa-miR-1185_st' 
13 460 'hsa-miR-381_st' 13 446 'hsa-miR-374b_st' 
14 250 'hsa-miR-190b_st' 14 419 'hsa-miR-346_st' 
14 85 'hsa-miR-1255a_st' 14 282 'hsa-miR-200c-star_st' 
14 800 'hsa-miR-877_st' 14 93 'hsa-miR-125b-1-star_st' 
15 282 'hsa-miR-200c-star_st' 15 74 'hsa-miR-1245_st' 
15 295 'hsa-miR-20b_st' 15 691 'hsa-miR-597_st' 
15 454 'hsa-miR-378-star_st' 15 372 'hsa-miR-30a_st' 
16 63 'hsa-miR-1229_st' 16 94 'hsa-miR-125b-2-star_st' 
16 320 'hsa-miR-222_st' 16 541 'hsa-miR-509-5p_st' 
16 747 'hsa-miR-647_st' 16 424 'hsa-miR-34c-3p_st' 
17 268 'hsa-miR-199a-3p_st' 17 844 'hsa-miR-99a_st' 
17 89 'hsa-miR-1258_st' 17 284 'hsa-miR-202-star_st' 
17 169 'hsa-miR-135b-star_st' 17 801 'hsa-miR-885-3p_st' 
18 290 'hsa-miR-208a_st' 18 533 'hsa-miR-505-star_st' 
18 376 'hsa-miR-30c-2-star_st' 18 406 'hsa-miR-338-3p_st' 
18 700 'hsa-miR-606_st' 18 819 'hsa-miR-924_st' 
19 695 'hsa-miR-601_st' 19 124 'hsa-miR-1283_st' 
19 676 'hsa-miR-584_st' 19 44 'hsa-miR-1201_st' 
19 287 'hsa-miR-204_st' 19 827 'hsa-miR-934_st' 
20 135 'hsa-miR-1290_st' 20 312 'hsa-miR-21_st' 
20 595 'hsa-miR-523-star_st' 20 342 'hsa-miR-27b_st' 
20 614 'hsa-miR-545-star_st' 20 82 'hsa-miR-1252_st' 
21 769 'hsa-miR-668_st' 21 379 'hsa-miR-30d_st' 
21 348 'hsa-miR-298_st' 21 638 'hsa-miR-550_st' 
21 179 'hsa-miR-140-3p_st' 21 618 'hsa-miR-548b-3p_st' 
22 341 'hsa-miR-27b-star_st' 22 228 'hsa-miR-181d_st' 
22 429 'hsa-miR-362-5p_st' 22 66 'hsa-miR-1233_st' 
22 41 'hsa-miR-1185_st' 22 596 'hsa-miR-523_st' 
23 659 'hsa-miR-570_st' 23 268 'hsa-miR-199a-3p_st' 
23 581 'hsa-miR-520a-3p_st' 23 68 'hsa-miR-1236_st' 
23 191 'hsa-miR-146a-star_st' 23 710 'hsa-miR-615-5p_st' 
24 314 'hsa-miR-220a_st'    
24 404 'hsa-miR-337-3p_st'    
24 239 'hsa-miR-186-star_st'    
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A.2 Hub genes in the healthy dataset 
Cluster Index 
Gene  
Index 
Gene Name 
Cluster 
Index 
Gene  
Index 
Gene Name 
1 668 'hsa-miR-577_st' 13 28 'hsa-miR-106b_st' 
1 379 'hsa-miR-30d_st' 13 795 'hsa-miR-875-3p_st' 
1 618 'hsa-miR-548b-3p_st' 14 163 'hsa-miR-132_st' 
2 615 'hsa-miR-545_st' 14 347 'hsa-miR-297_st' 
2 621 'hsa-miR-548c-5p_st' 14 334 'hsa-miR-26a-1-star_st' 
2 651 'hsa-miR-561_st' 15 388 'hsa-miR-320d_st' 
3 505 'hsa-miR-487a_st' 15 257 'hsa-miR-193b-star_st' 
3 645 'hsa-miR-555_st' 15 800 'hsa-miR-877_st' 
3 116 'hsa-miR-1275_st' 16 657 'hsa-miR-568_st' 
4 508 'hsa-miR-488_st' 16 189 'hsa-miR-145-star_st' 
4 736 'hsa-miR-636_st' 16 390 'hsa-miR-323-5p_st' 
4 353 'hsa-miR-29b-1-star_st' 17 514 'hsa-miR-492_st' 
5 838 'hsa-miR-944_st' 17 330 'hsa-miR-24-2-star_st' 
5 605 'hsa-miR-532-3p_st' 17 212 'hsa-miR-155_st' 
5 64 'hsa-miR-122_st' 18 269 'hsa-miR-199a-5p_st' 
6 231 'hsa-miR-1826_st' 18 122 'hsa-miR-1281_st' 
6 504 'hsa-miR-486-5p_st' 18 227 'hsa-miR-181c_st' 
6 396 'hsa-miR-329_st' 19 238 'hsa-miR-185_st' 
7 105 'hsa-miR-1268_st' 19 614 'hsa-miR-545-star_st' 
7 661 'hsa-miR-572_st' 19 758 'hsa-miR-657_st' 
7 152 'hsa-miR-1307_st' 20 38 'hsa-miR-1182_st' 
8 296 'hsa-miR-21-star_st' 20 258 'hsa-miR-193b_st' 
8 86 'hsa-miR-1255b_st' 20 159 'hsa-miR-1321_st' 
8 686 'hsa-miR-592_st' 21 207 'hsa-miR-152_st' 
9 534 'hsa-miR-505_st' 21 404 'hsa-miR-337-3p_st' 
9 730 'hsa-miR-630_st' 21 156 'hsa-miR-130b-star_st' 
9 449 'hsa-miR-376a_st' 22 442 'hsa-miR-373_st' 
10 52 'hsa-miR-1208_st' 22 781 'hsa-miR-760_st' 
10 528 'hsa-miR-501-5p_st' 22 824 'hsa-miR-92b_st' 
10 544 'hsa-miR-512-3p_st' 
11 43 'hsa-miR-1200_st' 
11 276 'hsa-miR-19b_st' 
11 560 'hsa-miR-517c_st' 
12 683 'hsa-miR-590-3p_st' 
12 839 'hsa-miR-95_st' 
12 377 'hsa-miR-30c_st' 
13 306 'hsa-miR-218-1-star_st' 
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A.3 The selected miRNA genes that were found to be overlapped with 
previous studies 
Gene name Breast cancer Study reference Other cancers study reference 
miR-1224-3p (Hao., et al., 2012)  
miR-129-5p (Brest et al., 2011) (Y. Liu et al., 2012) 
miR-138  (X. Liu et al., 2009; W. Wang, Zhao, 
Tan, Ren, & Qi, 2012) 
miR-182 (Guttilla & White, 2009; Moskwa, et al., 
2011) 
(Z. Liu et al., 2012) 
miR-185 (Imam, et al., 2010) (Watahiki et al., 2011) 
miR-221 (Lambertini, et al., 2012; Shah & Calin, 
2011; Stinson, et al., 2011) 
 
miR-376b (Lowery, et al., 2009)  
miR-499-3p (Fassan, et al., 2009)  
miR-576-3p   
miR-99b (Turcatel, et al., 2012) (Sun et al., 2011) 
miR-135a (Y. Chen, et al., 2012b) (Navarro et al., 2009; Zhou et al., 2012) 
miR-34a (L. Li, et al., 2012; Nugent, et al., 2012; 
Peurala, et al., 2011) 
(Genovese et al., 2012) 
miR-449a (Yang., et al., 2012) (Bou Kheir et al., 2011) 
Mir-502-5p 
 
 (Zhai et. al., 2012) 
miR-885-5p (Afanasyeva, et al., 2011) (Gui et al., 2010) 
miR-137 (Yuanyin Zhao, et al., 2012) (L. Chen et al., 2012) 
miR-30c (Tanic, et al., 2012)  
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miR-375 (Giricz, et al., 2012)  
let-7c (Boyerinas, et al., 2010; C. D. Johnson, et 
al., 2007; Yu, et al., 2007; Yingchun Zhao, 
et al., 2011) 
 
Mir-590 
 
 (Backes et.al., 2010) 
miR-1226 (JIN., et al., 2010)  
miR-1258  (H. Liu, Chen, Gao, & Jiang, 2012) 
miR-200b/c (Dykxhoorn, et al., 2009; Park, et al., 2008; 
Radisky, 2011) 
 
miR-125b-2 (H. Wang, et al., 2012) (Klusmann et al., 2010) 
miR-146b-3p  (Ragusa et al., 2010) 
miR-342-5p (Cittelly, et al., 2010; Romero-Cordoba, et 
al., 2012) 
 
miR-663  (Liu, Zhang, Wang, Xiong, Cui, 2011; 
Tili & Michaille, 2011) 
Mir-1181  
(Zhang et al., 2011) 
miR-199a-3p ( Shatseva, et al., 2011) (Sakurai et al., 2011) 
miR-199a-5p  (Duan et al., 2012; Sakurai, et al., 
2011) 
 
 
 
 
 
 
 
